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ABSTRACT 
Lauren Waldron: Identification and Characterization of the TBX5 proteome provides 
mechanistic insight into Holt-Oram syndrome 
(Under the direction of Frank Conlon) 
Congenital heart disease (CHD) remains the most common congenital 
malformation, with defects in cardiac chamber septation accounting for almost half of 
all CHD-related deaths in children. The health problem is compounded by the fact 
that most children are otherwise asymptomatic. The cardiac transcription factor 
TBX5 has been shown to be causative in patients with septal defects; however, its 
mechanism of action in normal development and in CHD has not been determined. 
To begin to address this question we have developed two different model systems 
that express an epitope-tagged version of TBX5 for in vivo isolation of endogenous 
tissue. In the Xenopus model, I have developed lines in two different species with 
the intent to isolate endogenous TBX5 protein complexes. In the mouse model, we 
have isolated and characterized the endogenous TBX5 cardiac interactome and 
report that TBX5, long considered to be a cardiac transcriptional activator, interacts 
biochemically and genetically with the chromatin remodeling repressor machinery of 
the Nucleosome Remodeling and Deacetylase (NuRD) complex. We report that the 
TBX5-NuRD interaction is essential for normal heart development and that patients 
with atrioventricular septal defects (AVSD) have mutations that disrupt the TBX5-
iv	  
NuRD interaction. We identify the direct transcriptional targets of TBX5 and 
show TBX5 acts to repress expression of neural and cancer associated gene 
programs in cardiac tissue and that a subset of these genes are disregulated by 
CHD patient mutations. We also define a new structural-functional domain of TBX5 
that is essential for interaction with the NuRD complex and show through 
phylogenetic analysis that this domain, and hence the interaction with NuRD, 
evolved during the early diversification of the vertebrates, simultaneous with the 
evolution of atrial septation. Thus, we report that the TBX5-NuRD interaction 
identified here plays a central role in cardiac development and in human CHD, as 
well as in the evolution of the mammalian heart.
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CHAPTER 1 
Introduction 
Congenital malformations, or structural birth defects, are the leading cause of 
infant mortality in the US and Europe (Dolk et al., 2010; Heron and Tejada-Vera, 
2009). Congenital heart disease (CHD) is the most common congenital 
malformation, occurring in 10 per 1000 (or 1%) of live births. Of these, atrial septal 
defects (ASD) are the most common, accounting for 11.6% of all congenital heart 
malformations (Morris et al., 2010). This health problem is compounded by the fact 
that most children are otherwise asymptomatic and that the disease has no 
identifiable cause in most cases. It is crucial to understand the molecular mechanism 
involved in atrial septum formation in order to properly treat patients with ASD. 
Development of the atrial septum 
Formation of the atrial septum begins early in development, during the 
process of cardiac looping. Atrial septation is a multi-phase process, and 
perturbation at any stage can lead to a subtype of ASD (Dhanantwari et al., 2009; 
Krishnan et al., 2014). At embryonic day (E) 10.5 in the developing mouse, the 
process of atrial septation begins with the formation of a muscular septum primum 
(SP), that grows from the roof of the atrium toward the atrioventricular canal (AVC). 
There is a mesenchymal cap (MC) at the lower end of the SP that is similar to an 
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endocardial cushion (EC). Initially, the MC does not connect to the AVC, which 
leaves an opening between the atria called the ostium primum (OP) (Figure 1.1A) 
(Lin et al., 2006). As development proceeds through E11.5, a secondary septum 
called the septum secundum (SS) is formed to the right of the SP by atrial roof 
infolding at the dorsal end. The SS then expands from the EC at the ventral end. 
Concurrently, the SP undergoes apoptosis to form a secondary ostium called the 
ostium secondum (OS) (Figure 1.1B). Eventually by E14.5, the EC has fused to the 
MC, and with the addition of the second-heart field (SHF)-derived mesenchyme to 
the base of the atrial septum, the OP is fused shut. This fusion is referred to as the 
dorsal mesenchymal protrusion (DMP).  The SS does not fuse to the AVC, leaving 
an opening known as the foramen ovale (FO) (Figure 1.1C). The FO allows for the 
bypass of blood from the right atrium to the left atrium, bypassing the lungs to allow 
continued systemic circulation of the blood. The FO fuses shut after birth via the 
valvula foraminis ovalis, which is a fold projecting from the FO to the atrium, due to 
increased pressure in the left atrium resulting from pulmonary circulation (Lin et al., 
2006). 
 Clinically, there are many different types of ASD. The most prevalent type is 
called ASD type 2, or ostium secundum atrial septal defect. ASD type 2 generates 
an incomplete connection between the SP and the SS (Figure 1.1D), and is caused 
by defects in the formation of either, or both, structures (Blom et al., 2005). This 
leads to defects in the formation of the OS and the FO. Many times, ASD type 2 is 
often difficult to distinguish from another type of cardiac defect called patent foramen 
ovale (PFO). PFO occurs when there is an incomplete connection between the 
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valvula formainis ovalis and the SS even though both are fully developed. PFO can 
refer to either a delayed closure of the FO, or in many cases the FO never fuses 
shut, as observed in approximately 25% of adults (Blom et al., 2005). This is 
different from ASD type 2 in that the valvula foraminis ovalis is underdeveloped in 
ASD type 2 and therefore incapable of closing the FO. 
 A second type of ASD, called ASD type 1, occurs at the formation of the OP. 
ASD type 1 rarely occurs in isolation: it is commonly occurs within a larger context of 
an atrioventricular septal defect (AVSD). AVSD is a more severe type of cardiac 
defect, in which the atrial septum does not fuse with the ventricular septum via the 
DMP (Figure 1.1E). There are many AVSD subtypes: incomplete AVSD, transitional 
AVSD, and complete AVSD, which is the most severe form (Jacobs et al., 2000). All 
AVSDs have a common valve between the atria and ventricles; the differences 
between AVSD subtypes are the amounts of shunting that occurs between 
chambers, as well as the AV valve morphology (Anderson et al., 1998). The valve 
defects are primarily due to defective in the EC development; therefore, AVSD is  
also referred to as an EC defect.  
 Incomplete AVSD is a lack of OP closure, which allows blood to shunt 
between both atria. Incomplete AVSDs primarily affect primarily the mitral valve, 
causing mitral insufficiency, but all other valves are present and functional (Jacobs 
et al., 2000).  Transitional AVSD is more similar to complete AVSD, but the leaflets 
of the common AV valve are fused to the ventricular septum, which essentially 
creates two distinct valvular orifices. Small ventricular septal defects (VSD) are 
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commonly observed in transitional AVSD. This also allows blood to shunt between 
ventricles, but fusion of AV valve leaflets to the ventricular septum prevents a more 
severe phenotype (Jacobs et al., 2000). Complete AVSD is characterized by the 
presence of a common AV valve, which results in a severely affected phenotype 
(Jacobs et al., 2000) (Anderson et al., 1998). 
Molecular mechanisms of atrial and atrioventricular septation 
 Four distinct mesenchymal tissues are required for the atrial and 
atrioventricular septa: the ECs (superior and inferior), MC, and DMP (Webb et al., 
1998). Defects in the formation or differentiation of any of these tissues will result in 
atrial or atrioventricular septation defects. Sequencing the DNA of patients with 
syndromic CHD has identified a number of genes responsible for atrial and 
atrioventricular septation (Table 1.1), whereas sequencing the DNA of patients with 
non-syndromic CHD has identified an additional subset of genes involved in 
septation (Table 1.2.). There are several mouse models of defective septation that 
have not yet been identified in humans (Table 1.3). The following sections briefly 
summarize the molecular mechanisms underlying AV septal complex formation. 
EC defects lead to septation defects 
The primary heart tube separates into different layers as it develops. The 
inner endocardium develops beneath the myocardium and is separated by a layer of 
extra-cellular matrix (ECM). The developing myocardium secretes additional ECM 
components, which results in the local formation of four ECs: the superior and 
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inferior cushions form first, followed by two lateral cushions in the left and right sides 
of the AV junction (de Lange et al., 2004; Wessels et al., 1996). The superior and 
inferior cushions form via an epithelial-mesenchymal transition (EMT) (Manasek, 
1970; Markwald et al., 1977; Markwald and Smith, 1972). Further development of 
the superior and inferior ECs produces the mitral valve aortic leaflet and the tricuspid 
valve septal leaflet. The developmental mechanism of the lateral ECs is still 
unknown although they are crucial for AV septum formation. The right lateral cushion 
is important for tricuspid valve leaflet development, whereas the left lateral cushion 
is important for mitral valve formation and development (de Lange et al., 2004).  
The endocardium undergoes EMT via signaling through the underlying 
myocardium. Signaling pathways regulating EMT include Notch, BMP (BMP2 and 
BMP4), TGFβ2, TGFβ3 and VEGF (Camenisch et al., 2002; Jiao et al., 2003; 
Liebner et al., 2004; Luna-Zurita et al., 2010; Ma et al., 2005; McCormack et al., 
2013; Rivera-Feliciano and Tabin, 2006; Rodgers et al., 2006; Timmerman et al., 
2004). Endocardial tissues in the cushions express downstream receptors and 
effectors of the myocardial signaling pathways, including ALK2 (ACVR1), ALK3 
(BMPR1A), and NOTCH-1, and thereby promote EMT. Defects in these signaling 
pathways have been linked to septation defects (Tables 1.1- 1.3). Myocardial tissues 
in the cushions express genes such as BMP2, TBX2, NFATC2, NFATC3, and 
NFATC4, which are important for EMT completion, and mutations in these genes 
have also been linked to septation defects (Chang et al., 2004; Harrelson et al., 
2004; Ma et al., 2005) (Tables 1.1-1.3). 
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One of the most common AVSD mouse models is the Trisomy 16 mouse, 
which is the mouse model of Down syndrome (DS) (Epstein et al., 1985; Miyabara et 
al., 1982). Trisomy 16 null ECs have different morphology and are larger than wild 
type ECs, which may interfere with DMP fusion with the ECs (Webb et al., 1996). In 
Trisomy 16 mice, the DMP is hypoplastic and does not bridge the space between 
the MC and the ECs, thereby leading to AVSD. AVSD is the most common cardiac 
malformation in DS (up to 30-40% of affected probands), and DS is commonly 
associated with AVSD, (Blom et al., 2003). Many studies have investigated the 
genetic cause of AVSD in DS. Recent work associated mutations in the VEGFA 
pathway (COL6A1, COL6A2, CRELD1, FBLN2, FRZB, and GATA5) with AVSD in 
DS by sequencing the DNA of 141 patients with AVSD/DS and comparing with the 
DNA sequence of DS patients without AVSD (Ackerman et al., 2012; Redig et al., 
2014; Robinson et al., 2003). Cell biological studies utilizing cell lines from DS 
patients found that the Sonic hedgehog (Shh) pathway and pathways involved in 
ciliogenesis are involved in AVSD-related DS (Ripoll et al., 2012). It is evident that 
there are many potential candidate genes related to cardiac defects in DS, including 
genes important for EC formation. However, DS is a very complex disorder and 
requires more research into the candidate genes. 
MC formation defects lead to septation defects 
 MS formation defects lead to defective EC development and septation. The 
MC initially forms off of the SP: as the SP grows and elongates the MC obtains a 
more prominent ridge-like structure (Arrechedera et al., 1987; Wessels et al., 2000) 
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that helps to close the OP.  The MC is contiguous with the DMP and the superior AV 
cushion at its posterior and anterior ends, respectively. (Wessels et al., 2000). The 
MC and the DMP are both mesenchymal structures on a molecular level, although 
they appear to originate from different lineages. Using a Tie2-Cre reporter mouse it 
was demonstrated that the MC is derived from endocardial lineage via EMT 
(Mommersteeg et al., 2006). This suggests that mutations in proteins required for 
ECM or EMT may lead to defects in ECs and the MC, which thereby lead to 
septation defects. 
DMP malformations lead to AVSD 
 The most well-studied event during septation is DMP formation. The MC 
originates from an endocardial lineage, whereas the DMP is derived from the SHF. 
The SHF is a population of cardiac progenitor cells located in the pharyngeal 
mesoderm that contributes to the elongating heart tube, a subset of the developing 
atrial myocardium, the developing DMP, cardiac smooth muscle cells, and 
endothelial cells (Cai et al., 2003; Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo et 
al., 2001).  
Many genes and pathways that are required for DMP formation have been 
identified. One of these is the hedgehog signaling pathway. Shh null embryos have 
defects in the SP and SS, and some null embryos also have defects in AV valve 
formation (Washington Smoak et al., 2005). Shh null embryos exhibit AVSD,  and 
Shh signaling within the DMP is required to prevent AVSD (Goddeeris et al., 2008). 
Knockout of the hedgehog receptor smoothened (Smo) in atrial progenitor cells 
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leads to AVSD (Hoffmann et al., 2009). Fate mapping of Shh receiving cells using a 
Gli1CreERT2 driver reveals contributions to the PS and DMP, and Shh signaling occurs 
in atrial septum progenitor cells before atrial septation begins (Hoffmann et al., 
2009). Shh is also required in the pulmonary endoderm for atrial septation 
(Hoffmann et al., 2009). 
Numerous studies have investigated hedgehog-dependent pathways involved 
in atrial septation and AVSD. Genetic studies indicate that Isl1 acts upstream of 
hedgehog signaling during atrial septum formation (Lin et al., 2006).  Isl1 and Shh 
are expressed in the posterior SHF (pSHF); therefore, Hoffmann et al. defined a 
SHF hedgehog-dependent regulatory network using transcriptional profiling to begin 
to elucidate the pathway. They found that Foxf1a and Foxf2, which are Forkhead 
box transcription factors, are Hedgehog targets in the SHF. Depletion of one copy 
each of Foxf1a and Foxf2 leads to AVSD and abolishes the DMP. A SHF-specific 
Foxf1a regulatory element was shown to bind both TBX5 and the hedgehog 
transcriptional regulators GLI1 and GLI3 in vivo (Hoffmann et al., 2014).  
 In addition to Shh and the VEGF pathways, mutations in the Wnt pathway 
also lead to DMP malformation and AVSD. Wnt signaling functions via β-catenin to 
maintain ISL1+ SHF progenitor cells in the anterior portion of the developing heart 
(Ai et al., 2007; Cohen et al., 2007; Kwon et al., 2007; Lin et al., 2007). Wnt2 ligand 
characterization and knockout in a mouse model indicates that WNT2 regulates 
expansion of SHF progenitors via β-catenin in the venous pole of the heart (Tian et 
al., 2010). Global Wnt2 depletion reduces the number of ISL1+ SHF progenitors, 
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reduces proliferation in the DMP, reduces DMP hypoplasia, and therefore leads to 
AVSD (Tian et al., 2010). 
Mutations in cardiac transcription factors lead to septation defects 
 Cardiac septation is mediated by a number of specific cardiac transcription 
factors in addition to proteins required for ECM, EMT, and AV septal complex 
formation. Members of the Nkx, Tbox, and Gata families are considered as 
canonical transcription factors that are required for multiple aspects of 
cardiogenesis. TBX5, NKX2-5, and GATA4 are expressed in the atria during 
septation, physically interact with each other at the correct time and place, and 
coordinately activate additional atrial genes (Bruneau et al., 2001; Garg et al., 2003; 
Hiroi et al., 2001; Takeuchi and Bruneau, 2009). Mutations in TBX5, NKX2-5, 
GATA4, TBX20, and GATA6 lead to septation defects in both humans and mice 
(Tables 1.1-1.3).  
TBX5 is required for atrial septation 
ASD is often observed in a proband in the context of a congenital syndrome. 
For example, the Holt-Oram syndrome (HOS), which is caused by mutations in 
TBX5, is characterized primarily by septal defects (Baban et al., 2014a; Basson et 
al., 1997; Basson et al., 1994; Basson et al., 1999; Cross et al., 2000; Li et al., 1997; 
Newbury-Ecob et al., 1996). Mice that are heterozygous for Tbx5 expression display 
ASD type 2 and, less abundantly, AVSD (Bruneau et al., 2001).  
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TBX5 is required in the SHF for atrial septation (Hoffmann et al., 2014; Xie et 
al., 2012). Tbx5 is expressed in the pSHF, DMP, and DMP-surrounding 
mesocardium as observed by in situ hybridization. Lineage tracing shows that Tbx5 
is not required in the myocardium or the endocardium for atrial septation; using a 
Tnt-Cre  or Tie2-Cre driver to deplete Tbx5 in the myocardium or endocardium, 
respectively, results in normal septation in mice. However, Tbx5 depletion in the 
pSHF using a Gli1-Cre driver results in approximately 40% penetrance of ASD (Xie 
et al., 2012). Xie et al. also performed fate-mapping to show that Tbx5 is essential 
for DMP development, and Tbx5 is required for atrial septum progenitor cell 
proliferation. The pathway involved in Tbx5-mediated atrial septation development 
has recently been elucidated. Tbx5 regulates hedgehog signaling in cardiac 
progenitor cells by regulating Gas1 and Osr expression (Xie et al., 2012), which 
drives atrial septation.  
Molecular genetics of Holt-Oram syndrome (HOS) 
HOS (OMIM 142900) is a heart-hand syndrome first described by Mary Holt and 
Samuel Oram in 1960 (Holt and Oram, 1960). HOS is the most common of three 
heart-hand syndromes, and affects approximately one in 100,000 live births (Csaba 
E, 1991). HOS has an autosomal dominant inheritance pattern, and probands have 
a variety of congenital heart defects and limb defects. To be formally diagnosed with 
HOS, patients must present with an upper limb defect involving the carpal bone and 
in many cases, radial or thenar bones (Basson et al., 1994; Li et al., 1997). 
Approximately 80% of HOS patients have CHD (Basson et al., 1999). The severity of 
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the limb and cardiac defects do not appear to be correlated, and while HOS is highly 
penetrant, the phenotype of probands seems to vary widely, even in families 
(Brassington et al., 2003).  
Cardiac defects in HOS patients 
The most common CHDs observed in HOS patients are ASDs, VSDs, or 
defects in the cardiac conduction system (CCS) (Basson et al., 1994; Bruneau et al., 
1999; Cross et al., 2000) (Newbury-Ecob et al., 1997). Approximately 40% of cases 
have CCS abnormalities alone (Newbury-Ecob et al., 1996). Disease severity and 
prognosis depends primarily on the cardiac defect severity; many ASDs and VSDs 
can be surgically corrected.  
More recent studies of HOS patients report more severe cardiac defects, 
such as AVSD (Figure 1.1E) (Baban et al., 2014a). These recent HOS cases were 
identified prenatally, or before the first year of the proband’s life, whereas probands 
in previous HOS case reports were diagnosed later in life. HOS prevalence may be 
statistically underreported because HOS is often undetected prenatally in spite of the 
existence of major structural anomalies. When a HOS diagnosis is discovered, up to 
55% of parents (11/20) are reported to electively terminate the pregnancy (Barisic et 
al., 2014). The linkage between AVSD and HOS prompted reexamination of earlier 
case reports, and nine patients with AVSD were re-discovered but not validated 
genetically, making AVSD a more common diagnostic phenotype of HOS (Baban et 
al., 2014a; Basson et al., 1994; Boehme and Shotar, 1989; Del Corso et al., 1991; 
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Holmes, 1965; Kumar et al., 1994; Marcus et al., 1985; Newbury-Ecob et al., 1996; 
Sletten and Pierpont, 1996; Smith et al., 1979; Terrett et al., 1994)  
The TBX5 mutation spectrum in HOS 
Linkage analysis of HOS in two affected families localized the HOS genetic 
defect on chromosome 12q (Basson et al., 1994; Basson et al., 1995; Bonnet et al., 
1994; Terrett et al., 1994; Terrett et al., 1996). Further analysis and direct 
sequencing of affected families determined that the causative gene was Tbx5, a 
member of the T-box transcription factor family (Li., 1997) (Basson 1997). Currently, 
there are approximately 200 cases of HOS with a molecular diagnosis by sequence 
analysis (Table 1.4). The most common TBX5 mutations are those affecting Tbx5 
mRNA splicing, or frameshift mutations caused by nucleic acid insertions or 
deletions. These mutations lead to truncation or premature stop of TBX5 protein. In 
most cases, truncated TBX5 is degraded by the nonsense-mediated decay system 
(Mori et al., 2006). In rare cases, translation of the TBX5 protein is extended, 
resulting in a gain-of-function phenotype that manifests as atypical HOS, which has 
a similar phenotype to that of loss-of-function TBX5 mutations (Bohm et al., 2008; 
Muru et al., 2011). TBX5 overexpression also leads to atypical HOS. Because TBX5 
overexpression and null mutation both have the same phenotype, one can 
hypothesize that proper TBX5 levels are crucial for cardiogenesis. (Fan et al., 
2003a; Fan et al., 2003b; Patel et al., 2012; Porto et al., 2010; Postma et al., 2008). 
A substantial number of probands contain a point mutation in TBX5. The 
overwhelming majority of TBX5 missense mutations are located in the T-box DNA- 
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binding domain. Functional analysis of many of these mutations (e.g., M74I, G80R, 
L94R, A143T, S154A, R237P, R237Q, R237W, R279X, and 1333delC) indicates 
that these mutant proteins cannot bind and activate downstream target genes such 
as Atrial natriuretic peptide (ANF/Nppa) (Baban et al., 2014a; Bohm et al., 2008; Fan 
et al., 2003b; Ghosh et al., 2001; Hiroi et al., 2001; Zhang et al., 2015; Zhou et al., 
2015). Many of these same missense mutations affect TBX5 interaction with partner 
proteins NKX2.5 and GATA4 (Boogerd et al., 2010; Fan et al., 2003a; Fan et al., 
2003b; Hiroi et al., 2001). Outside of the T-box DNA-binding domain, there are 
additional TBX5 missense mutations with unknown CHD molecular mechanisms: 
however, it was hypothesized that mutations in the TBX5 C-terminus affects the 
binding of TBX5 to the minor groove of DNA (Muller and Herrmann, 1997). My 
recent work identified a novel molecular mechanism for CHD in patients with 
mutations in the TBX5 C-terminus via interaction of TBX5 with a chromatin- 
remodeling network.  
Recent studies have discovered TBX5 mutations in a subset of CHD patients 
who do not meet the strict limb-related criteria for HOS. These patients exhibit a 
wide array of cardiac defects. Two studies concurrently reported two patients with 
dilated cardiomyopathy resulting from two different TBX5 missense mutations 
(Zhang et al., 2015; Zhou et al., 2015) An additional study was performed on 
probands with septation defects that were not diagnosed with HOS. The DNA of 
these patients was sequenced for mutations in Tbx5. This study identified almost 30 
TBX5 mutations that were associated with VSD, ASD, and AVSD. These include 
missense mutations, silent mutations, and intronic mutations. This study is 
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confounded by the fact that many of these were DS patients: because DS patients 
have a very high prevalence of AVSD, it is difficult to correlate genotype with 
phenotype in these cases. However, the study suggests a high prevalence of TBX5 
mutations in DS patients, which should be investigated further (Reamon-Buettner 
and Borlak, 2004b). 
Approximately 70% of individuals who meet the diagnostic criteria for HOS 
have a mutation in the TBX5 coding region (Basson et al., 1997; Basson et al., 1999; 
McDermott et al., 2005). This suggests that the remaining 30% of HOS patients may 
have a mutation in either a regulatory (non-coding) region of Tbx5, in a direct target 
gene of TBX5, or in a TBX5-interacting protein partner. Precedence for this was 
reported by Smemo et al who identified a variation in a Tbx5 enhancer in a patient 
with congenital heart disease (Smemo et al., 2012). To understand the mechanisms 
underlying HOS, it is crucial to identify the gene regulatory regions, the in vivo 
cardiac protein partners, and the downstream targets of TBX5.  
TBX5-interacting protein partners 
TBX5-interacting protein partners have been identified in in vitro experiments 
(e.g., GST-pulldowns) and in tissue culture cells. TBX5 contains two protein-protein 
interaction domains, one at the N-terminus into the T-box, and the other at the C-
terminal end. At the N-terminus, TBX5 interacts with the cardiac transcription factors 
TBX20 (Brown et al., 2005; Goetz et al., 2006), GATA4 (Garg et al., 2003; Maitra et 
al., 2009), NKX2.5 (Hiroi et al., 2001), and MEF2C (Ghosh et al., 2009). The TBX5-
TBX20 interaction is required to repress ectopic expression of ANF/Nppa (Brown et 
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al., 2005; Plageman and Yutzey, 2004).  Further evidence suggests that the TBX5-
TBX20 interaction is important for the regulation of cell polarity and adhesion genes. 
Depletion of both TBX20 and TBX5 protein in Xenopus embryos results in more 
severe cardiac defects than depletion of either protein alone, but cardiomyocyte 
marker expression is maintained (Brown et al., 2005). Tbx5 and Gata4 interact 
genetically; mice that are compound heterozygous for both genes exhibit 
atrioventricular septal defects and a thinning of the myocardial wall, which is a more 
severe phenotype than the ASD observed in Tbx5 heterozygous mice (Maitra et al., 
2009).  Additionally TBX5 and GATA4 have also been shown to interact 
biochemically with NKX2.5 to activate downstream expression of ANF/Nppa 
(Bruneau et al., 2001; Garg et al., 2003; Hiroi et al., 2001) and the gap junction 
protein GJA5/CX40 (Linhares et al., 2004). TBX5 also interacts with the transcription 
factor MEF2C to drive expression of alpha myosin heavy chain (Myh6) which 
patterns the heart (Ghosh et al., 2009).  
The TBX5 C-terminus interacts with non-cardiac specific proteins, and these 
interactions may have roles in protein regulation. TBX5 interacts with LMP4 to 
regular TBX5 nuclear localization (Camarata et al., 2006; Krause et al., 2004; Kulisz 
and Simon, 2008). In zebrafish, it has been demonstrated that the zebrafish ortholog 
of LMP4 (Pdlim7) interacts with zTbx5 to regulate the zTbx5 target genes nppa and 
tbx2b at the AV-boundary, and this interaction is required for AV valve formation 
(Camarata et al., 2010). The TBX5 C-terminus also interacts with TAZ and YAP to 
regulate TBX5-dependent promoters via the histone acetyltransferases p300 and 
PCAF (Murakami et al., 2005). The effects of these interactions on the developing 
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heart are unknown. My work shows that the TBX5 C-terminus also interacts with the 
NuRD complex to repress aberrant gene transcription of neural- and cancer- related 
genes. This suggests that the C-terminal TBX5 protein interaction domain may be 
important for TBX5 protein regulation.  
TBX5 interacts with a number of chromatin-remodeling proteins to modulate 
Tbx5 transcriptional activity. Tbx5 genetically interacts with the SWI/SNF protein 
BRG1, and depletion of BRG1 in mice using an Nkx2.5-Cre driver leads to 
embryonic lethality by E10.5 due to cardiac defects (VSD, double outlet right 
ventricle, patent foramen ovale, and dilation of the ventricles) and defective 
cardiomyocyte migration and shape (Takeuchi et al., 2011). TBX5 interacts with the 
BRG1-interacting factor BAF60C in tissue culture to mediate cardiac gene 
expression (Lickert et al., 2004). TBX5 also interacts with the histone-modifying 
protein HDAC3 to reduce Tbx5 transcriptional activity. Specifically, the interaction 
between HDAC3 and TBX5 leads to proper regulation of cardiac differentiation; mice 
lacking HDAC3 in cardiac progenitor cells display overdifferentiation of precursor 
cells, cardiac defects, and upregulation of TBX5 target genes (Lewandowski et al., 
2014). 
Dissertation goals 
 TBX5 is required during many phases of cardiac development, from the 
cardiac precursor cell stage to atrial septum. However, very little is known about the 
in vivo TBX5 protein interaction partners and gene targets. This is partially due to the 
fact that isolation and purification of TBX5 protein is difficult. TBX5 shares high 
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sequence homology with other T-box transcription factors within the T-box DNA- 
binding domain (Papaioannou and Silver, 1998). TBX5 is sequestered in the nucleus 
(Zaragoza et al., 2004), which makes the protein difficult to solubilize. A high affinity, 
high specificity antibody for TBX5 has not been produced. TBX5 has been difficult to 
purify; the complete crystal structure of TBX5 or any other T-box DNA-binding 
protein has not been obtained. However, the T-box domains of TBX5 and TBX3 
have been purified in the presence and absence of DNA (Coll et al., 2002; 
Stirnimann et al., 2010). . 
 We felt that it was necessary to bridge the current knowledge gap by 
determining the in vivo molecular mechanisms by which TBX5 regulates 
cardiogenesis. For the first step, we developed in vivo methods to isolate 
endogenous TBX5 protein using the Avi-tag/BirA system in Xenopus (Chapter 2) 
and mouse (Chapter 3) model systems. Chapter 2 describes the generation of 
Xenopus laevis and Xenopus tropicalis lines containing TBX5-Avitag. These frog 
lines are the first to express an epitope-tagged protein under its endogenous cardiac 
promoter, and this is the first Xenopus tropicalis line of any kind to display germline 
transmission. These frogs can be utilized to determine the in vivo TBX5 protein 
interaction partners and target genes. Chapter 3 describes a comprehensive study 
of the murine TBX5 cardiac proteome using a Tbx5Avi/Avi;ROSA26HA-BirA/BirA mouse 
line. We determine that TBX5 interacts with the Nucleosome Remodeling and 
Deacetylase (NuRD) complex in the heart. We establish a new role for TBX5 as a 
repressor of neural- and cancer- related genes and validated 11 new transcriptional 
targets of TBX5. We show that the TBX5-NuRD interaction is essential for normal 
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heart development, and patients with AVSD have mutations that disrupt the TBX5-
NuRD interaction. We also define a new structure-function domain of TBX5 that is 
essential for interaction with the NuRD complex and perform phylogenetic analysis 
to show that this domain, and hence the interaction with NuRD, evolved during early 
diversification of vertebrates, simultaneously with the evolution of atrial septation. 
Finally, we report that the TBX5-NuRD interaction has a central role in cardiac 
development, in human CHD, and in evolution of the mammalian heart. Collectively 
this work enhances the understanding of the molecular mechanisms of TBX5 
function in the developing heart. 
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Table 1.1 Genes involved in septum-related human syndromic CHD. 
Gene Syndrome OMIM Mouse 
Model  
available 
Phenotype Reference 
ATR Seckel 
Syndrome 
210600 Yes (no 
cardiac 
phenotype) 
ASD type 
2, AVSD, 
VSD 
(Howanietz et al., 
1989; Ucar et al., 
2004) 
BBS12, 
BBS10, 
TMEM67, 
MKS1 
Bardet-Biedl 
Syndrome 
209900 Yes (no 
cardiac 
phenotype) 
ASD type 
2, AVSD, 
VSD 
(Willaredt et al., 
2012) 
B9D1, 
TEMEM67, 
MKS1 
Mechel-
Gruber 
Syndrome 
249000 Yes (no 
cardiac 
phenotype) 
ASD type 
2, VSD 
(Weatherbee et al., 
2009; Willaredt et 
al., 2012) 
CHD7, 
SEMA3E 
CHARGE 
Syndrome 
214800 Yes ASD type 
2, VSD, 
AVSD 
(Bosman et al., 
2005; Corsten-
Janssen et al., 
2014; D'Alessandro 
et al., 2015; 
Issekutz et al., 
2005; Jongmans et 
al., 2006) 
CREBBP, 
EP300 
Rubenstein-
Schinzel 
Syndrome 
180849 Yes ASD type 
2, VSD 
(Oike et al., 1999; 
Stevens and 
Bhakta, 1995) 
CRELD 
(VEGA 
pathway), 
CALL 
3p Syndrome 606217 No AVSD (Ackerman et al., 
2012; Drumheller et 
al., 1996; Green et 
al., 2000; Kozma et 
al., 2004; Maslen et 
al., 2006; Robinson 
et al., 2003; Zatyka 
et al., 2005) 
CTNND2 Cri-Du-Chat 
Syndrome 
123450 No ASD type 
2, VSD 
(Chang et al., 2007) 
DHCR7 Smith-Lemli-
Poitz 
Syndrome 
270400 Yes (no 
cardiac 
phenotype)  
ASD type 
2, AVSD, 
VSD 
(Ryan et al., 1998; 
Smith et al., 1964; 
Wassif et al., 2001) 
ETS1 Jacobsen 
Syndrome 
147791 Yes (no 
reported 
atrial septal 
defect) 
ASD type 
2, VSD 
(Ye et al., 2010) 
EVC, EVC2 Ellis-van 
Creveld 
Syndrome 
225500 Yes (no 
cardiac 
phenotype) 
AVSD (Kamesui et al., 
1997; Ruiz-Perez et 
al., 2007; Tompson 
et al., 2007) 
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FGF8 22q11 
deletion 
syndrome 
(DiGeorge) 
188400 Yes ASD type 
2, VSD 
(Abu-Issa et al., 
2002; Frank et al., 
2002) 
GDF1 Ivemark 
Syndrome 
208530 Yes ASD type 
2, AVSD 
(Calabro et al., 
1988; Rankin et al., 
2000) 
GPC3 Simpson-
Golabi-
Behmel 
Syndrome 
312870 Yes  ASD type 
2, AVSD 
(mouse), 
VSD 
(Cano-Gauci et al., 
1999; Lin et al., 
1999; Ng et al., 
2009) 
JAG1,NOTCH Alagille 
Syndrome 
118450 Yes (no 
reported 
atrial septal 
defect) 
ASD, VSD (High et al., 2009; 
Hofmann et al., 
2012; Xie et al., 
2015) 
Kras pathway 
(KRAS, 
BRAF, MEK1, 
MEK2) 
Cardio-facio-
cutaneous 
Syndrome 
115150 Yes ASD type 
2, VSD 
(Armour and 
Allanson, 2008; 
Inoue et al., 2014) 
MKKS Kaufman-
McKusick 
Syndrome 
236700 Yes (no 
reported 
septal 
defect) 
AVSD (Fath et al., 2005; 
Owens et al., 2009) 
MLL2/KMT2D/
KDM6A 
Kabuki 
Syndrome 
147920 Yes (no 
reported 
cardiac 
defect) 
ASD type 
2, VSD 
(Bjornsson et al., 
2014; Digilio et al., 
2001; McMahon 
and Reardon, 2006; 
Niikawa et al., 
1988) 
NIPBL Cornelia de 
Lange 
Syndrome/Br
achmann de 
Lange 
Syndrome 
122470 Yes ASD type 
2, AVSD 
(D'Alessandro et 
al., 2015; Kawauchi 
et al., 2009; 
Selicorni et al., 
2009) 
NOTCH2 Alagille 
Syndrome 2 
610205 Yes ASD type 2 (McCright et al., 
2002; McDaniell et 
al., 2006) 
PITX2 Axenfield-
Reiger 
Syndrome 
180500 Yes ASD type 
2, VSD, 
AVSD 
(Ammirabile et al., 
2012; Cunningham 
et al., 1998; Feldt, 
1995; Kitamura et 
al., 1999) 
PTPN11 
(KRAS, 
SOS1, RAF1, 
BRAF, 
MKEK1, 
HRAS, NRAS, 
SHOC2, CBL, 
Noonan 
Syndrome 
163950 Yes ASD type 
2, VSD, 
AVSD 
(Araki et al., 2004; 
Burch et al., 1993; 
Croonen et al., 
2008; Marino et al., 
1999; Sznajer et al., 
2007) 
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NF1) 
TBX1 DiGeorge 
Syndrome 
188400 Yes AVSD, 
VSD 
(Rana et al., 2014) 
TBX5 Holt-Oram 
Syndrome 
142900 Yes  AVSD, 
ASD type 
2, VSD 
(Baban et al., 
2014a; Bruneau et 
al., 2001; Cross et 
al., 2000; Holt and 
Oram, 1960; 
Newbury-Ecob et 
al., 1996) 
TMEM67, 
KIF7 
Joubert 
Syndrome 
213300 Yes (no 
atrial septal 
defects 
reported) 
ASD type 
2, VSD 
(Abdelhamed et al., 
2015; Elmali et al., 
2007) 
Trisomy 13 Patau 
Syndrome 
- No ASD type 
2, VSD 
(Musewe et al., 
1990; Springett et 
al., 2015) 
Trisomy 18 Edwards 
Syndrome 
- No ASD type 
2, VSD 
(Bruns and 
Martinez, 2015; 
Oppenheimer-
Dekker et al., 1985; 
Springett et al., 
2015) 
Trisomy 21 
(AUTS2, 
CNN2, 
DSCR3, 
DYNLT3, 
NQO1, OFD1, 
PDIA4, PIGP, 
TTC3, 
TUBB2B, 
CRELD1, 
VEGFA 
pathway: 
COL6A1, 
COL6A2, 
FBLN2, 
FRZB, 
GATA5, SHH) 
Down 
Syndrome 
190685 Yes AVSD, 
VSD, ASD 
type 2 
(Ackerman et al., 
2012; Blom et al., 
2003; Epstein et al., 
1985; Freeman et 
al., 1998; Maslen et 
al., 2006; Miyabara 
et al., 1982; 
O'Doherty et al., 
2005; Park et al., 
1977; Ripoll et al., 
2012; Stoll et al., 
1998) 
Unknown 
(1q41-1q42) 
Fryns 
Syndrome 
229850 No ASD type 
2, VSD 
(Fryns et al., 1979; 
Lin et al., 2005) 
Unknown 
(8q24.13) 
Ritscher-
Schinzel 
Syndrome/ 
Cranial-
cerebello-
220210 No AVSD, 
ASD type I, 
ASD type 2 
(Hoo et al., 1994; 
Orstavik et al., 
1998; Ritscher et 
al., 1987) 
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cardiac (3C) 
Syndrome 
WHSC1 Wolf-
Hirschhorn 
Syndrome 
194190 Yes ASD type 
2, VSD 
(Hirschhorn et al., 
1965; Nimura et al., 
2009) 
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Table 1.2. Human genetic mutations associated with non-syndromic ASD. 
 
Gene OMIM Mouse Model? Phenotype Reference 
ACTC1 102540 Yes (no septal 
defect reported)  
ASD type 2, 
VSD 
(Matsson et al., 2008; 
Monserrat et al., 2007; 
Song et al., 2010) 
ALK2/ACVR1 102576 Yes AVSD (Smith et al., 2009; 
Wang et al., 2005) 
ALK3/BMPR1A 601299 Yes AVSD (Briggs et al., 2013; 
D'Alessandro et al., 
2015; Ma et al., 2005; 
Smith et al., 2009; 
Yang et al., 2006) 
ALK4/ACVR1B 601300 Yes (no cardiac 
defect reported)  
AVSD (Jornvall et al., 2004; 
Tomita-Mitchell et al., 
2012) 
APC 611371 Yes (no cardiac 
defect reported)  
AVSD (Oshima et al., 1995; 
Smith et al., 2009; Su 
et al., 1992) 
AVCR2B 602730 Yes ASD type 2, 
AVSD, VSD 
(Ma et al., 2012; Oh 
and Li, 1997) 
BMP4 112262 Yes AVSD, ASD 
type 2, VSD 
(Jiao et al., 2003; 
Posch et al., 2008) 
CEP152 613529 No AVSD (D'Alessandro et al., 
2015) 
CFC1 605194 Yes ASD type 2, 
VSD, AVSD 
(Gaio et al., 1999; 
Ozcelik et al., 2006; 
Wang et al., 2011) 
CITED2 602937 Yes ASD type 2, 
VSD 
(Bamforth et al., 2001; 
Bamforth et al., 2004; 
Barbera et al., 2002; 
Sperling et al., 2005; 
Yin et al., 2002) 
CRELD1 607171 No ASD type 2, 
AVSD, VSD 
(Maslen et al., 2006; 
Robinson et al., 2003; 
Zatyka et al., 2005) 
GATA4 600576 Yes ASD type 2, 
AVSD, VSD 
(Garg et al., 2003; 
Hirayama-Yamada et 
al., 2005; Moskowitz et 
al., 2011; Posch et al., 
2008; Reamon-
Buettner and Borlak, 
2005; Tomita-Mitchell 
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et al., 2007) 
GATA6 601656 Yes (no atrial 
septal defect 
reported) 
ASD type 2, 
AVSD, VSD 
(Lepore et al., 2006; 
Lin et al., 2010; Maitra 
et al., 2010; Morrisey et 
al., 1998; Wang et al., 
2012; Zheng et al., 
2012) 
GJA1 121014 Yes (no septal 
defect reported) 
ASD type 2, 
AVSD 
(Dasgupta et al., 2001; 
Reaume et al., 1995; 
Ya et al., 1998) 
HEY2 604674 Yes (no atrial 
septal defect 
reported) 
AVSD, VSD (Donovan et al., 2002; 
Fischer et al., 2004; 
Reamon-Buettner and 
Borlak, 2006) 
IFT25 - Yes AVSD (Keady et al., 2012) 
IFT88 600595 Yes ASD type 2, 
AVSD, VSD 
(Willaredt et al., 2012; 
Willaredt et al., 2008) 
LEFTY1/2 601877 Yes (no septal 
defect reported) 
AVSD (Kosaki et al., 1999; 
Meno et al., 2001) 
MDM4 602274 Yes (no cardiac 
defects 
reported) 
AVSD (D'Alessandro et al., 
2015; Xiong, 2013) 
MYH6 160710 Yes (no septal 
defect reported) 
ASD type 2 (Ching et al., 2005; 
Jiang et al., 2013) 
MYH7 160760 Yes (no septal 
defect reported) 
ASD type 2, 
VSD 
(Budde et al., 2007; 
Postma et al., 2011) 
NKX2.5 600584 Yes (no septal 
defect reported)  
ASD type 2, 
AVSD, VSD 
(Benson et al., 1999; 
Gutierrez-Roelens et 
al., 2006; Inga et al., 
2005; Reamon-
Buettner and Borlak, 
2004a; Schott et al., 
1998; Tanaka et al., 
1999) 
TBX5 601620 Yes ASD type 2, 
AVSD, VSD 
(Garg et al., 2003; 
Reamon-Buettner and 
Borlak, 2004b) 
TBX20 606061 Yes (no septal 
defect reported)  
ASD type 2 (Cai et al., 2005; Kirk et 
al., 2007; Posch et al., 
2010; Singh et al., 
2005; Stennard et al., 
2005) 
ZIC3 300265 Yes ASD type 2, 
AVSD, VSD 
(Ma et al., 2012; 
Purandare et al., 2002; 
Ware et al., 2004) 
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ZPFM2 (FOG2) 603693 Yes ASD type 2, 
AVSD, VSD 
(D'Alessandro et al., 
2015; Svensson et al., 
2000) 
3q22.1-3q26.1 
(FOXL2, NPHP3, 
FAM62C, CEP70, 
FAIM, PIK3CB, 
BPESC1) 
-  No AVSD (Erdogan et al., 2008; 
Priest et al., 2012) 
8p23.1 (GATA4, 
NEIL2, FDFT1, 
CSTB, SOX7) 
- No AVSD (Soemedi et al., 2012) 
(Tomita-Mitchell et al., 
2007) 
15q11.2 
(TUBGCP5, 
CYFIP1, NIPA1, 
NIPA2) 
- No ASD type 2, 
VSD 
(Soemedi et al., 2012) 
Xp22.2 (MID1) - No AVSD (Silversides et al., 
2012) 
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Table 1.3. Mouse genetic mutations associated with non-syndromic ASD. 
These defects are currently not associated with human patients with ASD.  
Gene OMIM Phenotype Reference 
Adam19 603640 ASD type 2, VSD (Zhou et al., 2004) 
Bmpr2 600799 ASD type 2, VSD (Beppu et al., 2009) 
Bmp6/7 112266/112267 ASD, VSD (Kim et al., 2001) 
Crtl1/Hapln1 118888 ASD type 2, 
AVSD, VSD 
(Watanabe and Yamada, 1999; 
Wirrig et al., 2007) 
Ctnnb1 116806 ASD type 2, VSD (Huh and Ornitz, 2010; Liebner 
et al., 2004; Lin et al., 2007) 
Cx40/Cx43 121013/121014 ASD type 2, 
AVSD 
(Kirchhoff et al., 2000) 
Ep300 602700 ASD type 2 (Shikama et al., 2003) 
EphA3 179611 ASD type 2, 
AVSD 
(Stephen et al., 2007) 
Ezh2 601573 AVSD type 2, 
VSD, AVSD 
(Chen et al., 2012) 
Fbln1 135820 ASD type 2, VSD (Cooley et al., 2008) 
Foxf1a/Fox2 - AVSD (Hoffmann et al., 2009) 
Has2 601636 Partial AVSD (Camenisch et al., 2000) 
Id2 600386 AVSD (Moskowitz et al., 2011) 
Nfatc 600489 AVSD, VSD (de la Pompa et al., 1998) 
Nt3 162600 ASD type 2, VSD (Donovan et al., 1996) 
Pdgfrα 173490 ASD type 2 (Bleyl et al., 2010) 
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Postn 608777 ASD type 2 (Norris et al., 2008) 
Rxrα 180245 AVSD, VSD (Dyson et al., 1995; Gruber et 
al., 1996) 
Shh 600725 ASD type 2/ 
AVSD 
(Goddeeris et al., 2008; 
Goddeeris et al., 2007; 
Washington Smoak et al., 2005) 
Sirt1 604479 ASD type 2, VSD (Cheng et al., 2003) 
Smo 601500 AVSD (Hoffmann et al., 2009) 
Tbx2 600747 AVSD (Harrelson et al., 2004) 
Tgfbr2 190182 ASD, VSD (Robson et al., 2010) 
Wnt2 147870 AVSD (Goss et al., 2009; Tian et al., 
2010) 
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Table 1.4. TBX5 mutations found in human patients with heart defects.  
Mutation 
 
Type of Mutation Cardiac phenotype Reference 
100delG 
(exon 2) 
Frameshift 1) ASD, VSD 
2) AVSD, VSD 
(Brassington et al., 2003) 
100-101insG 
(exon 2) 
Frameshift 1) ASD (2 patients) 
2) AV dissociation 
3) ASD, mitral valve 
defect 
(Borozdin et al., 2006; 
Brassington et al., 2003) 
Q49K Missense ASD (2 patients) (Yang et al., 2000) 
IVS2-1G>C Splice Mutation 1) VSD 
2) Unknown 
(Basson et al., 1999; Guo 
et al., 2015) 
IVS2-2C->A Splice Mutation Unknown (Basson et al., 1999) 
I54T Missense 1) ASD 
2) AVSD 
(Reamon-Buettner and 
Borlak, 2004b; Yang et al., 
2000) 
D61Y Missense Aortic/mitral valve 
prolapse 
(Dias et al., 2007) 
W64X Nonsense Unknown (Fan et al., 2003a) 
E69X Nonsense 1) AVSD 
2) Unknown (2 patients) 
(Basson et al., 1997; 
Basson et al., 1999; He et 
al., 2004) 
M74I Missense VSD, LV hypertrophy, 
ventricular tachycardia 
(Boogerd et al., 2010) 
M74V Missense ASD (Debeer et al., 2007) 
A79V Missense ASD (Reamon-Buettner and 
Borlak, 2004b) 
G80R  Missense Composite cardiac 
defects (19 patients) 
(Basson et al., 1999) 
IVS3-1 G>A Splice Mutation VSD (McDermott et al., 2005) 
IVS3-2 A>G Splice Mutation Conductive heart failure (Heinritz et al., 2005) 
246G>AA Frameshift Unknown (Basson et al., 1999) 
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K88X Nonsense 1) ASD, mitral valve 
prolapse 
2) None  
3) ASD  
(Garavelli et al., 2008) 
V89E Missense None (Furniss et al., 2009) 
280delC (exon 
4) 
Frameshift 1) VSD (2 patients) 
2) ASD, VSD 
(Heinritz et al., 2005) 
aa83insM Insertion Unknown (Basson et al., 1999) 
L94R Missense ASD, VSD (Boogerd et al., 2010) 
P96L Missense AVSD, Down Syndrome (Reamon-Buettner and 
Borlak, 2004b) 
Y100C Missense ASD (Reamon-Buettner and 
Borlak, 2004b) 
L102P Missense AVSD, Down Syndrome (Reamon-Buettner and 
Borlak, 2004b) 
I106V Missense None (2 patients) (Boogerd et al., 2010; 
McDermott et al., 2005) 
P108T Missense Tricuspid atresia (Yoshida et al., 2015) 
D111Y Missense DORV, VSD, ASD, PDA (Granados-Riveron et al., 
2012) 
Y114X Nonsense Conduction (McDermott et al., 2005) 
W121G Missense 1) ASD (3 patients) 
2) ASD, VSD 
(Brassington et al., 2003) 
IVS4+1G>T Splice Mutation VSD (McDermott et al., 2005) 
IVS4+2T->C Splice Mutation Unknown (Cross et al., 2000) 
G125R Missense 1) None (3 patients) 
2) atrial fibrillation (13 
patients) 
3) ASD 
4) VSD 
5) incomplete right 
bundle branch block 
(Postma et al., 2008) 
374delG (exon 
5) 
Frameshift ASD, VSD (Porto et al., 2010) 
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381-408del Deletion ASD, VSD, bradycardia, 
mitral valve prolapse (25 
patients) 
(Fan et al., 2003a) 
400-401insC 
(exon 5) 
Frameshift 1) VSD (3 patients) 
2) ASD 
3) ASD, VSD 
(Brassington et al., 2003) 
R134C Missense AVSD, Down Syndrome (Reamon-Buettner and 
Borlak, 2004b) 
Y136X Nonsense 1) ASD (6 patients) 
2) Conduction system 
defects, TOF 
(Gruenauer-Kloevekorn 
and Froster, 2003; Heinritz 
et al., 2005; McDermott et 
al., 2005) 
416delC Deletion ASD (Yang et al., 2000) 
aa140delD Deletion Unknown (Basson et al., 1999) 
420-432del Deletion Unknown (Basson et al., 1999) 
A143T Missense Dilated Cardiomyopathy (Zhou et al., 2015) 
T144I Missense AVSD, Down Syndrome (Reamon-Buettner and 
Borlak, 2004b) 
426-427insC 
(exon 5) 
Frameshift 1) ASD 
2) VSD (2 patients) 
3) ASD, VSD 
(Brassington et al., 2003) 
Q151X Nonsense ASD, mitral valve  (Borozdin et al., 2006) 
456delC (exon 
5) 
Frameshift ASD (Brassington et al., 2003) 
S154A Missense Dilated Cardiomyopathy (Zhang et al., 2015) 
467insA (exon 
5) 
Frameshift ASD (Heinritz et al., 2005) 
475-480dup6 Insertion ASD (Debeer et al., 2007) 
484ins46bp 
(exon5) 
Frameshift Aneurysm of the AS, 
brachycardia 
(Heinritz et al., 2005) 
504delT Frameshift 1) ASD, VSD, PDA 
2) mitral/tricuspid valve 
prolapse 
(Borozdin et al., 2006) 
G169R Missense Conotruncal 
malformation 
(Cross et al., 2000) 
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H170L Missense ASD, VSD (McDermott et al., 2005) 
E190X Missense Unknown (Basson et al., 1999) 
G195A Missense 1) PFO, assymetrical 
aortic valve 
2) Unknown 
(Brassington et al., 2003; 
Li et al., 1997) 
S196X Nonsense 1) VSD, TOF 
2) Unknown (2 patients) 
3) VSD (2 patients) 
(Basson et al., 1999; 
Brassington et al., 2003; 
Debeer et al., 2007; Li et 
al., 1997; McDermott et 
al., 2005) 
aa198insN Insertion Unknown (Basson et al., 1999) 
614-615 
insCCGT 
(exon 6) 
Frameshift 1) murmor in childhood, 
normal 
2) VSD 
(Brassington et al., 2003) 
641delG Frameshift 1) AVSD 
2) none 
3) Unknown 
(Borozdin et al., 2006) 
H220del Deletion AVSD, hypoplastic RV, 
AV insufficiency, 
pulmonary valve 
stenosis 
(Boogerd et al., 2010) 
T223M Missense 1) None (2 patients) 
2) ASD, VSD (4 
patients) 
3) VSD (2 patients) 
(Brassington et al., 2003) 
K226N Missense 1) ASD, pulmonary 
stenosis, mitral valve 
prolapse (2 patients) 
(Porto et al., 2010) 
T233M Missense ASD, VSD (McDermott et al., 2005) 
R237P Missense 1) ASD, persistent left 
superior vena cava 
2) ASD, VSD 
(Boogerd et al., 2010) 
R237Q Missense 1) PFO 
2) ASD (6 patients) 
3) ASD, incomplete right 
bundle branch block 
(Basson et al., 1997; 
Basson et al., 1999; 
Brassington et al., 2003; 
Debeer et al., 2007) 
R237W Missense 1) AVSD, VSD 
2) None 
3) ASD 
(Basson et al., 1999; 
Brassington et al., 2003) 
726-710del5 Deletion ASD (Debeer et al., 2007) 
727delG (exon 
8) 
Frameshift Unknown (Basson et al., 1999) 
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Q250X Nonsense ASD (McDermott et al., 2005) 
S252I Missense VSD (Cross et al., 2000) 
IVS7-1 G>A Splice Mutation VSD, conduction (McDermott et al., 2005) 
IVS7-3 C>G Splice Mutation ASD, VSD (Heinritz et al., 2005) 
IVS7+2 T>G Splice Mutation VSD (McDermott et al., 2005) 
S261C Missense 1) None (2 patients) 
2) DORV, AVSD 
(Brassington et al., 2003) 
V263M Missense Complete right bundle 
branch block, ASD, 
tricuspid valve prolapse, 
hypoplastic left ventricle 
(Faria et al., 2008) 
R264L Missense 1) VSD 
2) VSD, pulmonary 
atresia 
(Yoshida et al., 2015) 
K266R Missense AVSD, Down Syndrome (Reamon-Buettner and 
Borlak, 2004b) 
798delA (exon 
8) 
Frameshift ASD, VSD (Brassington et al., 2003) 
805delT Deletion Unknown (Cross et al., 2000) 
813-814 
delCA 
Frameshift ASD, Conduction 
system, LQT 
(McDermott et al., 2005) 
R279X Nonsense 1) Unknown 
2) ASD, VSD (2 
patients) 
3) AVSD 
4) VSD 
5) AVSD, aortic 
coarction, valve defects 
(Baban et al., 2014b; 
Brassington et al., 2003; 
Heinritz et al., 2005; Li et 
al., 1997; Porto et al., 
2010) 
Y291X Nonsense 1) VSD 
2) ASD 
(Borozdin et al., 2006) 
Q292R Missense AVSD (Reamon-Buettner and 
Borlak, 2004b) 
939delG Frameshift 1) ASD 
2) ASD, VSD 
(Borozdin et al., 2006) 
Q315X Nonsense ASD, VSD (McDermott et al., 2005) 
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E316X Nonsense Unknown (Cross et al., 2000) 
1024delT Frameshift ASD, VSD (Borozdin et al., 2006) 
Q362X Nonsense ASD, VSD, pulmonary 
vein anomaly 
(Heinritz et al., 2005) 
S372L Missense ASD, conduction (Baban et al., 2014b) 
1128delA Frameshift VSD, pulmonary 
hypertension 
(Debeer et al., 2007) 
aa 383insA Insertion Unknown (Li et al., 1997) 
aa 387insS Insertion Unknown (Basson et al., 1999) 
1304delT Deletion ASD, VSD, PDA, 
conduction 
(Muru et al., 2011) 
1333delC Frameshift 
(protein extended) 
ASD, VSD (Bohm et al., 2008) 
V452M Missense 1) None 
2) Truncus arteriosis 
(Brassington et al., 2003) 
Q456X Missense Patent ductus arteriosus (Borozdin et al., 2006) 
Exon 6 del Deletion 1) None 
2) ASD, VSD 
(Borozdin et al., 2006) 
Exon 9 del Deletion ASD (2 patients) (Borozdin et al., 2006) 
Ex3_9_del Deletion VSD (Akrami et al., 2001) 
Large 
intragenic 
duplication 
Duplication AVSD, pulmonary 
stenosis 
(Patel et al., 2012) 
Dup 12.q13.1-
>24.2 
Duplication VSD, FO (Dixon et al., 1993) 
T5:12 Translocation AVSD (Basson et al., 1999) 
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Figure 1.1: Formation of the atrial septum and atrial septal defects. (A) At 
E10.5, cardiac development at the beginning of atrial septation. (B) At E11.0 OS 
formation begins by apoptosis, and the SS arises to the right of the SP.  (C) At 
E14.5, septation is complete. The SS comes together leaving a space called the FO, 
which is responsible for shunting of blood until birth, when it is fused shut. The 
second heart field contributes to the dorsal mesenchymal protrusion, fusing the 
septum to the ECs, forming the AV septal complex. The valves are formed at this 
stage. Defects in this process lead to ASD type 2 (D) and ASD type 1/AVSD (E).
	  
35	  
REFERENCES 
 
Abdelhamed, Z.A., Natarajan, S., Wheway, G., Inglehearn, C.F., Toomes, C., 
Johnson, C.A., and Jagger, D.J. (2015). The Meckel-Gruber syndrome protein 
TMEM67 controls basal body positioning and epithelial branching morphogenesis in 
mice via the non-canonical Wnt pathway. Dis Model Mech 8, 527-541. 
Abu-Issa, R., Smyth, G., Smoak, I., Yamamura, K., and Meyers, E.N. (2002). Fgf8 is 
required for pharyngeal arch and cardiovascular development in the mouse. 
Development 129, 4613-4625. 
Ackerman, C., Locke, A.E., Feingold, E., Reshey, B., Espana, K., Thusberg, J., 
Mooney, S., Bean, L.J., Dooley, K.J., Cua, C.L., et al. (2012). An excess of 
deleterious variants in VEGF-A pathway genes in Down-syndrome-associated 
atrioventricular septal defects. Am J Hum Genet 91, 646-659. 
Ai, D., Fu, X., Wang, J., Lu, M.F., Chen, L., Baldini, A., Klein, W.H., and Martin, J.F. 
(2007). Canonical Wnt signaling functions in second heart field to promote right 
ventricular growth. Proc Natl Acad Sci U S A 104, 9319-9324. 
Akrami, S.M., Winter, R.M., Brook, J.D., and Armour, J.A. (2001). Detection of a 
large TBX5 deletion in a family with Holt-Oram syndrome. J Med Genet 38, E44. 
Ammirabile, G., Tessari, A., Pignataro, V., Szumska, D., Sutera Sardo, F., Benes, J., 
Jr., Balistreri, M., Bhattacharya, S., Sedmera, D., and Campione, M. (2012). Pitx2 
confers left morphological, molecular, and functional identity to the sinus venosus 
myocardium. Cardiovasc Res 93, 291-301. 
Anderson, R.H., Ho, S.Y., Falcao, S., Daliento, L., and Rigby, M.L. (1998). The 
diagnostic features of atrioventricular septal defect with common atrioventricular 
junction. Cardiol Young 8, 33-49. 
Araki, T., Mohi, M.G., Ismat, F.A., Bronson, R.T., Williams, I.R., Kutok, J.L., Yang, 
W., Pao, L.I., Gilliland, D.G., Epstein, J.A., et al. (2004). Mouse model of Noonan 
syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. 
Nat Med 10, 849-857. 
Armour, C.M., and Allanson, J.E. (2008). Further delineation of cardio-facio-
cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med 
Genet 45, 249-254. 
Arrechedera, H., Alvarez, M., Strauss, M., and Ayesta, C. (1987). Origin of 
mesenchymal tissue in the septum primum: a structural and ultrastructural study. J 
Mol Cell Cardiol 19, 641-651. 
36	  
Baban, A., Pitto, L., Pulignani, S., Cresci, M., Mariani, L., Gambacciani, C., Digilio, 
M.C., Pongiglione, G., and Albanese, S. (2014a). Holt-Oram syndrome with 
intermediate atrioventricular canal defect, and aortic coarctation: functional 
characterization of a de novo TBX5 mutation. Am J Med Genet A 164A, 1419-1424. 
Baban, A., Postma, A.V., Marini, M., Trocchio, G., Santilli, A., Pelegrini, M., Sirleto, 
P., Lerone, M., Albanese, S.B., Barnett, P., et al. (2014b). Identification of TBX5 
mutations in a series of 94 patients with Tetralogy of Fallot. Am J Med Genet A 
164A, 3100-3107. 
Bamforth, S.D., Braganca, J., Eloranta, J.J., Murdoch, J.N., Marques, F.I., Kranc, 
K.R., Farza, H., Henderson, D.J., Hurst, H.C., and Bhattacharya, S. (2001). Cardiac 
malformations, adrenal agenesis, neural crest defects and exencephaly in mice 
lacking Cited2, a new Tfap2 co-activator. Nat Genet 29, 469-474. 
Bamforth, S.D., Braganca, J., Farthing, C.R., Schneider, J.E., Broadbent, C., 
Michell, A.C., Clarke, K., Neubauer, S., Norris, D., Brown, N.A., et al. (2004). Cited2 
controls left-right patterning and heart development through a Nodal-Pitx2c pathway. 
Nat Genet 36, 1189-1196. 
Barbera, J.P., Rodriguez, T.A., Greene, N.D., Weninger, W.J., Simeone, A., Copp, 
A.J., Beddington, R.S., and Dunwoodie, S. (2002). Folic acid prevents exencephaly 
in Cited2 deficient mice. Hum Mol Genet 11, 283-293. 
Barisic, I., Boban, L., Greenlees, R., Garne, E., Wellesley, D., Calzolari, E., Addor, 
M.C., Arriola, L., Bergman, J.E., Braz, P., et al. (2014). Holt Oram syndrome: a 
registry-based study in Europe. Orphanet J Rare Dis 9, 156. 
Basson, C.T., Bachinsky, D.R., Lin, R.C., Levi, T., Elkins, J.A., Soults, J., Grayzel, 
D., Kroumpouzou, E., Traill, T.A., Leblanc-Straceski, J., et al. (1997). Mutations in 
human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram 
syndrome. Nat Genet 15, 30-35. 
Basson, C.T., Cowley, G.S., Solomon, S.D., Weissman, B., Poznanski, A.K., Traill, 
T.A., Seidman, J.G., and Seidman, C.E. (1994). The clinical and genetic spectrum of 
the Holt-Oram syndrome (heart-hand syndrome). N Engl J Med 330, 885-891. 
Basson, C.T., Huang, T., Lin, R.C., Bachinsky, D.R., Weremowicz, S., Vaglio, A., 
Bruzzone, R., Quadrelli, R., Lerone, M., Romeo, G., et al. (1999). Different TBX5 
interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl 
Acad Sci U S A 96, 2919-2924. 
Basson, C.T., Solomon, S.D., Weissman, B., MacRae, C.A., Poznanski, A.K., Prieto, 
F., Ruiz de la Fuente, S., Pease, W.E., Levin, S.E., Holmes, L.B., et al. (1995). 
Genetic heterogeneity of heart-hand syndromes. Circulation 91, 1326-1329. 
Benson, D.W., Silberbach, G.M., Kavanaugh-McHugh, A., Cottrill, C., Zhang, Y., 
Riggs, S., Smalls, O., Johnson, M.C., Watson, M.S., Seidman, J.G., et al. (1999). 
37	  
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac 
developmental pathways. J Clin Invest 104, 1567-1573. 
Beppu, H., Malhotra, R., Beppu, Y., Lepore, J.J., Parmacek, M.S., and Bloch, K.D. 
(2009). BMP type II receptor regulates positioning of outflow tract and remodeling of 
atrioventricular cushion during cardiogenesis. Dev Biol 331, 167-175. 
Bjornsson, H.T., Benjamin, J.S., Zhang, L., Weissman, J., Gerber, E.E., Chen, Y.C., 
Vaurio, R.G., Potter, M.C., Hansen, K.D., and Dietz, H.C. (2014). Histone 
deacetylase inhibition rescues structural and functional brain deficits in a mouse 
model of Kabuki syndrome. Sci Transl Med 6, 256ra135. 
Bleyl, S.B., Saijoh, Y., Bax, N.A., Gittenberger-de Groot, A.C., Wisse, L.J., 
Chapman, S.C., Hunter, J., Shiratori, H., Hamada, H., Yamada, S., et al. (2010). 
Dysregulation of the PDGFRA gene causes inflow tract anomalies including TAPVR: 
integrating evidence from human genetics and model organisms. Hum Mol Genet 
19, 1286-1301. 
Blom, N.A., Ottenkamp, J., Jongeneel, T.H., DeRuiter, M.C., and Gittenberger-de 
Groot, A.C. (2005). Morphogenetic differences of secundum atrial septal defects. 
Pediatr Cardiol 26, 338-343. 
Blom, N.A., Ottenkamp, J., Wenink, A.G., and Gittenberger-de Groot, A.C. (2003). 
Deficiency of the vestibular spine in atrioventricular septal defects in human fetuses 
with down syndrome. Am J Cardiol 91, 180-184. 
Boehme, D.H., and Shotar, A.O. (1989). A complex deformity of appendicular 
skeleton and shoulder with congenital heart disease in three generations of a 
Jordanian family. Clin Genet 36, 442-450. 
Bohm, J., Heinritz, W., Craig, A., Vujic, M., Ekman-Joelsson, B.M., Kohlhase, J., and 
Froster, U. (2008). Functional analysis of the novel TBX5 c.1333delC mutation 
resulting in an extended TBX5 protein. BMC Med Genet 9, 88. 
Bonnet, D., Pelet, A., Legeai-Mallet, L., Sidi, D., Mathieu, M., Parent, P., Plauchu, 
H., Serville, F., Schinzel, A., Weissenbach, J., et al. (1994). A gene for Holt-Oram 
syndrome maps to the distal long arm of chromosome 12. Nat Genet 6, 405-408. 
Boogerd, C.J., Dooijes, D., Ilgun, A., Mathijssen, I.B., Hordijk, R., van de Laar, I.M., 
Rump, P., Veenstra-Knol, H.E., Moorman, A.F., Barnett, P., et al. (2010). Functional 
analysis of novel TBX5 T-box mutations associated with Holt-Oram syndrome. 
Cardiovasc Res 88, 130-139. 
Borozdin, W., Bravo Ferrer Acosta, A.M., Bamshad, M.J., Botzenhart, E.M., Froster, 
U.G., Lemke, J., Schinzel, A., Spranger, S., McGaughran, J., Wand, D., et al. 
(2006). Expanding the spectrum of TBX5 mutations in Holt-Oram syndrome: 
detection of two intragenic deletions by quantitative real time PCR, and report of 
eight novel point mutations. Hum Mutat 27, 975-976. 
38	  
Bosman, E.A., Penn, A.C., Ambrose, J.C., Kettleborough, R., Stemple, D.L., and 
Steel, K.P. (2005). Multiple mutations in mouse Chd7 provide models for CHARGE 
syndrome. Hum Mol Genet 14, 3463-3476. 
Brassington, A.M., Sung, S.S., Toydemir, R.M., Le, T., Roeder, A.D., Rutherford, 
A.E., Whitby, F.G., Jorde, L.B., and Bamshad, M.J. (2003). Expressivity of Holt-
Oram syndrome is not predicted by TBX5 genotype. Am J Hum Genet 73, 74-85. 
Briggs, L.E., Phelps, A.L., Brown, E., Kakarla, J., Anderson, R.H., van den Hoff, 
M.J., and Wessels, A. (2013). Expression of the BMP receptor Alk3 in the second 
heart field is essential for development of the dorsal mesenchymal protrusion and 
atrioventricular septation. Circ Res 112, 1420-1432. 
Brown, D.D., Martz, S.N., Binder, O., Goetz, S.C., Price, B.M., Smith, J.C., and 
Conlon, F.L. (2005). Tbx5 and Tbx20 act synergistically to control vertebrate heart 
morphogenesis. Development 132, 553-563. 
Bruneau, B.G., Logan, M., Davis, N., Levi, T., Tabin, C.J., Seidman, J.G., and 
Seidman, C.E. (1999). Chamber-specific cardiac expression of Tbx5 and heart 
defects in Holt-Oram syndrome. Dev Biol 211, 100-108. 
Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S., 
Conner, D.A., Gessler, M., Nemer, M., Seidman, C.E., et al. (2001). A murine model 
of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in 
cardiogenesis and disease. Cell 106, 709-721. 
Bruns, D.A., and Martinez, A. (2015). An analysis of cardiac defects and surgical 
interventions in 84 cases with full trisomy 18. Am J Med Genet A. 
Budde, B.S., Binner, P., Waldmuller, S., Hohne, W., Blankenfeldt, W., Hassfeld, S., 
Bromsen, J., Dermintzoglou, A., Wieczorek, M., May, E., et al. (2007). 
Noncompaction of the ventricular myocardium is associated with a de novo mutation 
in the beta-myosin heavy chain gene. PLoS One 2, e1362. 
Burch, M., Sharland, M., Shinebourne, E., Smith, G., Patton, M., and McKenna, W. 
(1993). Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and 
echocardiographic assessment of 118 patients. J Am Coll Cardiol 22, 1189-1192. 
Cai, C.L., Liang, X., Shi, Y., Chu, P.H., Pfaff, S.L., Chen, J., and Evans, S. (2003). 
Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation 
and contributes a majority of cells to the heart. Dev Cell 5, 877-889. 
Cai, C.L., Zhou, W., Yang, L., Bu, L., Qyang, Y., Zhang, X., Li, X., Rosenfeld, M.G., 
Chen, J., and Evans, S. (2005). T-box genes coordinate regional rates of 
proliferation and regional specification during cardiogenesis. Development 132, 
2475-2487. 
39	  
Calabro, A., Taraschi, A., Lungarotti, M.S., and Ferdinandi, A. (1988). Familial situs 
inversus and congenital heart defects. Am J Med Genet 31, 689-690. 
Camarata, T., Bimber, B., Kulisz, A., Chew, T.L., Yeung, J., and Simon, H.G. (2006). 
LMP4 regulates Tbx5 protein subcellular localization and activity. J Cell Biol 174, 
339-348. 
Camarata, T., Krcmery, J., Snyder, D., Park, S., Topczewski, J., and Simon, H.G. 
(2010). Pdlim7 (LMP4) regulation of Tbx5 specifies zebrafish heart atrio-ventricular 
boundary and valve formation. Dev Biol 337, 233-245. 
Camenisch, T.D., Molin, D.G., Person, A., Runyan, R.B., Gittenberger-de Groot, 
A.C., McDonald, J.A., and Klewer, S.E. (2002). Temporal and distinct TGFbeta 
ligand requirements during mouse and avian endocardial cushion morphogenesis. 
Dev Biol 248, 170-181. 
Camenisch, T.D., Spicer, A.P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M.L., 
Calabro, A., Jr., Kubalak, S., Klewer, S.E., and McDonald, J.A. (2000). Disruption of 
hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-
mediated transformation of epithelium to mesenchyme. J Clin Invest 106, 349-360. 
Cano-Gauci, D.F., Song, H.H., Yang, H., McKerlie, C., Choo, B., Shi, W., Pullano, 
R., Piscione, T.D., Grisaru, S., Soon, S., et al. (1999). Glypican-3-deficient mice 
exhibit developmental overgrowth and some of the abnormalities typical of Simpson-
Golabi-Behmel syndrome. J Cell Biol 146, 255-264. 
Chang, C.P., Neilson, J.R., Bayle, J.H., Gestwicki, J.E., Kuo, A., Stankunas, K., 
Graef, I.A., and Crabtree, G.R. (2004). A field of myocardial-endocardial NFAT 
signaling underlies heart valve morphogenesis. Cell 118, 649-663. 
Chang, C.Y., Lin, S.P., Lin, H.Y., Chen, Y.J., Kao, H.A., Yeung, C.Y., Hsu, C.H., and 
Chi, H. (2007). Cri-du-chat syndrome. Acta Paediatr Taiwan 48, 328-331. 
Chen, L., Ma, Y., Kim, E.Y., Yu, W., Schwartz, R.J., Qian, L., and Wang, J. (2012). 
Conditional ablation of Ezh2 in murine hearts reveals its essential roles in 
endocardial cushion formation, cardiomyocyte proliferation and survival. PLoS One 
7, e31005. 
Cheng, H.L., Mostoslavsky, R., Saito, S., Manis, J.P., Gu, Y., Patel, P., Bronson, R., 
Appella, E., Alt, F.W., and Chua, K.F. (2003). Developmental defects and p53 
hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 
100, 10794-10799. 
Ching, Y.H., Ghosh, T.K., Cross, S.J., Packham, E.A., Honeyman, L., Loughna, S., 
Robinson, T.E., Dearlove, A.M., Ribas, G., Bonser, A.J., et al. (2005). Mutation in 
myosin heavy chain 6 causes atrial septal defect. Nat Genet 37, 423-428. 
40	  
Cohen, E.D., Wang, Z., Lepore, J.J., Lu, M.M., Taketo, M.M., Epstein, D.J., and 
Morrisey, E.E. (2007). Wnt/beta-catenin signaling promotes expansion of Isl-1-
positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest 
117, 1794-1804. 
Coll, M., Seidman, J.G., and Muller, C.W. (2002). Structure of the DNA-bound T-box 
domain of human TBX3, a transcription factor responsible for ulnar-mammary 
syndrome. Structure 10, 343-356. 
Cooley, M.A., Kern, C.B., Fresco, V.M., Wessels, A., Thompson, R.P., McQuinn, 
T.C., Twal, W.O., Mjaatvedt, C.H., Drake, C.J., and Argraves, W.S. (2008). Fibulin-1 
is required for morphogenesis of neural crest-derived structures. Dev Biol 319, 336-
345. 
Corsten-Janssen, N., du Marchie Sarvaas, G.J., Kerstjens-Frederikse, W.S., 
Hoefsloot, L.H., van Beynum, I.M., Kapusta, L., and van Ravenswaaij-Arts, C.M. 
(2014). CHD7 mutations are not a major cause of atrioventricular septal and 
conotruncal heart defects. Am J Med Genet A 164A, 3003-3009. 
Croonen, E.A., van der Burgt, I., Kapusta, L., and Draaisma, J.M. (2008). 
Electrocardiography in Noonan syndrome PTPN11 gene mutation--phenotype 
characterization. Am J Med Genet A 146A, 350-353. 
Cross, S.J., Ching, Y.H., Li, Q.Y., Armstrong-Buisseret, L., Spranger, S., Lyonnet, 
S., Bonnet, D., Penttinen, M., Jonveaux, P., Leheup, B., et al. (2000). The mutation 
spectrum in Holt-Oram syndrome. J Med Genet 37, 785-787. 
Csaba E, M.V., and Endre C (1991). Holt-Oram syndroma. Orvosi Hetilap 132, 73-
78. 
Cunningham, E.T., Jr., Eliott, D., Miller, N.R., Maumenee, I.H., and Green, W.R. 
(1998). Familial Axenfeld-Rieger anomaly, atrial septal defect, and sensorineural 
hearing loss: a possible new genetic syndrome. Arch Ophthalmol 116, 78-82. 
D'Alessandro, L.C., Al Turki, S., Manickaraj, A.K., Manase, D., Mulder, B.J., Bergin, 
L., Rosenberg, H.C., Mondal, T., Gordon, E., Lougheed, J., et al. (2015). Exome 
sequencing identifies rare variants in multiple genes in atrioventricular septal defect. 
Genet Med. 
Dasgupta, C., Martinez, A.M., Zuppan, C.W., Shah, M.M., Bailey, L.L., and Fletcher, 
W.H. (2001). Identification of connexin43 (alpha1) gap junction gene mutations in 
patients with hypoplastic left heart syndrome by denaturing gradient gel 
electrophoresis (DGGE). Mutat Res 479, 173-186. 
de la Pompa, J.L., Timmerman, L.A., Takimoto, H., Yoshida, H., Elia, A.J., Samper, 
E., Potter, J., Wakeham, A., Marengere, L., Langille, B.L., et al. (1998). Role of the 
NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 
392, 182-186. 
41	  
de Lange, F.J., Moorman, A.F., Anderson, R.H., Manner, J., Soufan, A.T., de Gier-
de Vries, C., Schneider, M.D., Webb, S., van den Hoff, M.J., and Christoffels, V.M. 
(2004). Lineage and morphogenetic analysis of the cardiac valves. Circ Res 95, 645-
654. 
Debeer, P., Race, V., Gewillig, M., Devriendt, K., and Frijns, J.P. (2007). Novel 
TBX5 mutations in patients with Holt-Oram syndrome. Clin Orthop Relat Res 462, 
20-26. 
Del Corso, L., Vannini, A., De Marco, S., Gnesi, A., and Pentimone, F. (1991). 
[Complete endocardial cushion defect and bone malformations of the hands. Holt-
Oram syndrome]. Minerva Med 82, 683-686. 
Dhanantwari, P., Lee, E., Krishnan, A., Samtani, R., Yamada, S., Anderson, S., 
Lockett, E., Donofrio, M., Shiota, K., Leatherbury, L., et al. (2009). Human cardiac 
development in the first trimester: a high-resolution magnetic resonance imaging and 
episcopic fluorescence image capture atlas. Circulation 120, 343-351. 
Dias, R.R., Albuquerque, J.M., Pereira, A.C., Stolf, N.A., Krieger, J.E., Mady, C., and 
Oliveira, S.A. (2007). Holt-Oram syndrome presenting as agenesis of the left 
pericardium. Int J Cardiol 114, 98-100. 
Digilio, M.C., Marino, B., Toscano, A., Giannotti, A., and Dallapiccola, B. (2001). 
Congenital heart defects in Kabuki syndrome. Am J Med Genet 100, 269-274. 
Dixon, J.W., Costa, T., and Teshima, I.E. (1993). Mosaicism for duplication 12q 
(12q13-->q24.2) in a dysmorphic male infant. J Med Genet 30, 70-72. 
Dolk, H., Loane, M., and Garne, E. (2010). The prevalence of congenital anomalies 
in Europe. Adv Exp Med Biol 686, 349-364. 
Donovan, J., Kordylewska, A., Jan, Y.N., and Utset, M.F. (2002). Tetralogy of fallot 
and other congenital heart defects in Hey2 mutant mice. Curr Biol 12, 1605-1610. 
Donovan, M.J., Hahn, R., Tessarollo, L., and Hempstead, B.L. (1996). Identification 
of an essential nonneuronal function of neurotrophin 3 in mammalian cardiac 
development. Nat Genet 14, 210-213. 
Drumheller, T., McGillivray, B.C., Behrner, D., MacLeod, P., McFadden, D.E., 
Roberson, J., Venditti, C., Chorney, K., Chorney, M., and Smith, D.I. (1996). Precise 
localisation of 3p25 breakpoints in four patients with the 3p-syndrome. J Med Genet 
33, 842-847. 
Dyson, E., Sucov, H.M., Kubalak, S.W., Schmid-Schonbein, G.W., DeLano, F.A., 
Evans, R.M., Ross, J., Jr., and Chien, K.R. (1995). Atrial-like phenotype is 
associated with embryonic ventricular failure in retinoid X receptor alpha -/- mice. 
Proc Natl Acad Sci U S A 92, 7386-7390. 
42	  
Elmali, M., Ozmen, Z., Ceyhun, M., Tokatlioglu, O., Incesu, L., and Diren, B. (2007). 
Joubert syndrome with atrial septal defect and persistent left superior vena cava. 
Diagn Interv Radiol 13, 94-96. 
Epstein, C.J., Cox, D.R., and Epstein, L.B. (1985). Mouse trisomy 16: an animal 
model of human trisomy 21 (Down syndrome). Ann N Y Acad Sci 450, 157-168. 
Erdogan, F., Larsen, L.A., Zhang, L., Tumer, Z., Tommerup, N., Chen, W., 
Jacobsen, J.R., Schubert, M., Jurkatis, J., Tzschach, A., et al. (2008). High 
frequency of submicroscopic genomic aberrations detected by tiling path array 
comparative genome hybridisation in patients with isolated congenital heart disease. 
J Med Genet 45, 704-709. 
Fan, C., Duhagon, M.A., Oberti, C., Chen, S., Hiroi, Y., Komuro, I., Duhagon, P.I., 
Canessa, R., and Wang, Q. (2003a). Novel TBX5 mutations and molecular 
mechanism for Holt-Oram syndrome. J Med Genet 40, e29. 
Fan, C., Liu, M., and Wang, Q. (2003b). Functional analysis of TBX5 missense 
mutations associated with Holt-Oram syndrome. J Biol Chem 278, 8780-8785. 
Faria, M.H., Rabenhorst, S.H., Pereira, A.C., and Krieger, J.E. (2008). A novel TBX5 
missense mutation (V263M) in a family with atrial septal defects and postaxial 
hexodactyly. Int J Cardiol 130, 30-35. 
Fath, M.A., Mullins, R.F., Searby, C., Nishimura, D.Y., Wei, J., Rahmouni, K., Davis, 
R.E., Tayeh, M.K., Andrews, M., Yang, B., et al. (2005). Mkks-null mice have a 
phenotype resembling Bardet-Biedl syndrome. Hum Mol Genet 14, 1109-1118. 
Feldt, R.H., Porter, C.J., Edwards, W.D., Puga, F.J., and Seward, J.B (1995). 
Atrioventricular septal defects. In Heart Disease in Infants, Children and 
Adolescents, G.C.E.e. al, ed. (Baltimore: Williams & Wilkins), pp. 704-710. 
Fischer, A., Schumacher, N., Maier, M., Sendtner, M., and Gessler, M. (2004). The 
Notch target genes Hey1 and Hey2 are required for embryonic vascular 
development. Genes Dev 18, 901-911. 
Frank, D.U., Fotheringham, L.K., Brewer, J.A., Muglia, L.J., Tristani-Firouzi, M., 
Capecchi, M.R., and Moon, A.M. (2002). An Fgf8 mouse mutant phenocopies 
human 22q11 deletion syndrome. Development 129, 4591-4603. 
Freeman, S.B., Taft, L.F., Dooley, K.J., Allran, K., Sherman, S.L., Hassold, T.J., 
Khoury, M.J., and Saker, D.M. (1998). Population-based study of congenital heart 
defects in Down syndrome. Am J Med Genet 80, 213-217. 
Fryns, J.P., Moerman, F., Goddeeris, P., Bossuyt, C., and Van den Berghe, H. 
(1979). A new lethal syndrome with cloudy corneae, diaphragmatic defects and 
distal limb deformities. Hum Genet 50, 65-70. 
43	  
Furniss, D., Kan, S.H., Taylor, I.B., Johnson, D., Critchley, P.S., Giele, H.P., and 
Wilkie, A.O. (2009). Genetic screening of 202 individuals with congenital limb 
malformations and requiring reconstructive surgery. J Med Genet 46, 730-735. 
Gaio, U., Schweickert, A., Fischer, A., Garratt, A.N., Muller, T., Ozcelik, C., Lankes, 
W., Strehle, M., Britsch, S., Blum, M., et al. (1999). A role of the cryptic gene in the 
correct establishment of the left-right axis. Curr Biol 9, 1339-1342. 
Garavelli, L., De Brasi, D., Verri, R., Guareschi, E., Cariola, F., Melis, D., Calcagno, 
G., Salvatore, F., Unger, S., Sebastio, G., et al. (2008). Holt-Oram syndrome 
associated with anomalies of the feet. Am J Med Genet A 146A, 1185-1189. 
Garg, V., Kathiriya, I.S., Barnes, R., Schluterman, M.K., King, I.N., Butler, C.A., 
Rothrock, C.R., Eapen, R.S., Hirayama-Yamada, K., Joo, K., et al. (2003). GATA4 
mutations cause human congenital heart defects and reveal an interaction with 
TBX5. Nature 424, 443-447. 
Ghosh, T.K., Packham, E.A., Bonser, A.J., Robinson, T.E., Cross, S.J., and Brook, 
J.D. (2001). Characterization of the TBX5 binding site and analysis of mutations that 
cause Holt-Oram syndrome. Hum Mol Genet 10, 1983-1994. 
Ghosh, T.K., Song, F.F., Packham, E.A., Buxton, S., Robinson, T.E., Ronksley, J., 
Self, T., Bonser, A.J., and Brook, J.D. (2009). Physical interaction between TBX5 
and MEF2C is required for early heart development. Mol Cell Biol 29, 2205-2218. 
Goddeeris, M.M., Rho, S., Petiet, A., Davenport, C.L., Johnson, G.A., Meyers, E.N., 
and Klingensmith, J. (2008). Intracardiac septation requires hedgehog-dependent 
cellular contributions from outside the heart. Development 135, 1887-1895. 
Goddeeris, M.M., Schwartz, R., Klingensmith, J., and Meyers, E.N. (2007). 
Independent requirements for Hedgehog signaling by both the anterior heart field 
and neural crest cells for outflow tract development. Development 134, 1593-1604. 
Goetz, S.C., Brown, D.D., and Conlon, F.L. (2006). TBX5 is required for embryonic 
cardiac cell cycle progression. Development 133, 2575-2584. 
Goss, A.M., Tian, Y., Tsukiyama, T., Cohen, E.D., Zhou, D., Lu, M.M., Yamaguchi, 
T.P., and Morrisey, E.E. (2009). Wnt2/2b and beta-catenin signaling are necessary 
and sufficient to specify lung progenitors in the foregut. Dev Cell 17, 290-298. 
Granados-Riveron, J.T., Pope, M., Bu'lock, F.A., Thornborough, C., Eason, J., 
Setchfield, K., Ketley, A., Kirk, E.P., Fatkin, D., Feneley, M.P., et al. (2012). 
Combined mutation screening of NKX2-5, GATA4, and TBX5 in congenital heart 
disease: multiple heterozygosity and novel mutations. Congenit Heart Dis 7, 151-
159. 
44	  
Green, E.K., Priestley, M.D., Waters, J., Maliszewska, C., Latif, F., and Maher, E.R. 
(2000). Detailed mapping of a congenital heart disease gene in chromosome 3p25. J 
Med Genet 37, 581-587. 
Gruber, P.J., Kubalak, S.W., Pexieder, T., Sucov, H.M., Evans, R.M., and Chien, 
K.R. (1996). RXR alpha deficiency confers genetic susceptibility for aortic sac, 
conotruncal, atrioventricular cushion, and ventricular muscle defects in mice. J Clin 
Invest 98, 1332-1343. 
Gruenauer-Kloevekorn, C., and Froster, U.G. (2003). Holt-Oram syndrome: a new 
mutation in the TBX5 gene in two unrelated families. Ann Genet 46, 19-23. 
Guo, Q., Shen, J., Liu, Y., Pu, T., Sun, K., and Chen, S. (2015). Exome Sequencing 
Identifies a c.148-1G>C Mutation of TBX5 in a Holt-Oram Family with Unusual 
Genotype-Phenotype Correlations. Cell Physiol Biochem 37, 1066-1074. 
Gutierrez-Roelens, I., De Roy, L., Ovaert, C., Sluysmans, T., Devriendt, K., Brunner, 
H.G., and Vikkula, M. (2006). A novel CSX/NKX2-5 mutation causes autosomal-
dominant AV block: are atrial fibrillation and syncopes part of the phenotype? Eur J 
Hum Genet 14, 1313-1316. 
Harrelson, Z., Kelly, R.G., Goldin, S.N., Gibson-Brown, J.J., Bollag, R.J., Silver, 
L.M., and Papaioannou, V.E. (2004). Tbx2 is essential for patterning the 
atrioventricular canal and for morphogenesis of the outflow tract during heart 
development. Development 131, 5041-5052. 
He, J., McDermott, D.A., Song, Y., Gilbert, F., Kligman, I., and Basson, C.T. (2004). 
Preimplantation genetic diagnosis of human congenital heart malformation and Holt-
Oram syndrome. Am J Med Genet A 126A, 93-98. 
Heinritz, W., Moschik, A., Kujat, A., Spranger, S., Heilbronner, H., Demuth, S., Bier, 
A., Tihanyi, M., Mundlos, S., Gruenauer-Kloevekorn, C., et al. (2005). Identification 
of new mutations in the TBX5 gene in patients with Holt-Oram syndrome. Heart 91, 
383-384. 
Heron, M., and Tejada-Vera, B. (2009). Deaths: leading causes for 2005. Natl Vital 
Stat Rep 58, 1-97. 
High, F.A., Jain, R., Stoller, J.Z., Antonucci, N.B., Lu, M.M., Loomes, K.M., Kaestner, 
K.H., Pear, W.S., and Epstein, J.A. (2009). Murine Jagged1/Notch signaling in the 
second heart field orchestrates Fgf8 expression and tissue-tissue interactions during 
outflow tract development. J Clin Invest 119, 1986-1996. 
Hirayama-Yamada, K., Kamisago, M., Akimoto, K., Aotsuka, H., Nakamura, Y., 
Tomita, H., Furutani, M., Imamura, S., Takao, A., Nakazawa, M., et al. (2005). 
Phenotypes with GATA4 or NKX2.5 mutations in familial atrial septal defect. Am J 
Med Genet A 135, 47-52. 
45	  
Hiroi, Y., Kudoh, S., Monzen, K., Ikeda, Y., Yazaki, Y., Nagai, R., and Komuro, I. 
(2001). Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte 
differentiation. Nat Genet 28, 276-280. 
Hirschhorn, K., Cooper, H.L., and Firschein, I.L. (1965). Deletion of short arms of 
chromosome 4-5 in a child with defects of midline fusion. Humangenetik 1, 479-482. 
Hoffmann, A.D., Peterson, M.A., Friedland-Little, J.M., Anderson, S.A., and 
Moskowitz, I.P. (2009). sonic hedgehog is required in pulmonary endoderm for atrial 
septation. Development 136, 1761-1770. 
Hoffmann, A.D., Yang, X.H., Burnicka-Turek, O., Bosman, J.D., Ren, X., Steimle, 
J.D., Vokes, S.A., McMahon, A.P., Kalinichenko, V.V., and Moskowitz, I.P. (2014). 
Foxf genes integrate tbx5 and hedgehog pathways in the second heart field for 
cardiac septation. PLoS Genet 10, e1004604. 
Hofmann, J.J., Briot, A., Enciso, J., Zovein, A.C., Ren, S., Zhang, Z.W., Radtke, F., 
Simons, M., Wang, Y., and Iruela-Arispe, M.L. (2012). Endothelial deletion of murine 
Jag1 leads to valve calcification and congenital heart defects associated with Alagille 
syndrome. Development 139, 4449-4460. 
Holmes, L.B. (1965). CONGENITAL HEART DISEASE AND UPPER-EXTREMITY 
DEFORMITIES: A REPORT OF TWO FAMILIES. N Engl J Med 272, 437-444. 
Holt, M., and Oram, S. (1960). Familial heart disease with skeletal malformations. Br 
Heart J 22, 236-242. 
Hoo, J.J., Kreiter, M., Halverson, N., and Perszyk, A. (1994). 3C (cranio-cerebello-
cardiac) syndrome: a recently delineated and easily recognizable congenital 
malformation syndrome. Am J Med Genet 52, 66-69. 
Howanietz, H., Frisch, H., Jedlicka-Kohler, I., and Steger, H. (1989). [Seckel 
dwarfism based on a personal case]. Klin Padiatr 201, 139-141. 
Huh, S.H., and Ornitz, D.M. (2010). Beta-catenin deficiency causes DiGeorge 
syndrome-like phenotypes through regulation of Tbx1. Development 137, 1137-
1147. 
Inga, A., Reamon-Buettner, S.M., Borlak, J., and Resnick, M.A. (2005). Functional 
dissection of sequence-specific NKX2-5 DNA binding domain mutations associated 
with human heart septation defects using a yeast-based system. Hum Mol Genet 14, 
1965-1975. 
Inoue, S., Moriya, M., Watanabe, Y., Miyagawa-Tomita, S., Niihori, T., Oba, D., Ono, 
M., Kure, S., Ogura, T., Matsubara, Y., et al. (2014). New BRAF knockin mice 
provide a pathogenetic mechanism of developmental defects and a therapeutic 
approach in cardio-facio-cutaneous syndrome. Hum Mol Genet 23, 6553-6566. 
46	  
Issekutz, K.A., Graham, J.M., Jr., Prasad, C., Smith, I.M., and Blake, K.D. (2005). An 
epidemiological analysis of CHARGE syndrome: preliminary results from a Canadian 
study. Am J Med Genet A 133A, 309-317. 
Jacobs, J.P., Burke, R.P., Quintessenza, J.A., and Mavroudis, C. (2000). Congenital 
Heart Surgery Nomenclature and Database Project: atrioventricular canal defect. 
Ann Thorac Surg 69, S36-43. 
Jiang, J., Wakimoto, H., Seidman, J.G., and Seidman, C.E. (2013). Allele-specific 
silencing of mutant Myh6 transcripts in mice suppresses hypertrophic 
cardiomyopathy. Science 342, 111-114. 
Jiao, K., Kulessa, H., Tompkins, K., Zhou, Y., Batts, L., Baldwin, H.S., and Hogan, 
B.L. (2003). An essential role of Bmp4 in the atrioventricular septation of the mouse 
heart. Genes Dev 17, 2362-2367. 
Jongmans, M.C., Admiraal, R.J., van der Donk, K.P., Vissers, L.E., Baas, A.F., 
Kapusta, L., van Hagen, J.M., Donnai, D., de Ravel, T.J., Veltman, J.A., et al. 
(2006). CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 
gene. J Med Genet 43, 306-314. 
Jornvall, H., Reissmann, E., Andersson, O., Mehrkash, M., and Ibanez, C.F. (2004). 
ALK7, a receptor for nodal, is dispensable for embryogenesis and left-right 
patterning in the mouse. Mol Cell Biol 24, 9383-9389. 
Kamesui, T., Seki, M., Tsubota, M., Endo, M., Watanabe, S., and Sato, H. (1997). [A 
case of Ellis-van Creveld syndrome with partial atrioventricular septal defect and 
double orifice mitral valve]. Nihon Kyobu Geka Gakkai Zasshi 45, 589-593. 
Kawauchi, S., Calof, A.L., Santos, R., Lopez-Burks, M.E., Young, C.M., Hoang, 
M.P., Chua, A., Lao, T., Lechner, M.S., Daniel, J.A., et al. (2009). Multiple organ 
system defects and transcriptional dysregulation in the Nipbl(+/-) mouse, a model of 
Cornelia de Lange Syndrome. PLoS Genet 5, e1000650. 
Keady, B.T., Samtani, R., Tobita, K., Tsuchya, M., San Agustin, J.T., Follit, J.A., 
Jonassen, J.A., Subramanian, R., Lo, C.W., and Pazour, G.J. (2012). IFT25 links the 
signal-dependent movement of Hedgehog components to intraflagellar transport. 
Dev Cell 22, 940-951. 
Kelly, R.G., Brown, N.A., and Buckingham, M.E. (2001). The arterial pole of the 
mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 
1, 435-440. 
Kim, R.Y., Robertson, E.J., and Solloway, M.J. (2001). Bmp6 and Bmp7 are required 
for cushion formation and septation in the developing mouse heart. Dev Biol 235, 
449-466. 
47	  
Kirchhoff, S., Kim, J.S., Hagendorff, A., Thonnissen, E., Kruger, O., Lamers, W.H., 
and Willecke, K. (2000). Abnormal cardiac conduction and morphogenesis in 
connexin40 and connexin43 double-deficient mice. Circ Res 87, 399-405. 
Kirk, E.P., Sunde, M., Costa, M.W., Rankin, S.A., Wolstein, O., Castro, M.L., Butler, 
T.L., Hyun, C., Guo, G., Otway, R., et al. (2007). Mutations in cardiac T-box factor 
gene TBX20 are associated with diverse cardiac pathologies, including defects of 
septation and valvulogenesis and cardiomyopathy. Am J Hum Genet 81, 280-291. 
Kitamura, K., Miura, H., Miyagawa-Tomita, S., Yanazawa, M., Katoh-Fukui, Y., 
Suzuki, R., Ohuchi, H., Suehiro, A., Motegi, Y., Nakahara, Y., et al. (1999). Mouse 
Pitx2 deficiency leads to anomalies of the ventral body wall, heart, extra- and 
periocular mesoderm and right pulmonary isomerism. Development 126, 5749-5758. 
Kosaki, K., Bassi, M.T., Kosaki, R., Lewin, M., Belmont, J., Schauer, G., and Casey, 
B. (1999). Characterization and mutation analysis of human LEFTY A and LEFTY B, 
homologues of murine genes implicated in left-right axis development. Am J Hum 
Genet 64, 712-721. 
Kozma, C., Slavotinek, A.M., and Meck, J.M. (2004). Segregation of a t(1;3) 
translocation in multiple affected family members with both types of adjacent-1 
segregants. Am J Med Genet A 124A, 118-128. 
Krause, A., Zacharias, W., Camarata, T., Linkhart, B., Law, E., Lischke, A., Miljan, 
E., and Simon, H.G. (2004). Tbx5 and Tbx4 transcription factors interact with a new 
chicken PDZ-LIM protein in limb and heart development. Dev Biol 273, 106-120. 
Krishnan, A., Samtani, R., Dhanantwari, P., Lee, E., Yamada, S., Shiota, K., 
Donofrio, M.T., Leatherbury, L., and Lo, C.W. (2014). A detailed comparison of 
mouse and human cardiac development. Pediatr Res 76, 500-507. 
Kulisz, A., and Simon, H.G. (2008). An evolutionarily conserved nuclear export 
signal facilitates cytoplasmic localization of the Tbx5 transcription factor. Mol Cell 
Biol 28, 1553-1564. 
Kumar, A., Van Mierop, L.H., and Epstein, M.L. (1994). Pathogenetic implications of 
muscular ventricular septal defect in Holt-Oram syndrome. Am J Cardiol 73, 993-
995. 
Kwon, C., Arnold, J., Hsiao, E.C., Taketo, M.M., Conklin, B.R., and Srivastava, D. 
(2007). Canonical Wnt signaling is a positive regulator of mammalian cardiac 
progenitors. Proc Natl Acad Sci U S A 104, 10894-10899. 
Lepore, J.J., Mericko, P.A., Cheng, L., Lu, M.M., Morrisey, E.E., and Parmacek, 
M.S. (2006). GATA-6 regulates semaphorin 3C and is required in cardiac neural 
crest for cardiovascular morphogenesis. J Clin Invest 116, 929-939. 
48	  
Lewandowski, S.L., Janardhan, H.P., Smee, K.M., Bachman, M., Sun, Z., Lazar, 
M.A., and Trivedi, C.M. (2014). Histone deacetylase 3 modulates Tbx5 activity to 
regulate early cardiogenesis. Hum Mol Genet 23, 3801-3809. 
Li, Q.Y., Newbury-Ecob, R.A., Terrett, J.A., Wilson, D.I., Curtis, A.R., Yi, C.H., 
Gebuhr, T., Bullen, P.J., Robson, S.C., Strachan, T., et al. (1997). Holt-Oram 
syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene 
family. Nat Genet 15, 21-29. 
Lickert, H., Takeuchi, J.K., Von Both, I., Walls, J.R., McAuliffe, F., Adamson, S.L., 
Henkelman, R.M., Wrana, J.L., Rossant, J., and Bruneau, B.G. (2004). Baf60c is 
essential for function of BAF chromatin remodelling complexes in heart 
development. Nature 432, 107-112. 
Liebner, S., Cattelino, A., Gallini, R., Rudini, N., Iurlaro, M., Piccolo, S., and Dejana, 
E. (2004). Beta-catenin is required for endothelial-mesenchymal transformation 
during heart cushion development in the mouse. J Cell Biol 166, 359-367. 
Lin, A.E., Neri, G., Hughes-Benzie, R., and Weksberg, R. (1999). Cardiac anomalies 
in the Simpson-Golabi-Behmel syndrome. Am J Med Genet 83, 378-381. 
Lin, A.E., Pober, B.R., Mullen, M.P., and Slavotinek, A.M. (2005). Cardiovascular 
malformations in Fryns syndrome: is there a pathogenic role for neural crest cells? 
Am J Med Genet A 139, 186-193. 
Lin, L., Bu, L., Cai, C.L., Zhang, X., and Evans, S. (2006). Isl1 is upstream of sonic 
hedgehog in a pathway required for cardiac morphogenesis. Dev Biol 295, 756-763. 
Lin, L., Cui, L., Zhou, W., Dufort, D., Zhang, X., Cai, C.L., Bu, L., Yang, L., Martin, J., 
Kemler, R., et al. (2007). Beta-catenin directly regulates Islet1 expression in 
cardiovascular progenitors and is required for multiple aspects of cardiogenesis. 
Proc Natl Acad Sci U S A 104, 9313-9318. 
Lin, X., Huo, Z., Liu, X., Zhang, Y., Li, L., Zhao, H., Yan, B., Liu, Y., Yang, Y., and 
Chen, Y.H. (2010). A novel GATA6 mutation in patients with tetralogy of Fallot or 
atrial septal defect. J Hum Genet 55, 662-667. 
Linhares, V.L., Almeida, N.A., Menezes, D.C., Elliott, D.A., Lai, D., Beyer, E.C., 
Campos de Carvalho, A.C., and Costa, M.W. (2004). Transcriptional regulation of 
the murine Connexin40 promoter by cardiac factors Nkx2-5, GATA4 and Tbx5. 
Cardiovasc Res 64, 402-411. 
Luna-Zurita, L., Prados, B., Grego-Bessa, J., Luxan, G., del Monte, G., Benguria, A., 
Adams, R.H., Perez-Pomares, J.M., and de la Pompa, J.L. (2010). Integration of a 
Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness 
regulates murine cardiac valve formation. J Clin Invest 120, 3493-3507. 
49	  
Ma, L., Lu, M.F., Schwartz, R.J., and Martin, J.F. (2005). Bmp2 is essential for 
cardiac cushion epithelial-mesenchymal transition and myocardial patterning. 
Development 132, 5601-5611. 
Ma, L., Selamet Tierney, E.S., Lee, T., Lanzano, P., and Chung, W.K. (2012). 
Mutations in ZIC3 and ACVR2B are a common cause of heterotaxy and associated 
cardiovascular anomalies. Cardiol Young 22, 194-201. 
Maitra, M., Koenig, S.N., Srivastava, D., and Garg, V. (2010). Identification of 
GATA6 sequence variants in patients with congenital heart defects. Pediatr Res 68, 
281-285. 
Maitra, M., Schluterman, M.K., Nichols, H.A., Richardson, J.A., Lo, C.W., Srivastava, 
D., and Garg, V. (2009). Interaction of Gata4 and Gata6 with Tbx5 is critical for 
normal cardiac development. Dev Biol 326, 368-377. 
Manasek, F.J. (1970). Sulfated extracellular matrix production in the embryonic heart 
and adjacent tissues. J Exp Zool 174, 415-439. 
Marcus, R.H., Marcus, B.D., and Levin, S.E. (1985). The upper limb-cardiovascular 
syndrome (Holt-Oram syndrome) in a South African family. S Afr Med J 67, 1013-
1014. 
Marino, B., Digilio, M.C., Toscano, A., Giannotti, A., and Dallapiccola, B. (1999). 
Congenital heart diseases in children with Noonan syndrome: An expanded cardiac 
spectrum with high prevalence of atrioventricular canal. J Pediatr 135, 703-706. 
Markwald, R.R., Fitzharris, T.P., and Manasek, F.J. (1977). Structural development 
of endocardial cushions. Am J Anat 148, 85-119. 
Markwald, R.R., and Smith, W.N. (1972). Distribution of mucosubstances in the 
developing rat heart. J Histochem Cytochem 20, 896-907. 
Maslen, C.L., Babcock, D., Robinson, S.W., Bean, L.J., Dooley, K.J., Willour, V.L., 
and Sherman, S.L. (2006). CRELD1 mutations contribute to the occurrence of 
cardiac atrioventricular septal defects in Down syndrome. Am J Med Genet A 140, 
2501-2505. 
Matsson, H., Eason, J., Bookwalter, C.S., Klar, J., Gustavsson, P., Sunnegardh, J., 
Enell, H., Jonzon, A., Vikkula, M., Gutierrez, I., et al. (2008). Alpha-cardiac actin 
mutations produce atrial septal defects. Hum Mol Genet 17, 256-265. 
McCormack, N., Molloy, E.L., and O'Dea, S. (2013). Bone morphogenetic proteins 
enhance an epithelial-mesenchymal transition in normal airway epithelial cells during 
restitution of a disrupted epithelium. Respir Res 14, 36. 
50	  
McCright, B., Lozier, J., and Gridley, T. (2002). A mouse model of Alagille syndrome: 
Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129, 1075-
1082. 
McDaniell, R., Warthen, D.M., Sanchez-Lara, P.A., Pai, A., Krantz, I.D., Piccoli, D.A., 
and Spinner, N.B. (2006). NOTCH2 mutations cause Alagille syndrome, a 
heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 79, 169-
173. 
McDermott, D.A., Bressan, M.C., He, J., Lee, J.S., Aftimos, S., Brueckner, M., 
Gilbert, F., Graham, G.E., Hannibal, M.C., Innis, J.W., et al. (2005). TBX5 genetic 
testing validates strict clinical criteria for Holt-Oram syndrome. Pediatr Res 58, 981-
986. 
McMahon, C.J., and Reardon, W. (2006). The spectrum of congenital cardiac 
malformations encountered in six children with Kabuki syndrome. Cardiol Young 16, 
30-33. 
Meno, C., Takeuchi, J., Sakuma, R., Koshiba-Takeuchi, K., Ohishi, S., Saijoh, Y., 
Miyazaki, J., ten Dijke, P., Ogura, T., and Hamada, H. (2001). Diffusion of nodal 
signaling activity in the absence of the feedback inhibitor Lefty2. Dev Cell 1, 127-
138. 
Miyabara, S., Gropp, A., and Winking, H. (1982). Trisomy 16 in the mouse fetus 
associated with generalized edema and cardiovascular and urinary tract anomalies. 
Teratology 25, 369-380. 
Mjaatvedt, C.H., Nakaoka, T., Moreno-Rodriguez, R., Norris, R.A., Kern, M.J., 
Eisenberg, C.A., Turner, D., and Markwald, R.R. (2001). The outflow tract of the 
heart is recruited from a novel heart-forming field. Dev Biol 238, 97-109. 
Mommersteeg, M.T., Soufan, A.T., de Lange, F.J., van den Hoff, M.J., Anderson, 
R.H., Christoffels, V.M., and Moorman, A.F. (2006). Two distinct pools of 
mesenchyme contribute to the development of the atrial septum. Circ Res 99, 351-
353. 
Monserrat, L., Hermida-Prieto, M., Fernandez, X., Rodriguez, I., Dumont, C., Cazon, 
L., Cuesta, M.G., Gonzalez-Juanatey, C., Peteiro, J., Alvarez, N., et al. (2007). 
Mutation in the alpha-cardiac actin gene associated with apical hypertrophic 
cardiomyopathy, left ventricular non-compaction, and septal defects. Eur Heart J 28, 
1953-1961. 
Mori, A.D., Zhu, Y., Vahora, I., Nieman, B., Koshiba-Takeuchi, K., Davidson, L., 
Pizard, A., Seidman, J.G., Seidman, C.E., Chen, X.J., et al. (2006). Tbx5-dependent 
rheostatic control of cardiac gene expression and morphogenesis. Dev Biol 297, 
566-586. 
51	  
Morrisey, E.E., Tang, Z., Sigrist, K., Lu, M.M., Jiang, F., Ip, H.S., and Parmacek, 
M.S. (1998). GATA6 regulates HNF4 and is required for differentiation of visceral 
endoderm in the mouse embryo. Genes Dev 12, 3579-3590. 
Moskowitz, I.P., Wang, J., Peterson, M.A., Pu, W.T., Mackinnon, A.C., Oxburgh, L., 
Chu, G.C., Sarkar, M., Berul, C., Smoot, L., et al. (2011). Transcription factor genes 
Smad4 and Gata4 cooperatively regulate cardiac valve development. [corrected]. 
Proc Natl Acad Sci U S A 108, 4006-4011. 
Muller, C.W., and Herrmann, B.G. (1997). Crystallographic structure of the T 
domain-DNA complex of the Brachyury transcription factor. Nature 389, 884-888. 
Murakami, M., Nakagawa, M., Olson, E.N., and Nakagawa, O. (2005). A WW 
domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated 
in Holt-Oram syndrome. Proc Natl Acad Sci U S A 102, 18034-18039. 
Muru, K., Kalev, I., Teek, R., Sonajalg, M., Kuuse, K., Reimand, T., and Ounap, K. 
(2011). A Boy with Holt-Oram Syndrome Caused by Novel Mutation c.1304delT in 
the TBX5 Gene. Mol Syndromol 1, 307-310. 
Musewe, N.N., Alexander, D.J., Teshima, I., Smallhorn, J.F., and Freedom, R.M. 
(1990). Echocardiographic evaluation of the spectrum of cardiac anomalies 
associated with trisomy 13 and trisomy 18. J Am Coll Cardiol 15, 673-677. 
Newbury-Ecob, R.A., Leanage, R., Raeburn, J.A., and Young, I.D. (1996). Holt-
Oram syndrome: a clinical genetic study. J Med Genet 33, 300-307. 
Ng, A., Wong, M., Viviano, B., Erlich, J.M., Alba, G., Pflederer, C., Jay, P.Y., and 
Saunders, S. (2009). Loss of glypican-3 function causes growth factor-dependent 
defects in cardiac and coronary vascular development. Dev Biol 335, 208-215. 
Niikawa, N., Kuroki, Y., Kajii, T., Matsuura, N., Ishikiriyama, S., Tonoki, H., Ishikawa, 
N., Yamada, Y., Fujita, M., Umemoto, H., et al. (1988). Kabuki make-up (Niikawa-
Kuroki) syndrome: a study of 62 patients. Am J Med Genet 31, 565-589. 
Nimura, K., Ura, K., Shiratori, H., Ikawa, M., Okabe, M., Schwartz, R.J., and Kaneda, 
Y. (2009). A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-
Hirschhorn syndrome. Nature 460, 287-291. 
Norris, R.A., Moreno-Rodriguez, R.A., Sugi, Y., Hoffman, S., Amos, J., Hart, M.M., 
Potts, J.D., Goodwin, R.L., and Markwald, R.R. (2008). Periostin regulates 
atrioventricular valve maturation. Dev Biol 316, 200-213. 
O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M.L., Cooke, S., Sesay, 
A., Modino, S., Vanes, L., Hernandez, D., et al. (2005). An aneuploid mouse strain 
carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 
2033-2037. 
52	  
Oh, S.P., and Li, E. (1997). The signaling pathway mediated by the type IIB activin 
receptor controls axial patterning and lateral asymmetry in the mouse. Genes Dev 
11, 1812-1826. 
Oike, Y., Hata, A., Mamiya, T., Kaname, T., Noda, Y., Suzuki, M., Yasue, H., 
Nabeshima, T., Araki, K., and Yamamura, K. (1999). Truncated CBP protein leads to 
classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a 
dominant-negative mechanism. Hum Mol Genet 8, 387-396. 
Oppenheimer-Dekker, A., Gittenberger-de Groot, A.C., Bartelings, M.M., Wenink, 
A.C., Moene, R.J., and van der Harten, J.J. (1985). Abnormal architecture of the 
ventricles in hearts with an overriding aortic valve and a perimembranous ventricular 
septal defect ("Eisenmenger VSD"). Int J Cardiol 9, 341-355. 
Orstavik, K.H., Bechensteen, A.G., Fugelseth, D., and Orderud, W. (1998). Sibs with 
Ritscher-Schinzel (3C) syndrome and anal malformations. Am J Med Genet 75, 300-
303. 
Oshima, M., Oshima, H., Kitagawa, K., Kobayashi, M., Itakura, C., and Taketo, M. 
(1995). Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal 
polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A 92, 4482-
4486. 
Owens, G.E., Gomez-Fifer, C., Gelehrter, S., and Owens, S.T. (2009). Outcomes for 
patients with unbalanced atrioventricular septal defects. Pediatr Cardiol 30, 431-435. 
Ozcelik, C., Bit-Avragim, N., Panek, A., Gaio, U., Geier, C., Lange, P.E., Dietz, R., 
Posch, M.G., Perrot, A., and Stiller, B. (2006). Mutations in the EGF-CFC gene 
cryptic are an infrequent cause of congenital heart disease. Pediatr Cardiol 27, 695-
698. 
Papaioannou, V.E., and Silver, L.M. (1998). The T-box gene family. Bioessays 20, 9-
19. 
Park, S.C., Mathews, R.A., Zuberbuhler, J.R., Rowe, R.D., Neches, W.H., and 
Lenox, C.C. (1977). Down syndrome with congenital heart malformation. Am J Dis 
Child 131, 29-33. 
Patel, C., Silcock, L., McMullan, D., Brueton, L., and Cox, H. (2012). TBX5 intragenic 
duplication: a family with an atypical Holt-Oram syndrome phenotype. Eur J Hum 
Genet 20, 863-869. 
Plageman, T.F., Jr., and Yutzey, K.E. (2004). Differential expression and function of 
Tbx5 and Tbx20 in cardiac development. J Biol Chem 279, 19026-19034. 
Porto, M.P., Vergani, N., Carvalho, A.C., Cernach, M.C., Brunoni, D., and Perez, 
A.B. (2010). Novel mutations in the TBX5 gene in patients with Holt-Oram 
Syndrome. Genet Mol Biol 33, 232-236. 
53	  
Posch, M.G., Gramlich, M., Sunde, M., Schmitt, K.R., Lee, S.H., Richter, S., Kersten, 
A., Perrot, A., Panek, A.N., Al Khatib, I.H., et al. (2010). A gain-of-function TBX20 
mutation causes congenital atrial septal defects, patent foramen ovale and cardiac 
valve defects. J Med Genet 47, 230-235. 
Posch, M.G., Perrot, A., Schmitt, K., Mittelhaus, S., Esenwein, E.M., Stiller, B., 
Geier, C., Dietz, R., Gessner, R., Ozcelik, C., et al. (2008). Mutations in GATA4, 
NKX2.5, CRELD1, and BMP4 are infrequently found in patients with congenital 
cardiac septal defects. Am J Med Genet A 146A, 251-253. 
Postma, A.V., van de Meerakker, J.B., Mathijssen, I.B., Barnett, P., Christoffels, 
V.M., Ilgun, A., Lam, J., Wilde, A.A., Lekanne Deprez, R.H., and Moorman, A.F. 
(2008). A gain-of-function TBX5 mutation is associated with atypical Holt-Oram 
syndrome and paroxysmal atrial fibrillation. Circ Res 102, 1433-1442. 
Postma, A.V., van Engelen, K., van de Meerakker, J., Rahman, T., Probst, S., 
Baars, M.J., Bauer, U., Pickardt, T., Sperling, S.R., Berger, F., et al. (2011). 
Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet 
4, 43-50. 
Priest, J.R., Girirajan, S., Vu, T.H., Olson, A., Eichler, E.E., and Portman, M.A. 
(2012). Rare copy number variants in isolated sporadic and syndromic 
atrioventricular septal defects. Am J Med Genet A 158A, 1279-1284. 
Purandare, S.M., Ware, S.M., Kwan, K.M., Gebbia, M., Bassi, M.T., Deng, J.M., 
Vogel, H., Behringer, R.R., Belmont, J.W., and Casey, B. (2002). A complex 
syndrome of left-right axis, central nervous system and axial skeleton defects in Zic3 
mutant mice. Development 129, 2293-2302. 
Rana, M.S., Theveniau-Ruissy, M., De Bono, C., Mesbah, K., Francou, A., Rammah, 
M., Dominguez, J.N., Roux, M., Laforest, B., Anderson, R.H., et al. (2014). Tbx1 
coordinates addition of posterior second heart field progenitor cells to the arterial 
and venous poles of the heart. Circ Res 115, 790-799. 
Rankin, C.T., Bunton, T., Lawler, A.M., and Lee, S.J. (2000). Regulation of left-right 
patterning in mice by growth/differentiation factor-1. Nat Genet 24, 262-265. 
Reamon-Buettner, S.M., and Borlak, J. (2004a). Somatic NKX2-5 mutations as a 
novel mechanism of disease in complex congenital heart disease. J Med Genet 41, 
684-690. 
Reamon-Buettner, S.M., and Borlak, J. (2004b). TBX5 mutations in non-Holt-Oram 
syndrome (HOS) malformed hearts. Hum Mutat 24, 104. 
Reamon-Buettner, S.M., and Borlak, J. (2005). GATA4 zinc finger mutations as a 
molecular rationale for septation defects of the human heart. J Med Genet 42, e32. 
54	  
Reamon-Buettner, S.M., and Borlak, J. (2006). HEY2 mutations in malformed 
hearts. Hum Mutat 27, 118. 
Reaume, A.G., de Sousa, P.A., Kulkarni, S., Langille, B.L., Zhu, D., Davies, T.C., 
Juneja, S.C., Kidder, G.M., and Rossant, J. (1995). Cardiac malformation in 
neonatal mice lacking connexin43. Science 267, 1831-1834. 
Redig, J.K., Fouad, G.T., Babcock, D., Reshey, B., Feingold, E., Reeves, R.H., and 
Maslen, C.L. (2014). Allelic Interaction between and in the Pathogenesis of Cardiac 
Atrioventricular Septal Defects. AIMS Genet 1, 1-19. 
Ripoll, C., Rivals, I., Ait Yahya-Graison, E., Dauphinot, L., Paly, E., Mircher, C., 
Ravel, A., Grattau, Y., Blehaut, H., Megarbane, A., et al. (2012). Molecular 
signatures of cardiac defects in Down syndrome lymphoblastoid cell lines suggest 
altered ciliome and Hedgehog pathways. PLoS One 7, e41616. 
Ritscher, D., Schinzel, A., Boltshauser, E., Briner, J., Arbenz, U., and Sigg, P. 
(1987). Dandy-Walker(like) malformation, atrio-ventricular septal defect and a similar 
pattern of minor anomalies in 2 sisters: a new syndrome? Am J Med Genet 26, 481-
491. 
Rivera-Feliciano, J., and Tabin, C.J. (2006). Bmp2 instructs cardiac progenitors to 
form the heart-valve-inducing field. Dev Biol 295, 580-588. 
Robinson, S.W., Morris, C.D., Goldmuntz, E., Reller, M.D., Jones, M.A., Steiner, 
R.D., and Maslen, C.L. (2003). Missense mutations in CRELD1 are associated with 
cardiac atrioventricular septal defects. Am J Hum Genet 72, 1047-1052. 
Robson, A., Allinson, K.R., Anderson, R.H., Henderson, D.J., and Arthur, H.M. 
(2010). The TGFbeta type II receptor plays a critical role in the endothelial cells 
during cardiac development. Dev Dyn 239, 2435-2442. 
Rodgers, L.S., Lalani, S., Hardy, K.M., Xiang, X., Broka, D., Antin, P.B., and 
Camenisch, T.D. (2006). Depolymerized hyaluronan induces vascular endothelial 
growth factor, a negative regulator of developmental epithelial-to-mesenchymal 
transformation. Circ Res 99, 583-589. 
Ruiz-Perez, V.L., Blair, H.J., Rodriguez-Andres, M.E., Blanco, M.J., Wilson, A., Liu, 
Y.N., Miles, C., Peters, H., and Goodship, J.A. (2007). Evc is a positive mediator of 
Ihh-regulated bone growth that localises at the base of chondrocyte cilia. 
Development 134, 2903-2912. 
Ryan, A.K., Bartlett, K., Clayton, P., Eaton, S., Mills, L., Donnai, D., Winter, R.M., 
and Burn, J. (1998). Smith-Lemli-Opitz syndrome: a variable clinical and biochemical 
phenotype. J Med Genet 35, 558-565. 
55	  
Schott, J.J., Benson, D.W., Basson, C.T., Pease, W., Silberbach, G.M., Moak, J.P., 
Maron, B.J., Seidman, C.E., and Seidman, J.G. (1998). Congenital heart disease 
caused by mutations in the transcription factor NKX2-5. Science 281, 108-111. 
Selicorni, A., Colli, A.M., Passarini, A., Milani, D., Cereda, A., Cerutti, M., Maitz, S., 
Alloni, V., Salvini, L., Galli, M.A., et al. (2009). Analysis of congenital heart defects in 
87 consecutive patients with Brachmann-de Lange syndrome. Am J Med Genet A 
149A, 1268-1272. 
Shikama, N., Lutz, W., Kretzschmar, R., Sauter, N., Roth, J.F., Marino, S., Wittwer, 
J., Scheidweiler, A., and Eckner, R. (2003). Essential function of p300 
acetyltransferase activity in heart, lung and small intestine formation. EMBO J 22, 
5175-5185. 
Silversides, C.K., Lionel, A.C., Costain, G., Merico, D., Migita, O., Liu, B., Yuen, T., 
Rickaby, J., Thiruvahindrapuram, B., Marshall, C.R., et al. (2012). Rare copy number 
variations in adults with tetralogy of Fallot implicate novel risk gene pathways. PLoS 
Genet 8, e1002843. 
Singh, M.K., Christoffels, V.M., Dias, J.M., Trowe, M.O., Petry, M., Schuster-
Gossler, K., Burger, A., Ericson, J., and Kispert, A. (2005). Tbx20 is essential for 
cardiac chamber differentiation and repression of Tbx2. Development 132, 2697-
2707. 
Sletten, L.J., and Pierpont, M.E. (1996). Variation in severity of cardiac disease in 
Holt-Oram syndrome. Am J Med Genet 65, 128-132. 
Smemo, S., Campos, L.C., Moskowitz, I.P., Krieger, J.E., Pereira, A.C., and 
Nobrega, M.A. (2012). Regulatory variation in a TBX5 enhancer leads to isolated 
congenital heart disease. Hum Mol Genet 21, 3255-3263. 
Smith, A.T., Sack, G.H., Jr., and Taylor, G.J. (1979). Holt-Oram syndrome. J Pediatr 
95, 538-543. 
Smith, D.W., Lemli, L., and Opitz, J.M. (1964). A NEWLY RECOGNIZED 
SYNDROME OF MULTIPLE CONGENITAL ANOMALIES. J Pediatr 64, 210-217. 
Smith, K.A., Joziasse, I.C., Chocron, S., van Dinther, M., Guryev, V., Verhoeven, 
M.C., Rehmann, H., van der Smagt, J.J., Doevendans, P.A., Cuppen, E., et al. 
(2009). Dominant-negative ALK2 allele associates with congenital heart defects. 
Circulation 119, 3062-3069. 
Soemedi, R., Wilson, I.J., Bentham, J., Darlay, R., Topf, A., Zelenika, D., Cosgrove, 
C., Setchfield, K., Thornborough, C., Granados-Riveron, J., et al. (2012). 
Contribution of global rare copy-number variants to the risk of sporadic congenital 
heart disease. Am J Hum Genet 91, 489-501. 
56	  
Song, W., Dyer, E., Stuckey, D., Leung, M.C., Memo, M., Mansfield, C., Ferenczi, 
M., Liu, K., Redwood, C., Nowak, K., et al. (2010). Investigation of a transgenic 
mouse model of familial dilated cardiomyopathy. J Mol Cell Cardiol 49, 380-389. 
Sperling, S., Grimm, C.H., Dunkel, I., Mebus, S., Sperling, H.P., Ebner, A., Galli, R., 
Lehrach, H., Fusch, C., Berger, F., et al. (2005). Identification and functional analysis 
of CITED2 mutations in patients with congenital heart defects. Hum Mutat 26, 575-
582. 
Springett, A., Wellesley, D., Greenlees, R., Loane, M., Addor, M.C., Arriola, L., 
Bergman, J., Cavero-Carbonell, C., Csaky-Szunyogh, M., Draper, E.S., et al. (2015). 
Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based 
study in 16 european countries, 2000-2011. Am J Med Genet A. 
Stennard, F.A., Costa, M.W., Lai, D., Biben, C., Furtado, M.B., Solloway, M.J., 
McCulley, D.J., Leimena, C., Preis, J.I., Dunwoodie, S.L., et al. (2005). Murine T-box 
transcription factor Tbx20 acts as a repressor during heart development, and is 
essential for adult heart integrity, function and adaptation. Development 132, 2451-
2462. 
Stephen, L.J., Fawkes, A.L., Verhoeve, A., Lemke, G., and Brown, A. (2007). A 
critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 
302, 66-79. 
Stevens, C.A., and Bhakta, M.G. (1995). Cardiac abnormalities in the Rubinstein-
Taybi syndrome. Am J Med Genet 59, 346-348. 
Stirnimann, C.U., Ptchelkine, D., Grimm, C., and Muller, C.W. (2010). Structural 
basis of TBX5-DNA recognition: the T-box domain in its DNA-bound and -unbound 
form. J Mol Biol 400, 71-81. 
Stoll, C., Alembik, Y., Dott, B., and Roth, M.P. (1998). Study of Down syndrome in 
238,942 consecutive births. Ann Genet 41, 44-51. 
Su, L.K., Kinzler, K.W., Vogelstein, B., Preisinger, A.C., Moser, A.R., Luongo, C., 
Gould, K.A., and Dove, W.F. (1992). Multiple intestinal neoplasia caused by a 
mutation in the murine homolog of the APC gene. Science 256, 668-670. 
Svensson, E.C., Huggins, G.S., Lin, H., Clendenin, C., Jiang, F., Tufts, R., Dardik, 
F.B., and Leiden, J.M. (2000). A syndrome of tricuspid atresia in mice with a 
targeted mutation of the gene encoding Fog-2. Nat Genet 25, 353-356. 
Sznajer, Y., Keren, B., Baumann, C., Pereira, S., Alberti, C., Elion, J., Cave, H., and 
Verloes, A. (2007). The spectrum of cardiac anomalies in Noonan syndrome as a 
result of mutations in the PTPN11 gene. Pediatrics 119, e1325-1331. 
Takeuchi, J.K., and Bruneau, B.G. (2009). Directed transdifferentiation of mouse 
mesoderm to heart tissue by defined factors. Nature 459, 708-711. 
57	  
Takeuchi, J.K., Lou, X., Alexander, J.M., Sugizaki, H., Delgado-Olguin, P., Holloway, 
A.K., Mori, A.D., Wylie, J.N., Munson, C., Zhu, Y., et al. (2011). Chromatin 
remodelling complex dosage modulates transcription factor function in heart 
development. Nat Commun 2, 187. 
Tanaka, M., Chen, Z., Bartunkova, S., Yamasaki, N., and Izumo, S. (1999). The 
cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes 
essential for heart development. Development 126, 1269-1280. 
Terrett, J.A., Newbury-Ecob, R., Cross, G.S., Fenton, I., Raeburn, J.A., Young, I.D., 
and Brook, J.D. (1994). Holt-Oram syndrome is a genetically heterogeneous disease 
with one locus mapping to human chromosome 12q. Nat Genet 6, 401-404. 
Terrett, J.A., Newbury-Ecob, R., Smith, N.M., Li, Q.Y., Garrett, C., Cox, P., Bonnet, 
D., Lyonnet, S., Munnich, A., Buckler, A.J., et al. (1996). A translocation at 12q2 
refines the interval containing the Holt-Oram syndrome 1 gene. Am J Hum Genet 59, 
1337-1341. 
Tian, Y., Yuan, L., Goss, A.M., Wang, T., Yang, J., Lepore, J.J., Zhou, D., Schwartz, 
R.J., Patel, V., Cohen, E.D., et al. (2010). Characterization and in vivo 
pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac inflow tract 
development. Dev Cell 18, 275-287. 
Timmerman, L.A., Grego-Bessa, J., Raya, A., Bertran, E., Perez-Pomares, J.M., 
Diez, J., Aranda, S., Palomo, S., McCormick, F., Izpisua-Belmonte, J.C., et al. 
(2004). Notch promotes epithelial-mesenchymal transition during cardiac 
development and oncogenic transformation. Genes Dev 18, 99-115. 
Tomita-Mitchell, A., Mahnke, D.K., Struble, C.A., Tuffnell, M.E., Stamm, K.D., 
Hidestrand, M., Harris, S.E., Goetsch, M.A., Simpson, P.M., Bick, D.P., et al. (2012). 
Human gene copy number spectra analysis in congenital heart malformations. 
Physiol Genomics 44, 518-541. 
Tomita-Mitchell, A., Maslen, C.L., Morris, C.D., Garg, V., and Goldmuntz, E. (2007). 
GATA4 sequence variants in patients with congenital heart disease. J Med Genet 
44, 779-783. 
Tompson, S.W., Ruiz-Perez, V.L., Blair, H.J., Barton, S., Navarro, V., Robson, J.L., 
Wright, M.J., and Goodship, J.A. (2007). Sequencing EVC and EVC2 identifies 
mutations in two-thirds of Ellis-van Creveld syndrome patients. Hum Genet 120, 
663-670. 
Ucar, B., Kilic, Z., Dinleyici, E.C., Yakut, A., and Dogruel, N. (2004). Seckel 
syndrome associated with atrioventricular canal defect: a case report. Clin 
Dysmorphol 13, 53-55. 
58	  
Waldo, K.L., Kumiski, D.H., Wallis, K.T., Stadt, H.A., Hutson, M.R., Platt, D.H., and 
Kirby, M.L. (2001). Conotruncal myocardium arises from a secondary heart field. 
Development 128, 3179-3188. 
Wang, B., Wang, J., Liu, S., Han, X., Xie, X., Tao, Y., Yan, J., and Ma, X. (2011). 
CFC1 mutations in Chinese children with congenital heart disease. Int J Cardiol 146, 
86-88. 
Wang, J., Luo, X.J., Xin, Y.F., Liu, Y., Liu, Z.M., Wang, Q., Li, R.G., Fang, W.Y., 
Wang, X.Z., and Yang, Y.Q. (2012). Novel GATA6 mutations associated with 
congenital ventricular septal defect or tetralogy of fallot. DNA Cell Biol 31, 1610-
1617. 
Wang, J., Sridurongrit, S., Dudas, M., Thomas, P., Nagy, A., Schneider, M.D., 
Epstein, J.A., and Kaartinen, V. (2005). Atrioventricular cushion transformation is 
mediated by ALK2 in the developing mouse heart. Dev Biol 286, 299-310. 
Ware, S.M., Peng, J., Zhu, L., Fernbach, S., Colicos, S., Casey, B., Towbin, J., and 
Belmont, J.W. (2004). Identification and functional analysis of ZIC3 mutations in 
heterotaxy and related congenital heart defects. Am J Hum Genet 74, 93-105. 
Washington Smoak, I., Byrd, N.A., Abu-Issa, R., Goddeeris, M.M., Anderson, R., 
Morris, J., Yamamura, K., Klingensmith, J., and Meyers, E.N. (2005). Sonic 
hedgehog is required for cardiac outflow tract and neural crest cell development. 
Dev Biol 283, 357-372. 
Wassif, C.A., Zhu, P., Kratz, L., Krakowiak, P.A., Battaile, K.P., Weight, F.F., 
Grinberg, A., Steiner, R.D., Nwokoro, N.A., Kelley, R.I., et al. (2001). Biochemical, 
phenotypic and neurophysiological characterization of a genetic mouse model of 
RSH/Smith--Lemli--Opitz syndrome. Hum Mol Genet 10, 555-564. 
Watanabe, H., and Yamada, Y. (1999). Mice lacking link protein develop dwarfism 
and craniofacial abnormalities. Nat Genet 21, 225-229. 
Weatherbee, S.D., Niswander, L.A., and Anderson, K.V. (2009). A mouse model for 
Meckel syndrome reveals Mks1 is required for ciliogenesis and Hedgehog signaling. 
Hum Mol Genet 18, 4565-4575. 
Webb, S., Anderson, R.H., and Brown, N.A. (1996). Endocardial cushion 
development and heart loop architecture in the trisomy 16 mouse. Dev Dyn 206, 
301-309. 
Webb, S., Brown, N.A., and Anderson, R.H. (1998). Formation of the atrioventricular 
septal structures in the normal mouse. Circ Res 82, 645-656. 
Wessels, A., Anderson, R.H., Markwald, R.R., Webb, S., Brown, N.A., Viragh, S., 
Moorman, A.F., and Lamers, W.H. (2000). Atrial development in the human heart: 
59	  
an immunohistochemical study with emphasis on the role of mesenchymal tissues. 
Anat Rec 259, 288-300. 
Wessels, A., Markman, M.W., Vermeulen, J.L., Anderson, R.H., Moorman, A.F., and 
Lamers, W.H. (1996). The development of the atrioventricular junction in the human 
heart. Circ Res 78, 110-117. 
Willaredt, M.A., Gorgas, K., Gardner, H.A., and Tucker, K.L. (2012). Multiple 
essential roles for primary cilia in heart development. Cilia 1, 23. 
Willaredt, M.A., Hasenpusch-Theil, K., Gardner, H.A., Kitanovic, I., Hirschfeld-
Warneken, V.C., Gojak, C.P., Gorgas, K., Bradford, C.L., Spatz, J., Wolfl, S., et al. 
(2008). A crucial role for primary cilia in cortical morphogenesis. J Neurosci 28, 
12887-12900. 
Wirrig, E.E., Snarr, B.S., Chintalapudi, M.R., O'Neal J, L., Phelps, A.L., Barth, J.L., 
Fresco, V.M., Kern, C.B., Mjaatvedt, C.H., Toole, B.P., et al. (2007). Cartilage link 
protein 1 (Crtl1), an extracellular matrix component playing an important role in heart 
development. Dev Biol 310, 291-303. 
Xie, L., Hoffmann, A.D., Burnicka-Turek, O., Friedland-Little, J.M., Zhang, K., and 
Moskowitz, I.P. (2012). Tbx5-hedgehog molecular networks are essential in the 
second heart field for atrial septation. Dev Cell 23, 280-291. 
Xie, X., Lu, Y., Wang, X., Wu, B., and Yu, H. (2015). JAGGED1 gene variations in 
Chinese twin sisters with Alagille syndrome. Int J Clin Exp Pathol 8, 8506-8511. 
Xiong, S. (2013). Mouse models of Mdm2 and Mdm4 and their clinical implications. 
Chin J Cancer 32, 371-375. 
Ya, J., Erdtsieck-Ernste, E.B., de Boer, P.A., van Kempen, M.J., Jongsma, H., Gros, 
D., Moorman, A.F., and Lamers, W.H. (1998). Heart defects in connexin43-deficient 
mice. Circ Res 82, 360-366. 
Yang, J., Hu, D., Xia, J., Yang, Y., Ying, B., Hu, J., and Zhou, X. (2000). Three novel 
TBX5 mutations in Chinese patients with Holt-Oram syndrome. Am J Med Genet 92, 
237-240. 
Yang, L., Cai, C.L., Lin, L., Qyang, Y., Chung, C., Monteiro, R.M., Mummery, C.L., 
Fishman, G.I., Cogen, A., and Evans, S. (2006). Isl1Cre reveals a common Bmp 
pathway in heart and limb development. Development 133, 1575-1585. 
Ye, M., Coldren, C., Liang, X., Mattina, T., Goldmuntz, E., Benson, D.W., Ivy, D., 
Perryman, M.B., Garrett-Sinha, L.A., and Grossfeld, P. (2010). Deletion of ETS-1, a 
gene in the Jacobsen syndrome critical region, causes ventricular septal defects and 
abnormal ventricular morphology in mice. Hum Mol Genet 19, 648-656. 
60	  
Yin, Z., Haynie, J., Yang, X., Han, B., Kiatchoosakun, S., Restivo, J., Yuan, S., 
Prabhakar, N.R., Herrup, K., Conlon, R.A., et al. (2002). The essential role of Cited2, 
a negative regulator for HIF-1alpha, in heart development and neurulation. Proc Natl 
Acad Sci U S A 99, 10488-10493. 
Yoshida, A., Morisaki, H., Nakaji, M., Kitano, M., Kim, K.S., Sagawa, K., Ishikawa, 
S., Satokata, I., Mitani, Y., Kato, H., et al. (2015). Genetic mutation analysis in 
Japanese patients with non-syndromic congenital heart disease. J Hum Genet. 
Zaragoza, M.V., Lewis, L.E., Sun, G., Wang, E., Li, L., Said-Salman, I., Feucht, L., 
and Huang, T. (2004). Identification of the TBX5 transactivating domain and the 
nuclear localization signal. Gene 330, 9-18. 
Zatyka, M., Priestley, M., Ladusans, E.J., Fryer, A.E., Mason, J., Latif, F., and 
Maher, E.R. (2005). Analysis of CRELD1 as a candidate 3p25 atrioventicular septal 
defect locus (AVSD2). Clin Genet 67, 526-528. 
Zhang, X.L., Qiu, X.B., Yuan, F., Wang, J., Zhao, C.M., Li, R.G., Xu, L., Xu, Y.J., 
Shi, H.Y., Hou, X.M., et al. (2015). TBX5 loss-of-function mutation contributes to 
familial dilated cardiomyopathy. Biochem Biophys Res Commun 459, 166-171. 
Zheng, G.F., Wei, D., Zhao, H., Zhou, N., Yang, Y.Q., and Liu, X.Y. (2012). A novel 
GATA6 mutation associated with congenital ventricular septal defect. Int J Mol Med 
29, 1065-1071. 
Zhou, H.M., Weskamp, G., Chesneau, V., Sahin, U., Vortkamp, A., Horiuchi, K., 
Chiusaroli, R., Hahn, R., Wilkes, D., Fisher, P., et al. (2004). Essential role for 
ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 24, 96-104. 
Zhou, W., Zhao, L., Jiang, J.Q., Jiang, W.F., Yang, Y.Q., and Qiu, X.B. (2015). A 
novel TBX5 loss-of-function mutation associated with sporadic dilated 
cardiomyopathy. Int J Mol Med 36, 282-288. 
 
 
	   61	  
 
 
CHAPTER 2 
Generating a Xenopus line expressing Tbx5Avi to study TBX5 functional 
mechanisms in vivo 
Overview 
This work was performed by myself, Erika Paden (a previous graduate 
student in the lab), Michelle Villasmil (a previous postdoc in the lab), and Lauren 
Kuchenbrod (our lab technician).  Erika Paden performed data mining for 
phosphorylated TBX5 and generated the Tbx5 enhancer construct driving GFP 
expression. I generated the TBX5 phosphorylation mutations and performed all of 
the transient transcriptional assays. I also generated the Tbx5Avi construct and 
performed all Xenopus tropicalis transgenic injections, genotyping, and animal 
husbandry. Lauren Kuchenbrod performed Xenopus laevis injections and is currently 
maintaining all transgenic lines in our Xenopus facility. Michelle performed 
subsequent protein expression analysis of TBX5Avi. The mouse experiment was 
performed in the laboratory of Benoit Bruneau. The project was conceived by Frank 
Conlon. 
Clinical studies provide direct evidence for a role for T-box transcription 
factors in heart development and human disease.  Specifically, mutations in Tbx5 
have been associated with the human congenital heart disease Holt-Oram syndrome 
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(HOS), which is characterized by a wide array of cardiac abnormalities.  HOS 
mutations can lead to TBX5 overexpression and depletion, which increases and 
decreases TBX5 activity, indicating that proper TBX5 levels are essential for normal 
cardiac development.  Despite the crucial role for TBX5 in development and disease, 
little is known about TBX5 functional mechanisms. We performed data mining of 
phosphoproteomes and identified a set of in vivo phosphorylated residues in a 
previously uncharacterized region of the TBX5 protein. Transcriptional analysis and 
bioassays indicate that phosphorylation of TBX5 at a single threonine residue 
inhibits its transcriptional activity.  Preliminary data suggests that phosphorylation at 
this residue reduces protein stability. We hypothesize that TBX5 phosphorylation 
mediates novel protein-protein interactions that regulate TBX5 levels and activity. 
We have generated a novel Xenopus line expressing epitope-tagged Tbx5Avi to 
determine the TBX5 protein interactome. 
 
INTRODUCTION 
The T-box gene family is a large family of transcription factors that are 
required for early cell fate decision, differentiation and organogenesis (Papaioannou 
and Silver, 1998; Smith, 1999; Wilson and Conlon, 2002). T-box gene mutation 
studies in mice and zebrafish result in dramatic phenotypes and suggest that these 
genes may have crucial roles in a number of human congenital malformations 
(Wilson and Conlon, 2002). Clinical studies provided direct evidence for a role for T-
box genes in human congenital heart disease (CHD). Tbx1 is deleted in most 
patients with DiGeorge syndrome (Chieffo et al., 1997; Lindsay et al., 2001), Tbx20 
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mutations that reduce or up-regulate TBX20 expression are associated with a wide 
range of cardiac abnormalities (Kirk et al., 2007; Posch et al., 2010; Qian et al., 
2008), and Tbx5 mutations are associated with the CHD Holt-Oram syndrome 
(HOS) (Hammer et al., 2008; Kirk et al., 2007; Li et al., 1997; Lindsay et al., 2001; 
Mandel et al., 2005; Qian et al., 2008; Scambler, 2000).  This dissertation 
investigates the molecular mechanism of TBX5 activity in HOS. 
Tbx5 was initially identified in mouse (Bollag et al., 1994), and its homologs 
have been characterized in a number of vertebrate organisms including zebrafish 
(Begemann and Ingham, 2000; Ruvinsky et al., 2000; Tamura et al., 1999), Xenopus 
(Brown et al., 2005; Goetz et al., 2006; Horb and Thomsen, 1999), chicken (Gibson-
Brown et al., 1998; Ohuchi et al., 1998), and human (Basson et al., 1997; Li et al., 
1997). Amino acid sequence homology analysis indicates that Tbx5 is highly 
conserved throughout evolution, with approximately 70% conservation between 
human and Xenopus full length Tbx5, and more than 90% conservation within the T-
box DNA-binding domain. Initial studies in mouse showed that Tbx5 expression was 
restricted to a subset of cells in the developing eye, heart, and limb (Chapman et al., 
1996). Similar results have been observed in other vertebrates (Begemann and 
Ingham, 2000; Brown et al., 2005; Gibson-Brown et al., 1998; Horb and Thomsen, 
1999; Li et al., 1997).  Studies in Xenopus (Brown et al., 2005; Horb and Thomsen, 
1999; Showell et al., 2006) report that Tbx5 is expressed in the migrating heart 
primordia of the neurula stage (stage 20) embryo. By stage 24, the Tbx5 expression 
pattern becomes restricted to the developing heart, a dorsal stripe corresponding to 
the common cardinal vein, and the dorsal part of the eye.  Whole-mount and 
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sectioned in situ tissue samples at tadpole stages show high levels of Tbx5 
expression in the common cardinal vein, hepatic vein, and the ventricle, with lower 
levels detected in the atria and the in-flow tract (Horb and Thomsen, 1999; Showell 
et al., 2006). TBX5 is one of the earliest markers of the cardiac lineage in all 
vertebrates. Recent studies show that TBX5 is one of three cardiac transcription 
factors (along with GATA4 and MEF2C) that coordinately function to directly 
reprogram fibroblasts into differentiated cardiomyocytes. These differentiated 
cardiomyocytes have similar molecular, anatomical, and physiological properties as 
endogenous cardiomyocytes (Ieda et al., 2010; Qian et al., 2012). 
Holt-Oram syndrome (HOS), also known as heart-hand syndrome, is a 
congenital autosomal dominant disorder that primarily affects the heart and upper 
limbs (Holt and Oram, 1960). The cardiac defects include atrial septal defects (ASD), 
ventricular septal defects (VSD), and/or defects in the cardiac conduction system 
(Basson et al., 1994; Benson et al., 1996; Cross et al., 2000; McDermott et al., 2005; 
Newbury-Ecob et al., 1996). HOS is often caused by mutations in the coding region 
of the T-box transcription factor Tbx5 (Basson et al., 1997; Basson et al., 1999; Li et 
al., 1997). More than 70% of patients with HOS have a mutation in the Tbx5 coding 
region, and 85% of those mutations occur de novo (McDermott et al., 2005). Most 
HOS mutations are predicted to result in TBX5 haploinsufficiency (Basson et al., 
1999; Li et al., 1997); however, TBX5 overexpression also can result in HOS 
(termed atypical HOS) (Brassington et al., 2003; Dixon et al., 1993; Garavelli et al., 
2008; Lehner et al., 2003; McDermott et al., 2005; Newbury-Ecob et al., 1996; 
Postma et al., 2008; Sletten and Pierpont, 1996; van Bever et al., 1996).  These 
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results are consistent with numerous overexpression and depletion experiments in a 
number of model organisms, including mouse (Bruneau et al., 2001; Liberatore et 
al., 2000; Moskowitz et al., 2004), chicken (Hatcher et al., 2004; Hatcher et al., 
2001), Xenopus (Brown et al., 2005; Goetz et al., 2006; Horb and Thomsen, 1999), 
and zebrafish (Garrity et al., 2002).  Collectively, these studies demonstrate that 
proper TBX5 levels are essential for proper heart development, and even a slight 
alteration in TBX5 levels can lead to human congenital heart disease. These results 
suggest that human CHD is likely associated with TBX5 function. 
In this chapter, we determined how alterations in TBX5 levels could lead to 
CHD. We performed data mining studies and showed that TBX5 is phosphorylated 
in vivo.  We characterized the phosphorylated residues, and observed that mutated 
TBX5 at T278 increases TBX5-mediated transcriptional activation of the downstream 
target genes in Xenopus. We showed that the increase in transcriptional activity is 
not due to changes in nuclear localization; rather, it seems likely that mutation at this 
residue leads to changes in protein stability. We hypothesized that TBX5 
phosphorylation mediates protein-protein interactions that regulate protein turnover.  
For further analysis, it is crucial to isolate the TBX5 transcriptional complex from 
Xenopus heart tissue by immunoisolation. Due to the lack of a high specificity, high 
affinity TBX5 antibody, past attempts at purifying endogenous TBX5 transcriptional 
complexes by our lab and others have been unsuccessful. To circumvent this 
problem we have generated Xenopus laevis and Xenopus troplicalis transgenic lines 
expressing epitope-tagged TBX5 under the control of a novel endogenous cardiac 
enhancer. These studies are currently ongoing. 
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MATERIALS AND METHODS 
Plasmid Construction 
Xenopus tropicalis TBX5 was cloned into pcDNA3.1-C-HA using NheI and 
NotI restriction sites. Site-directed mutagenesis was performed using the 
QuikChange II Site Directed Mutagenesis kit (Agilent, Santa Clara, USA). Primer 
sequences are presented in Table S2.1. 
Xenopus transcriptional assays 
For transient transcription assays, all Xenopus embryos were injected at the 
one-cell stage with 100 pg UAS-SV40-Luciferase reporter plasmid, 10 pg Renilla 
reporter plasmid, and in the presence or absence of 1 ng of wild type Tbx5, mutant 
Tbx5 mRNA (1ng). Injected embryos were cultured until stage 10.5 (Nieuwkoop, 
1994). Ten injected embryos (in triplicate) were lysed in 50 µL Passive Lysis Buffer 
(Promega, Madison, USA). Then, 20 µL of cleared lysate were assayed using the 
Dual-Luciferase Reporter Assay System (Promega, Madison, USA). The results of 
transcriptional assays are plotted as the average relative transcription ± SEM. 
Statistical significance was determined by Student’s t-test. 
Cell transfection and nuclear isolation 
COS-7 cells were transfected using FuGene6 according to the manufacturer’s 
protocol (Promega, Madison, USA). Cells were harvested 48 hours after 
transfection. Nuclear extracts were prepared using the CelLytic NuCLEAR Extraction 
Kit according to the manufacturer’s protocol (Sigma, St. Louis, USA). Briefly, cells 
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were washed in PBS, scraped, and isolated. Cells were lysed in 5x cell pellet volume 
of lysis buffer (5 mM Tris HCl, pH 7.5, 1 mM MgCl2, 1.5 mM CaCl2, 150 mM sucrose, 
1 mM DTT, 0.1 µL Sigma protease inhibitor cocktail P8340) for 15 minutes on ice.  
Then, 10% IGEPAL was added to the cell lysate to a final concentration of 0.6%, 
and the lysate was vortexed for 10 s and centrifuged for 30 s at 10,000 x g. The 
cytoplasmic supernatant was collected and the nuclear pellet was extracted using 
extraction buffer (2/3 volume of total cell pellet, 70 uL) (20 mM HEPES, pH 7.9, 4.5 
mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, 25% glycerol, 1 mM DTT and 1µL Sigma 
protease inhibitor cocktail P8340). Protein concentrations in cytoplasmic and nuclear 
fractions were determined by Bradford assays to ensure equal protein loading. 
Xenopus tropicalis transgenesis  
Xenopus tropicalis embryos were transformed using restricted emzyme 
mediated-integration (REMI). DNA constructs were linearized using SalI, and 
transgenesis was performed according to Kroll and Amaya as described previously 
(Amaya and Kroll, 1999; Amin et al., 2014; Kroll and Amaya, 1996; Mandel et al., 
2010).  Frogs were genotyped using primers (forward, 
CTAACCACAGCCCATTCTCT; reverse, ACAGAGCCTGTACCATCC. Primers were 
designed for Xenopus tropicalis Tbx5 exons 8 and 9. 
Xenopus protein extraction 
Batches of 10 embryos were lysed in a minimal volume of lysis buffer (50mM 
Tris pH 7.6, 150 mM NaCl, 6 mM EDTA, 1% Triton X-100, 1x protease inhibitor 
(Sigma, St. Louis, USA)). Lysate was sonicated for 15 minutes, (30s on/30s off) at 
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4C°, and centrifuged for 10 min at 15,000rpm. The supernatant was then collected 
and isolated from the lipid layer on top of the lysate and the insoluble pellet and then 
prepared for western blot. 
RESULTS 
TBX5 is phosphorylated in vivo 
Data mining was performed in our laboratory to identify the phosphproteome 
of adult mice. These results indicated that TBX5 is phosphorylated in vivo at four 
residues (S261, T262, S276, and T278) (Villen et al., 2007). Three of these residues 
(S261, T262, and T278) are evolutionarily conserved across all TBX5 orthologs 
including Xenopus, mouse, and human (Table 2.1).  The phosphorylation sites map 
to an uncharacterized region of the TBX5 protein in the C-terminal region, located 3’ 
to the T-box DNA binding domain (Figure 2.1).  
 
Mutation of phosphorylation residue T278 increases transcriptional activity. 
To determine the importance of the potentially phosphorylated residues for 
TBX5-mediated transcriptional activation of target genes, we mutated all three 
residues to alanine, which generates the triple phospho-dead mutant TBX5S261A-
T262A-T278A) in the Xenopus tropicalis ortholog of TBX5. Combinatorial mutation of all 
three residues significantly increased the level of TBX5-mediated transcriptional 
activation of its downstream target ANF/Nppa (Bruneau et al., 2001; Fan et al., 
2003; Garg et al., 2003; Hiroi et al., 2001) in Xenopus transcriptional assays (Figure 
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2.2A). By contrast, mutation of all three residues to aspartic acid or glutamic acid 
generates the triple phospho-mimetic mutant TBX5S261D-T262E-T278E /TBX5S261E-T262E-
T278E), which results in transcriptional activity similar to that of wild type TBX5. 
Therefore, we conclude that TBX5 phosphorylation at these residues reduces TBX5 
transcriptional activity. 
To determine the crucial residues involved in TBX5 transcriptional activity, we 
performed transcriptional assays in Xenopus expressing single point mutations of 
TBX5 (TBX5S261A, TBX5T262A, or TBX5T278A). Mutation of residues S261 and T262 
had minimal effects on TBX5 transcriptional activity, whereas mutation of T278 to 
alanine recapitulated the increased TBX5 transcriptional activity observed in the 
triple phospho-dead mutant (Figure 2.2B). We conclude that residue T278 is 
phosphorylated to reduce TBX5-mediated transcriptional activation of the ANF 
promoter. 
 
Mutation of phosphorylation residue T278 does not affect TBX5 localization 
 There are a number of processes that can explain changes in the 
transcriptional activity of a transcription factor. Phosphorylation of TBX5 may change 
TBX5 nuclear localization, and thereby affect TBX5-mediated transcriptional 
activation of downstream target genes. To determine whether TBX5 phosphorylation 
changes the protein localization, we overexpressed wild type TBX5 and TBX5T278A in 
COS-7 cells and isolated nuclear and cytoplasmic extracts. Endogenous TBX5 is 
predominantly expressed in the nucleus, but cytoplasmic localization of TBX5 is also 
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observed when TBX5 is overexpressed. However, we detected no change in TBX5 
localization in the mutated TBX5T278 protein (Figure S2.1). 
 
Mutation of TBX5 at T278 may affect TBX5 stability 
Ubiquitin-mediated degradation pathways are known to process 
phosphorylated proteins. To assess the effects of TBX5 phosphorylation on protein 
stability, we expressed HA-tagged wild type TBX5 and TBX5T278A in Xenopus 
embryos. Embryos were collected at gastrulation (stage 10), early neurula (stage 
20), mid neurula (stage 26), and at the formation of the three-chambered heart 
(stage 33/34). At early gastrulation both wild type TBX5 and mutated TBX5T278A-HA 
proteins are expressed. However, we were not able to detect TBX5 protein in any 
samples after gastrulation (Figure 2.3, data at later stages not shown). We do 
consistently observe greater levels of TBX5T278A protein expression at early stages 
even after normalizing for total protein level via Bradford assay (Figure 2.3 and 
Figure S2.1). Therefore, we hypothesize that phosphorylation of TBX5 may affect 
the protein half-life, turnover, or degradation. 
 
Isolating the endogenous cardiac regulatory element of Tbx5 
We hypothesize that phosphorylation of TBX5 mediates protein-protein 
interactions that regulate protein turnover. To test this, it is crucial to isolate the 
endogenous TBX5 transcriptional complex from Xenopus heart tissue by 
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immunoisolation. Currently, there is no high specificity, high affinity TBX5 antibody, 
and all previous attempts to isolate endogenous TBX5 and TBX5 protein complexes 
by us and others have failed. Therefore, it is necessary to express tagged TBX5 
under its endogenous cardiac enhancer element to isolate TBX5.  
To determine the endogenous cardiac regulatory elements of TBX5, we fused 
11 kB of the Xenopus tropicalis Tbx5 promoter and intragenic region, a non-coding 
exon, and the beginning of the first coding exon in frame to drive EGFP expression 
(Figure 2.4A). EGFP is expressed in the developing heart (Figure 2.4B-D) and the 
developing eye (data not shown) with the correct spatiotemporal localization and 
patterning as that of endogenous TBX5 expression. To confirm that this sequence 
contains a true enhancer, we utilized the same region to generate transgenic mouse 
embryos. The results show that EGFP expression in the mouse is the same as 
EGFP expression in Xenopus embryos (Figure 2.4 E-J). These data indicate that 
reporter constructs containing the Tbx5 5’ UTR and promoter sequence faithfully 
recapitulate endogenous Tbx5 expression in living Xenopus and mouse embryos.   
 
Generation of transgenic Xenopus expressing Tbx5Avi 
To isolate endogenous TBX5 from Xenopus embryos, we utilized the 
endogenous cardiac enhancer element to express TBX5 protein labeled with the 
biotin acceptor peptide (Avi), V5, and 6x His tags (Figure 2.5A). The Avi tag is a 
small peptide tag that is biotinylated in the presence of the bacterial enzyme BirA. 
Thus, the Avitag/BirA system combines minimal structural invasiveness with the 
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robust specificity of the biotin-streptavidin interaction. This is the strongest non-
covalent peptide-ligand interaction in nature; the affinity of this interaction greatly 
exceeds that of any antibody-antigen interaction (Bayer and Wilchek, 1980; Maine et 
al., 2010; Roesli et al., 2006; van Werven and Timmers, 2006; Wang et al., 2006). 
Both Xenopus laevis and Xenopus tropicalis eggs were injected with the 
Tbx5Avi construct using restriction enzyme mediated integration transgenesis. Briefly, 
sperm nuclei are incubated with linearized DNA and a restriction enzyme, along with 
egg extract that promotes chromatin decondensation. The sperm nuclei/DNA/egg 
extract mixture is then injected into an unfertilized egg, where the foreign DNA 
randomly integrates into multiple genomic loci during the DNA repair process, ideally 
before the first cleavage (Kroll and Amaya, 1996).  
 Tadpoles were genotyped for the presence of the Tbx5Avi transgene using 
primers designed to Tbx5 exons 8 and 9 (Figure 2.5B). Designing primer sequences 
that flank intron 8 allows us to distinguish between wild type Tbx5 genomic DNA and 
the Tbx5Avi transgene. Approximately 70% of our transgenic tadpoles were positive 
for Tbx5Avi.  
To determine if Tbx5Avi transmits through the germline, transgenicTbx5Avi 
Xenopus tadpoles were grown to sexual maturity. Five X. tropicalis females and one 
male were backcrossed to wild type frogs to test for germline transmission. 
Approximately 50% of the founder frogs (three females) transmitted Tbx5Avi through 
the germline. In the F1 population, more than 90% of tadpoles genotyped from these 
three females were positive for Tbx5Avi. Fourteen X. laevis males and five females 
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were backcrossed to wild type and 74% of the founder frogs (nine males and five 
females) transmitted Tbx5Avi through the germline. These results germline 
transmission, and we are continuing to expand the Tbx5Avi lines. We also generated 
X, laevis transgenic lines expressing the BirA biotin ligase (Amin et al., 2014), and 
are working to cross these lines to generate frogs expressing endogenously 
biotinylated TBX5Avi in the cardiac lineage. 
 
TBX5Avi is expressed in Xenopus 
 The presence of the Tbx5Avi transgene does not necessarily correlate with 
protein expression. Although TBX5Avi protein expression is driven by the 
endogenous Tbx5 cardiac enhancer, it is still possible that the transgene integrated 
into a locus where TBX5Avi protein cannot be expressed. To confirm that TBX5Avi 
protein is expressed in our developing embryos, we tested protein expression in 
Tbx5Avi X. laevis tadpoles during heart development. Western blot analysis shows 
that TBX5Avi is expressed in embryos from both founder females by stage 46 (Figure 
2.6).  
DISCUSSION 
The genetic requirement for for Tbx5 during cardiogenesis is evolutionarily 
conserved from Xenopus to human, and TBX5 is mutated in a large percentage of 
HOS patients. Some patients with HOS express TBX5 mutations that lead to protein 
depletion, whereas others lead to protein and overexpression, but both cases result 
in similar phenotypes (Cross et al., 2000; Postma et al., 2008). These observations 
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are consistent with numerous overexpression and depletion experiments in a 
number of model organisms, including mouse (Bruneau et al., 2001; Liberatore et 
al., 2000; Moskowitz et al., 2004), chicken (Hatcher et al., 2004; Hatcher et al., 
2001), Xenopus (Brown et al., 2005; Goetz et al., 2006; Horb and Thomsen, 1999), 
and zebrafish (Garrity et al., 2002). Collectively, these studies indicate that the 
proper gene dosage of Tbx5 and appropriate levels of TBX5 protein are required for 
cardiogenesis, and slight alteration in levels of TBX5 can lead to CHD.  
 
Analysis of TBX5 phosphorylation in Xenopus 
 A large percentage of TBX5 mutations resulting in HOS are missense 
mutations, which are less likely to result loss of TBX5 protein than a truncation or a 
frameshift mutation. Many of these mutations affect serine or threonine residues. 
Therefore, we therefore hypothesized that TBX5 phosphorylation could have a role 
in protein regulation. We performed data mining to analyze the phospho-proteome 
and found that TBX5 is phosphorylated in the mouse liver in vivo (Villen et al., 2007) 
at four residues, three of which are conserved in Xenopus. Mutation of T278 to the 
phospho-dead alanine increases the levels of TBX5-mediated transcriptional 
activation of the target gene Anf promoter. TBX5 phosphorylation affects protein 
nuclear localization, protein stability, and the ability to interact with additional 
proteins. We suggest that the point mutant TBX5T278A is more stable than wild type 
TBX5, but this requires further validation by performing protein stability assays using 
cycloheximide. 
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Characterization of the endogenous Tbx5 cardiac enhancer region 
 Xenopus embryos are an ideal system for characterizing enhancer elements; 
it is a relatively inexpensive system for introducing potential regulatory regions into 
the developing embryo, and hundreds of transgenic embryos can be generated in a 
matter of days. A number of studies have utilized Xenopus embryos to analyze 
enhancer elements for a number of cardiac genes, including studies from our lab on 
Tbx20 (Amaya and Kroll, 1999; Garriock et al., 2005; Latinkić  et al., 2004; Latinkić 
et al., 2002; Mandel et al., 2010; Small and Krieg, 2003; Smith et al., 2005; Smith et 
al., 2006; Sparrow et al., 2000).  The current studies have identified the enhancer 
element region of Tbx5, which can be added to the small number of crucial cardiac 
genes with known regulatory elements. 
Generation of TBX5Avi transgenic lines and future studies 
 Our studies are among the first to generate a Xenopus line expressing an 
epitope-tagged protein under its endogenous cardiac promoter. There are a number 
of uses for this animal model that will provide a deeper understanding of TBX5 
function and activity in the developing heart. 
 We hypothesized that phosphorylation of TBX5 at residue T278 mediates 
protein-protein interactions that regulate protein turnover. We intend to isolate 
epitope-tagged TBX5 protein from the developing Xenopus heart and perform 
phosphoproteomics analysis to confirm that T278 is phosphorylated in the heart. We 
then will utilize these transgenic frogs to isolate epitope-tagged TBX5 transcriptional 
complexes from the heart. We will construct a TBX5 transcriptional network of 
	   76	  
proteins required for cardiogenesis. In the future, we intend to generate a similar line 
of frogs expressing Tbx5T278A-Avi. Analysis of the TBX5 transcriptional network and 
interactome in these transgenic frogs expressing the phospho-dead Tbx5T278A-Avi 
protein will provide more information about the function of TBX5 phosphorylation 
during cardiogenesis. 
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FIGURES 
Figure 2.1. Schematic of Xenopus tropicalis TBX5 structure. TBX5 contains a T-
box DNA binding domain, characteristic of all T-box transcription factors. It also 
contains a small N-terminal protein-protein interaction (PPI) domain and a larger 
putative C-terminal PPI, two nuclear localization signals (NLS), and a C-terminal 
transcription activation domain (AD). Phosphorylation residues S261, T262, and 
T278 are not located inside a known functional domain.  
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Figure 2.2.  Mutation of phosphorylation residue T278 increases TBX5-
mediated transcriptional actvity. Transcription assays were performed by 
microinjection of Tbx5 mRNA (wild type or mutant), along with ANF-Firefly 
Luciferase and Renilla Luciferase reporter plasmids into Xenopus embryos at the 
one cell stage. All values are normalized to ANF-luciferase alone (bar 1), and all 
values are statistically significant compared to ANF-luciferase alone (p-values not 
shown). (A) Mutation of all three phosphorylation residues combinatorially. (B) 
Mutation of each phosphorylation residue individually. 
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Figure 2.3. Mutation of phosphorylation residue T278 may affect protein 
stability. Western blot shows more phospho-dead mutant TBX5 than wild type 
TBX5 at early stages, suggesting that mutant protein may be more stable. Beta-
Tubulin was used to demonstrate equal loading of protein. 
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Figure 2.4. Characterization of the Tbx5 enhancer regulatory element. (A) 
Schematic of 11 KB of Tbx5 promoter/intragenic region, a non-coding exon, and the 
beginning of a coding exon fused in frame to drive EGFP expression. (B-D) Ventral 
view of a late tadpole stage transgenic embryo. (C) EGFP is expressed in the heart 
(white box) under the control of the Tbx5 regulatory element. Autofluorescence is 
seen in the gut (white arrow). (D) Enlargement of the heart shows EGFP expression 
in the atria (A) and the ventricle (V). (E-G) Bright field images of E10.5 transgenic 
mouse embryo. (H-J) EGFP is expressed in the heart under the control of the Tbx5 
regulatory element in the left ventricle and both atria. 
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Figure 2.5. Generation of Tbx5Avi Xenopus transgenic lines. (A) Schematic of the 
Tbx5Avi transgenic construct. 11 KB of Tbx5 regulatory region now drives expression 
of Xenopus tropicalis Tbx5 fused in frame to the Avi, V5, and 6XHis tags. (B) 
Genotyping analysis of Tbx5Avi tadpoles. DNA was isolated from tails clipped from 
late tadpole stage embryos. Tadpoles were genotyped for the presence of Tbx5Avi 
(top panel) and the presence of DNA using Xenopus Twist (bottom panel). 
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Figure 2.6. TBX5Avi protein is expressed at stage 46 in Xenopus embryos. 
Western blot analysis shows TBX5Avi protein from two different founder females by 
stage 46. TBX5Avi expression is notably decreased before this stage. 
GAPDHexpression levels were examined to ensure equal protein loading. 
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Tables 
Table 2.1: Evolutionary Conservation of amino acid sequence flanking TBX5 
phosphorylation sites. Phosphorylation residues (red, bold) are conserved from 
Xenopus to human. 
Organism Sequence 
Xenopus laevis 256 PVVPR ST VRQKVSSNHSPFSQE T RNITG   283 
Xenopus tropicalis 256 PVVPR ST VRQKVSSNHSPFSQE T RNITG   283  
Mus musculus 256 PVVPR ST VRHKVTSNHSPFSSE T RALST   283 
Homo sapiens 253 PVVPR ST VRQKVASNHSPFSSE T RALST   280 
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Supplemental Figure 
Figure S2.1. Phosphorlyation of Tbx5 has no effect on Tbx5 localization. COS-
7 cells were transfected with HA-tagged wild type Tbx5 or Tbx5T278A. Nuclear 
extracts were prepared and all protein samples were normalized using Bradford 
assays.  
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Supplemental Tables 
Table S2.1. Site directed mutagenesis primers 
Mutation Forward Primer Sequence Reverse Primer Sequence 
S261A CAGTAGTCCCTAGGGCCACA
GTCC 
CAGTAGTCCCTAGGGCCACAGTCC 
S261A-
T262A 
TACCCAGTAGTCCCAAGAGC
CGCAGTCCGTCAGAAGGTGT
CC 
GGACACCTTCTGACGGACTGCGGCT
CTTGGGACTACTGGGTA 
S261D- 
T262E 
CCCAGTAGTCCCAAGAGACG
AAGTCCGTCAGAAGGTG 
CACCTTCTGACGGACTTCGTCTCTTG
GGACTACTGGG 
S261E- 
T262E 
CACCTTCTGACGGACTTCCT
CTCTTGGGACTACTGGG 
CCCAGTAGTCCCAAGAGAGGAAGTC
CGTCAGAAGGTG 
T262A CCAGTAGTCCCAAGAAGCGC
AGTCCGTCAGAAG 
CTTCTGACGGACTGCGCTTCTTGGGA
CTACTGG 
T278A CCATTCTCTCAAGAAGCACG
CAACATTACAGGATCC 
GGATCCTGTAATGTTGCGTGCTTCTT
GAGAGAATGG 
T278E GCCCATTCTCTCAAGAAGAA
CGCAACATTACAGGATCCTC 
GAGGATCCTGTAATGTTGCGTTCTTC
TTGAGAGAATGGGC 
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CHAPTER 3 
The cardiac TBX5 interactome reveals a chromatin remodeling network 
essential for atrial septation 
Overview 
This work was submitted to Developmental Cell. The project was 
conceived by myself, Frank Conlon, Ileana Cristea and Ivan Moskowitz. Kerry 
Dorr performed Southern analysis to determine Tbx5Avi positive clones. Junghun 
Kweon and Jeffrey Steimle performed all experiments and analysis related to the 
Tbx5+/-; Mta1+/- mouse, and Caralynn Wilczewski performed the Mta1-/- 
experiment and analysis. Brenda Temple modeled the TBX5 protein structure, 
and generated the TBX5 evolutionary tree, Todd Greco and I analyzed 
proteomics data. Nicholas Gomez performed large scale bioinformatics analysis 
of TBX5 binding motifs and pathway analysis. Ian Davis provided additional 
bioinformatics expertise. Ileana Cristea provided additional proteomics expertise. 
Ivan Moskowitz provided RNA-seq data. I performed all other experiments. Frank 
Conlon and I wrote the manuscript with contributions and comments from all 
authors. 
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 Congenital heart disease (CHD) is the most common congenital 
malformation, with defects in cardiac chamber septation accounting for almost 
half of all CHD-related deaths in children. The cardiac transcription factor TBX5 
has been shown to be causative in patients with septal defects; however, its 
mechanism of action in normal development and in CHD has not been 
determined. We have isolated and characterized the endogenous TBX5 cardiac 
interactome and report that TBX5, long considered to be a cardiac transcriptional 
activator, interacts biochemically and genetically with the chromatin remodeling 
repressor machinery of the Nucleosome Remodeling and Deacetylase (NuRD) 
complex. We report that the TBX5-NuRD interaction is essential for normal heart 
development and that patients with atrioventricular septal defects (AVSD) have 
mutations that disrupt the TBX5-NuRD interaction. We identify the direct 
transcriptional targets of TBX5 and show that TBX5 acts to repress expression of 
neural- and cancer- associated gene programs in cardiac tissue. Furthermore, a 
subset of these genes are disregulated by CHD patient mutations. We also 
define a new structural-functional domain of TBX5 essential for interaction with 
the NuRD complex, and show through phylogenetic analysis that this domain 
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evolved during the early diversification of vertebrates, simultaneous with the 
evolution of atrial septation. We define a novel TBX5-NuRD interaction that is 
essential to cardiac development and the evolution of the mammalian heart, and 
that when altered may contribute to human CHD. 
 
INTRODUCTION 
Congenital malformations, or structural birth defects, are the leading 
cause of infant mortality in the US and Europe (Dolk et al., 2010; Heron and 
Tejada-Vera, 2009). Congenital heart disease (CHD) remains the most common 
congenital malformation, with atrial septal defects present in 56 per 100,000 live 
births (Morris, 2010). Holt Oram Syndrome (HOS) is an autosomal disorder 
associated with cardiac septal defects and is caused by dominant mutations in 
the T-box transcription factor Tbx5 (Basson et al., 1997; Basson et al., 1994; 
Basson et al., 1999; Cross et al., 2000; Holt and Oram, 1960; Li et al., 1997). 
Mice heterozygous for a null mutation in Tbx5 display many of the phenotypic 
abnormalities of HOS, while mice homozygous for a null mutation in Tbx5 die by 
E10.5 due to cardiac defects (Bruneau et al., 1999; Bruneau et al., 2001; 
Moskowitz et al., 2007; Moskowitz et al., 2004). In addition to its role in 
cardiogenesis, Tbx5 is one of the key factors essential for cellular reprogramming 
of fibroblasts into induced cardiomyocytes (Ieda et al., 2010; Qian et al., 2012).   
 While Tbx5 is an essential transcription factor for heart development and 
reprogramming, and its disease relevance is well established, there are many 
critical unanswered questions about the mechanism of TBX5 function. For 
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example, it is not understood what proteins complex with TBX5 during different 
stages of cardiac development and homeostasis, how these interactions regulate 
TBX5's choice of distinct transcriptional targets, or how these interactions 
function to activate and/or repress target gene transcription. It is also not known 
how these events, when disrupted, manifest as CHD. To these ends, we initiated 
a directed proteomic-based approach to identify endogenous cardiac proteins 
that function in physical association with TBX5. 
 Here we report the discovery that TBX5 interacts biochemically and 
genetically with the transcriptional repression machinery of the Nucleosome 
Remodeling and Deacetylase (NuRD) complex to repress inappropriate 
expression of neural and cancer related genes in the developing heart. We have 
further uncovered a novel domain of TBX5, show that it forms an α-Helix, and 
show that TBX5 mis-sense mutations associated with septal defects in human 
patients map to this domain. Moreover, we demonstrate that HOS patient mis-
sense mutations in this domain disrupt the TBX5-NuRD interaction and elicit 
misexpression of neural and cancer genes that are normally repressed by TBX5. 
Through phylogenetic analysis across numerous vertebrate species, we find that 
the NuRD-interaction domain of TBX5, and hence the interaction of TBX5 with 
NuRD, evolved during the early diversification of vertebrates, simultaneous with 
the evolution of atrial septation. Thus, the TBX5-NuRD interaction identified here 
plays a central role in both cardiac development and human congenital heart 
defects, as well as the evolution of the mammalian heart. 
 96	  
MATERIALS AND METHODS 
Generation of Tbx5Avi mice 
The targeting construct used to create a conditional knock-in allele of 
Tbx5Avi was created in collaboration with the UNC Animal Models Core and the 
UNC BAC Core (Chapel Hill). Briefly, the biotin acceptor peptide (Avi) targeting 
cassette was inserted in frame to the terminal exon of the Tbx5 gene. Targeted 
ES cells were selected and introduced into B6 mouse blastocysts. High-chimera 
males were mated with B6 females to produce F1 heterozygotes (Tbx5Avi-Neo/+). 
Incorporation of the Tbx5Avi construct was confirmed by PCR and Southern 
analysis (Figure S3.1B), while presence of Tbx5Avi mRNA was confirmed by RT-
PCR (Figure S3.1D). F1 heterozygotes were crossed with Sox2-Cre mice 
(Hayashi et al., 2002) to remove the neomycin selection cassette in the F2 
generation (Figure S3.1C). F2 compound heterozygous mice were intercrossed 
to remove the Sox2-Cre allele and establish Tbx5Avi/Avi homozygous lines. 
Tbx5Avi/Avi mice were crossed to Rosa26BirA mice (JAX), which have been 
previously described (Driegen et al., 2005), and those progeny intercrossed to 
obtain compound homozygotes. Genotyping was performed by PCR. Genotyping 
primers can be found in Supplemental Experimental Procedures. Southern probe 
was designed to Tbx5 intron 8. Genomic DNA was digested with EcoRV or 
BamHI. Animal care and animal experiments were conducted in accordance with 
the Animal Care Committee at the University of North Carolina, Chapel Hill. 
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Preparation of cardiac nuclei 
Frozen hearts from 4 week old Tbx5Avi/Avi; Rosa26BirA/BirA (n=3, 2 
replicates) and Tbx5Avi/Avi or Rosa26BirA/BirA control mice (n=3, 1 replicate per 
genotype) were homogenized using a mortar and pestle in liquid nitrogen. Nuclei 
were prepared as previously described (Franklin et al., 2011) and snap frozen in 
liquid N2.  
 
Solubilization of protein complexes 
Plasmids were transfected into HEK-293 cells, which were harvested and 
lysed as previously described (Kaltenbrun et al., 2013). E9.5 hearts were 
harvested in PBS and lysed as previously described (Kaltenbrun et al., 2013). 
Cells and nuclear pellets were resuspended in lysis buffer (200mM K-HEPES pH 
7.4, 1.1M KOAc, 20mM MgCl2, 1% Tween-20, 10µM ZnCl2, 10mM CaCl2, 0.5% 
Triton X-100, 500 mM NaCl, 1X protease inhibitors (Roche), 1X phosphatase 
inhibitors (Sigma), optimized for TBX5 complexes. Nuclei were then 
homogenized using a Polytron (Kinematica), and processed for affinity 
purification or immunoprecipitation as previously described (Kaltenbrun et al., 
2013). 
 
Conjugation of magnetic beads and affinity purification 
Conjugation of V5 (Invitrogen R960-CUS) or TBX5 (Aviva ARP33403-
P050) antibody to magnetic beads (Invitrogen), and immunoisolation of protein 
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complexes was performed as previously described (Cristea et al., 2005; 
Kaltenbrun et al., 2013), but modified as follows for streptavidin-coated beads. 
Affinity purifications were performed using streptavidin conjugated Dynabeads 
(Invitrogen) by slow rocking at RT for 30 minutes. The isolated protein complex 
was eluted from the beads for 20 min at 95°C in 40µL elution buffer (80mM 
NaOAc pH 9.0, 95% formamide). Western blots were probed with mouse anti-V5 
(1:5000, Invitrogen R960-CUS), rabbit anti-CHD4 (1:500, Active Motif 39289), 
mouse anti-HDAC2 (1:1000, Abcam Ab51832), rabbit anti-MTA1 (1:5000, Bethyl 
A300-280A), rabbit anti-TBX5 (1:1000, Aviva ARP33403-P050, using light chain-
specific rabbit secondary), goat anti-TBX5 (1:500, Santa Cruz SC-17866), and 
mouse anti-GFP (1:10000, Clontech 63281). 
 
Mass spectrometry 
Isolated protein complexes were analyzed by mass spectrometry as 
previously described (Kaltenbrun et al., 2013). Briefly, tandem mass spectra 
were extracted by Proteome Discoverer (Thermo Fisher Scientific), and all 
MS/MS samples were analyzed with SEQUEST (Thermo Fisher Scientific; 
version 1.2.0.208), set up to search the human and mouse UniProt-SwissProt 
protein sequence database, assuming digestion pattern with trypsin. Scaffold 
(version Scaffold_3_00_06, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS-based peptide and protein identifications. Peptide sequences 
were deemed a match if they could be established at >95.0% probability as 
specified by the Peptide Prophet algorithm (Keller et al., 2002). In turn, protein 
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identifications were deemed a match if they could be established at >99.0% 
probability by the ProteinProphet algorithm and have at least two sequenced 
peptides. Protein identifications and associated spectral counts were exported to 
Excel for further data processing. 
 
Interaction bioinformatics analysis 
Protein identifications were filtered to exclude non-specific associations. 
Proteins were retained as specific candidates if they (1) had at least two spectral 
counts in both Tbx5Avi/Avi; Rosa26BirA/BirA replicates with at least 4 spectral counts 
in one replicate, and (2) were uniquely identified or had at least a 2.5-fold 
spectral count enrichment in the Tbx5Avi/Avi; Rosa26BirA/BirA condition versus the 
controls. Candidates were assigned gene ontology classification using the 
UniProt GOA annotations from within the Cytoscape (v3.2) platform (Cline et al., 
2007). Gene symbols were submitted to the web-based STRING database 
(Franceschini et al., 2013) for interaction network analysis. Interactions with a 
combined STRING score of > 0.4 (medium confidence) were retained, exported, 
and further visualized in Cytoscape. 
 
RNA extraction and RT-PCR 
Adult (n=2) hearts were cryolysed (2.5 min/cycle, 30 Hz, 20 cycles) in 
Trizol (Invitrogen) to macerate heart tissue. RNA was extracted using Trizol and 
purified on RNeasy columns (Qiagen). cDNA synthesis was performed from 0.5-
 100	  
1 µg of RNA using random primers and SuperScript II reverse transcriptase 
(Invitrogen). Expression levels were assessed using GoTaq Green Master Mix 
(Promega) and Taq polymerase on a GeneAmp PCR System (Applied 
Biosystems). PCR products were analyzed by 1.5% agarose gel electrophoresis. 
RT-PCR primer sequences are provided in supplemental Experimental 
Procedures. 
 
Transcriptional assays 
ChIP peak regions from our candidate genes of interest were amplified 
from mouse genomic DNA and subcloned into the PGL3-Promoter Luciferase 
vector (Promega). Primer sequences for each candidate gene are provided in 
Supplemental Experimental Procedures. HEK-293 cells were transfected with 
600ng total DNA in 12 well plates using FuGene6 (Promega) and harvested 48 
hours later for transcription assay. Transcriptional assays were performed using 
Dual Reporter Assay System (Promega) according to the manufacturer’s protocol 
in three biological and three technical replicates per assay.  
 
DNA constructs 
Generation of the Tbx5Avi targeting construct for embryonic stem cells and 
generation of chimeric mice was performed by JrGang Chen (UNC BAC Core-
Chapel Hill). Tbx5-Avi-V5 was generated by synthesizing an oligo encoding the 
Avi tag (5’ ggc ctg aac gac atc ttc gag gct cag aaa atc gaa tgg cac gaa 3’) and 
subcloning it into the pcDNA3.1/V5-His TOPO vector (Invitrogen). Full length and 
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truncated versions of mouse Tbx5 were then subcloned into pcDNA3.1-Avi-V5. 
pEF1α-BirA-V5-Neo was generously provided by Stuart Orkin (Harvard 
University) (Kim et al., 2009). GFP tagged full length, C-terminal, and N-terminal 
human CHD4 constructs were generously provided by Stephen Jackson 
(Cambridge) (Polo et al., 2010). Site-directed mutagenesis primers are available 
in Supplemental Experimental Procedures. 
 
Genetic interaction and histology  
Tbx5fl/fl mice were generously provided by Jon and Christine Seidman 
(Harvard Medical School). The Tbx5+/- mouse has been previously reported 
(Bruneau et al., 2001). The Mta1+/- mouse line was generated by Harold Olivey 
(Indiana University Northwest) and generously provided by Eric Svensson 
(Novartis Institutes for Biomedial Research). All mice are in a mixed 
B6/129/SvEv/CD-1 background and all mouse experiments were performed 
according to a protocol reviewed and approved by the Institutional Animal Care 
and Use Committee of the University of Chicago, in compliance with the USA 
Public Health Service Policy on Humane Care and Use of Laboratory Animals. 
E13.5 and E14.5 wild type, Tbx5+/-, Mta1+/,- and Tbx5+/-;Mta1+/- embryos were 
dissected from timed matings. Embryos were fixed in 4% PFA overnight and sent 
to the Human Tissue Resource Center at the University of Chicago for paraffin 
embedding, sectioning, and H&E staining. Slides were imaged on a Leica 
DM2500 microscope and QImaging Retiga 2000R 1394 Color Cooled camera. 
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Mta1-/- null hearts were sectioned and prepared as previously described (Dorr et 
al., 2015).  
RNA-seq 
Heart tube dissections were performed as described previously (Hoffmann 
et al., 2014). Briefly, E9.5 Tbx5+/+ and Tbx5-/- heart tubes were dissected away 
from the body nearest the myocardial reflections and four heart tubes were 
pooled to isolate sufficient RNA. Genotypes were assigned via PCR. Pools of 
tissue were mechanically homogenized in TRIzol Reagent (Invitrogen, Carlsbad 
CA) and then RNA was isolated in accordance with the manufacturer’s 
instructions. RNA resuspended in water was further purified with 500 µl of 1-
butanol (4 times) and 500 µl diethyl ether (twice) (Krebs et al., 2009). Isolated 
RNA underwent library preparation and 51-bp single-ended RNA sequencing at 
the Genomics Core Facility at The University of Chicago. Briefly, mRNA was 
selected using an oligo-dT pulldown, and barcoded libraries were prepared 
according to Illumina's instructions accompanying the TruSeq RNA Sample prep 
kit v2 (Part# RS-122-2001). Library fragments of ~275 bps (insert plus adaptor 
and PCR primer sequences) were quantitated using the Agilent Bio-analyzer 
2100 and pooled in equimolar amounts. The pooled libraries were sequenced on 
the HiSeq2500 in Rapid Run Mode following the manufacturer's protocols 
(Invitrogen, 2013). 
 The raw data output from the Illumina Genome Analyzer was in phred-
scaled base-64 fastq format, representing the sequence and quality scores for 
each read. The single-ended 51-bp reads were filtered based on their quality 
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scores using FastQC toolkit (Andrews S, 2010) , selecting for the 37-bp reads on 
the right with a minimum quality score of 35 in 75% of the bases of the read. The 
reads passing the filter were aligned to the mouse genome mm10 assembly by 
Tophat (version 2.0.6) using default parameters (Kim et al., 2013). The output 
SAM files were filtered for alignment sorted, and converted to BAM files using 
Samtools (Li et al., 2009). Hit counts were estimated and normalized by both 
each transcript's length and the total yield of the sequencer using Cufflinks 
(version 2.1.1, default parameters and “-p 2”) (Trapnell et al., 2012). Among all 
Cufflinks reported transcript abundances, the Fragments Per Kilobase of exon 
per Million fragments mapped (FPKM), values larger than 0.125 in all samples 
were kept for the following statistical analysis. This filter guaranteed the median 
correlation coefficient >0.96 between any two biological replicates while kept 
~65% of all transcripts, including 11789 coding genes (Ensembl annotation, 
mm10, 2014 April version). Differential expression between mutant samples 
(n=2) and wild types (n=4) was tested using Cuffdiff (v2.1.1) (Trapnell et al., 
2012) Although Cuffdiff lacks power for designs with fewer than three replicates 
per group, the low variability of the two biological replicates in all cases (r>0.96) 
guarantees the statistic power of a fold change to reveal biologically meaningful 
results. All genes with an adjusted p-value less than 0.05 and the absolute fold 
change larger than 1.57 were called significant.  
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Large Scale bioinformatics analysis of TBX5 binding sites 
Differentially expressed genes were determined by q-value (<0.05) and 
status (“OK”).  Those genes that did not meet the status threshold were given a 
non-significant q-value (qval=1). TBX5 ChIP-Seq FASTQ data was downloaded 
from GEO (GSE21529).  Tags were filtered using Tag-dust (Lassmann et al., 
2009) and aligned to the mouse genome (mm9) using bowtie (Langmead et al., 
2009).  Peaks were called using MACS2 (Zhang et al., 2008) with default 
parameters.  Peaks were associated with differentially expressed genes and 
differential motif enrichment was determined using BETA (Wang et al., 2013) 
with the following options –-pn 40000 and –-df 0.05 –-da 1.  Because BETA uses 
a curated database that lacks the TBX5 motif, TBX5 peaks associated with 
differentially regulated genes were also analyzed for motif enrichment using 
HOMER (Heinz et al., 2010). Genes associated with TBX5 regulation were then 
analyzed for pathway enrichment using DAVID (Huang da et al., 2009).  The top 
10 (by p-value) KEGG pathways are shown for both activated and repressed 
genes.  
 
Chromatin IP 
HEK-293 cells were transfected with the Kctd16-Luciferase construct used 
in transcriptional assays, as well as wild type TBX5 or TBX5S261C (20 µg total 
DNA) using FuGene 6 (Promega). Cells were fixed in 1% PFA for 10 minutes at 
RT. 10 million cells were used per ChIP. Cells were lysed in ChIP Buffer (50mM 
Tris pH 7.5, 140 mM NaCl, 1mM EDTA, 1 mM EGTA, 0.1% sodium 
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deoxycholate, 0.1% SDS), sonicated using a Branson 450d, 12 cycles, 30s/cycle 
(1s on, 0.5s off), 30% amplitude), and spun at top speed to isolate chromatin. 
Triton X-100 was added to 1%, and the chromatin was added to CHD4-
conjugated Protein G beads (Life Technologies) at 4°C O/N. ChIP was resumed 
using ChIP Protocol (Agilent). ChIP primer sequence is available in 
Supplemental Experimental Procedures. 
 
TBX5 NID Modelling 
The mouse TBX5 sequence was submitted to the DisProt PONDR-FIT 
disorder predictor in order to identify disordered regions in the protein. Both the 
entire protein and just the NID region were submitted to the fold recognition 
server HHpred (http://toolkit.tuebingen.mpg.de/hhpred) to determine if any 
suitable templates were available for structural modeling. A small coil-to-helical 
region involving residues 255-264 was predicted by HHpred. This region of TBX5 
was modeled based on the correspondingly small region of the structure of the 
CRISPR-associated protein [PDB ID 3VZI]. 
 
RESULTS 
Generation of the Tbx5Avi allele 
Past attempts to isolate endogenous T-box protein complexes have been 
hampered by their relative low abundance and insolubility. Therefore, we 
introduced an Avitag epitope into the murine Tbx5 locus via homologous 
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recombination to generate a Tbx5Avi allele (Figure S3.1). The Avitag is a small 
peptide tag that is biotinylated in the presence of the bacterial enzyme BirA. 
Thus, the Avitag/BirA system combines minimal structural invasiveness with the 
specificity and strength of the biotin-streptavidin interaction. This is the strongest 
non-covalent peptide-ligand interaction in nature, and therefore the affinity greatly 
exceeds that of any antibody-antigen interaction (Bayer and Wilchek, 1980; 
Maine et al., 2010; Roesli et al., 2006; van Werven and Timmers, 2006; Wang et 
al., 2006); Tbx5Avi mice were mated to mice ubiquitously expressing BirA 
(Rosa26BirA) (Driegen et al., 2005). The Tbx5Avi; Rosa26BirA compound 
homozygous mice show no overt phenotype, have no cardiac phenotype, and 
are fertile. Thus, the Avitag appears to have no effect on TBX5 activity, and 
expression of biotinylated TBX5Avi is not deleterious to embryonic development. 
 
Isolation and characterization of the endogenous TBX5 interactome  
To define the TBX5 cardiac interactome, we performed mass 
spectrometry analysis of affinity-purified TBX5 complexes from 
Tbx5Avi/Avi;Rosa26BirA/BirA cardiac nuclei (Figure 3.1A). We used an unbiased gene 
ontology-based bioinformatics classification to screen the functions of proteins 
associated with TBX5 at a statistical relevance versus Tbx5Avi/Avi alone (no BirA) 
and Rosa26BirA/BirA  alone. This analysis defined a subset of 58 candidate 
interactions (Table S3.1). We analyzed these candidates by functional network 
analysis; drawing upon the STRING database of protein-protein interactions, 40 
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out of the 58 candidates were assigned to a single interconnected network 
(Figure 3.1B, S3.2).  
  
TBX5 interacts with components of the Nucleosome Remodeling and 
Deacetylase (NuRD) complex in vivo 
Analysis of the TBX5 interaction network identified the Heterodimeric 
Facilitates Chromatin Transcription (FACT) complex and several members of the 
transcription initiation factor TFIID complex, both of which play roles in RNA Pol 
II-dependent gene transcription (Berk, 1999; Saunders et al., 2003) (Figure 
3.1B). TBX5 has been long considered to be a cardiac transcriptional activator. 
Surprisingly, in our analysis we identified TBX5 in association with multiple 
components of the NuRD complex (Figure 3.1B, C), which in most instances 
functions as a chromatin modifying complex that represses gene transcription 
(Wade et al., 1998; Xue et al., 1998). We find TBX5 in association with six 
components of the NuRD transcriptional repression complex: CHD4, MTA1, 
RBBP4, GATAD2a, GATAD2b, and HDAC2. All the components required for a 
functional NuRD complex were identified in association with TBX5, as CHD3 
commonly acts in a mutually exclusive manner with CHD4, RBBP7 and RBBP4 
act redundantly, and an additional component of the NuRD complex, MBD3, has 
been suggested to be dispensable for transcription factor recruitment (e.g., by 
hunchback (Kehle et al., 1998)). We confirmed the interaction of TBX5 with 
multiple members of the NuRD complex in adult cardiac nuclear extracts (Figure 
3.1C).  
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As TBX5 has been shown to be required for cardiogenesis at E9.5 
(Bruneau et al., 2001), we established expression of components of the NuRD 
complex in cardiac tissue at E9.5 (Figure S3.2B). We found that members of the 
NuRD complex are ubiquitously expressed in the heart at this stage. We further 
demonstrate that endogenous TBX5 (untagged TBX5) interacts with CHD4 at 
E9.5 (Figure 3.1D).  
 
TBX5 and MTA1 and atrial septation   
To further define the relationship between TBX5 and the NuRD complex, 
we generated mice heterozygous null for Tbx5 and a central component of the 
NuRD complex, Mta1 (Figure 3.2, S3.3, 3.4). At E13.5, Mta1+/- mice have no 
apparent cardiac defects (Figure 3.2C), whereas Tbx5+/- mice exhibit partially 
penetrant cardiac defects as previously described, including atrial septal defects 
(ASD), ventricular septal defects (VSD) and atrioventricular septal defects 
(AVSDs) (Figure 3.2D) (Baban et al., 2014; Basson et al., 1994; Basson et al., 
1999; Benson et al., 1996; Bruneau et al., 1999; Bruneau et al., 2001; McDermott 
et al., 2005). Tbx5+/-; Mta1+/- heterozygous null embryos demonstrated a higher 
frequency of AVSDs than either single heterozygote alone (n=12/14 
heterozygous null vs 4/10 Tbx5-/-) (p<0.03) (Figure 3.2E, S3.3D). Furthermore, 
Mta1-/- hearts also do not have AVSDs at this stage (Figure S3.4). Tbx5+/-; Mta1+/- 
heterozygous null embryos also showed defects in the formation of the dorsal 
mesenchymal protrusion (DMP), similar to Tbx5+/- mice. We find no change in the 
left ventricular chamber width or left ventricular wall thickness (Figure S3.3E-F) 
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and further observe that the inferior and superior cushions are present and 
normal in size, and that the AV valves are apparent (Figure S3.3G-L). To rule out 
a developmental delay in septation in the Tbx5+/-; Mta1+/- heterozygous null 
embryos, we examined Tbx5+/-; Mta1+/- heterozygous null embryos at E14.5 and 
consistently observe AVSDs at this time point (Figure S3.3M-N). Taken together, 
these results demonstrate an additive genetic requirement for Tbx5 and Mta1, 
providing genetic evidence for a role for the TBX5-NuRD interaction in atrial 
septum formation. 
 
TBX5 acts to repress neural and cancer related genes in cardiac tissue 
The finding that TBX5 and components of the NuRD complex interact 
biochemically and genetically led us to hypothesize that TBX5 can function to 
repress aberrant gene expression in the developing heart. To test this 
hypothesis, we performed transcriptional profiling of embryonic Tbx5 null hearts 
to determine the gene targets of TBX5 repression. We performed RNA-seq 
analysis at E9.5 from wild type and Tbx5-/- hearts to define genes differentially 
expressed between wild type and Tbx5 null hearts (Figure 3.3A, Table S3.2). 
From this data, we found 1171 genes significantly downregulated in the Tbx5 null 
heart and 1361 genes significantly upregulated in the Tbx5 null heart (Table 
S3.2). We overlaid TBX5 ChIP-seq data (He et al., 2011) with genes upregulated 
in the Tbx5 null heart. From this analysis, we identified 928 genes that were 
potentially directly repressed by TBX5 (Table S3.3). 
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 To validate the genes putatively repressed by TBX5, we rank ordered the 
928 genes based first on relative change in expression between wild-type and 
Tbx5-/- hearts and then the number of reads in the ChIP-seq data set (Table 
S3.3). From this list, we cloned the top 15 of the ChIP peak sequence elements 
from 14 genes and performed transcriptional assays (Figure 3.3B-M, S3.5). Of 
the candidate genes tested, 11 were repressed by TBX5. This set of genes could 
be divided into two categories: Casz1, Fgf11, Gad1, Kcne3, Kctd16, Nxph4, 
Plekha2, and Sncb are expressed in neural lineages (Diez-Roux et al., 2011; 
Dorr et al., 2015; Liu et al., 2011; Metz et al., 2011; Smallwood et al., 1996; 
Sopher et al., 2001; Trifonov et al., 2014; Wang et al., 2014), while Casz1, 
Col20a1, Fgf11, Gad1, Klf4, Mef2b, and Plekha2 are expressed in a divergent 
subset of cancers (Costantini et al., 2009; Evans and Liu, 2008; Hu et al., 2015; 
Huang et al., 2013; Kimura et al., 2013; Ying et al., 2013). Altogether, these data 
demonstrate that TBX5 function is essential for in vivo transcriptional repression 
and prevention of ectopic expression of neural and cancer related genes in the 
heart. 
 
TBX5 binds to the same consensus site in activated and repressed target genes 
As we have now shown TBX5 to act as both a transcriptional activator and 
a transcriptional repressor, we sought to characterize differences between TBX5 
activated genes and TBX5 repressed genes. Therefore, we performed 
bioinformatics analysis on TBX5 binding sites on a larger scale. From our ChIP-
seq and RNA-seq data, 71,624 TBX5 peak regions were identified by enrichment 
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of signal using MACS2 (Zhang et al., 2008).  These peak regions demonstrated a 
significant association with genes that were differentially regulated between Tbx5 
wild type and Tbx5-/- hearts. Given that a large number of peaks can skew results 
in gene-association analyses, we varied the number of analyzed peaks from 
10,000 to 70,000 in increments of 10,000.  In every instance, TBX5 was 
significantly associated with differentially expressed genes (data not shown). We 
selected the top 40,000 peaks for subsequent analyses since the inclusion of 
additional peaks minimally increased the number of associated genes (data not 
shown).  We identified an association between TBX5 and 82% of genes 
differentially expressed between Tbx5 wild type and Tbx5-/ -hearts (2988 of 3634, 
Figure S3.6A). Of these genes, about half were activated and half were 
repressed by TBX5. Both groups demonstrated a statistically significant 
enrichment in TBX5 binding sites in the TBX5 ChIP-peak regions (activated 4.88 
x 10-141, repressed p = 1.29 x 10-142, KS test, Figure S6B).  Genes repressed by 
TBX5 were enriched in pathways involved in cancer as well as cardiac diseases, 
while genes activated by TBX5 were enriched in pathways involved in cell cycle 
and DNA replication, a known function of TBX5 (Figure S3.6C) (Goetz et al., 
2006). Interestingly, the TBX5 consensus motif was found equally abundant at 
regions associated with activated and repressed genes (Figure S3.6D).  
 
TBX5 interacts with the NuRD complex through a coil-α-helix domain 
To gain insight into the mechanisms of TBX5-NuRD mediated repression, 
we mapped the protein interaction domains of TBX5 and the catalytic core 
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component of the NuRD complex, CHD4 (Figure 3.4). Streptavidin pulldown of 
TBX5 complexes demonstrated that an N-terminal human CHD4 region 
containing one pair of plant homeodomains (Phd) and one pair of chromo 
domains was required for interaction with mouse TBX5 (Figure 3.4A, C). 
However, we found that deletion of either the Phd or chromo domains does not 
ablate the interaction between TBX5 and CHD4, demonstrating that the Phd and 
chromo domains are not required for the interaction between TBX5 and CHD4 
(Figure 3.4D). We further demonstrated that a TBX5 region C-terminal to the T-
box was necessary and sufficient for interaction with CHD4 (amino acids 238-
340) (Figure 3.4B, E-F). As the majority of the TBX5 protein interactions occur N-
terminal to and within the T-box, we sought to characterize this protein-protein 
interaction motif.  We noted that this previously uncharacterized region was 
highly conserved across 48 TBX5 orthologues (Figure 3.5B), and that this 
domain was predicted to form a Coil followed by an α-Helix (Figure 3.5C, D). We 
have termed this structural-functional region of TBX5 the NuRD Interaction 
Domain (TBX5NID) (Figure 3.5A). 
 
The TBX5-NuRD interaction is essential for cardiac development and function in 
humans 
The majority of TBX5 mutations associated with CHD are located within 
the T-box, with most causing either a loss of TBX5 DNA binding or degradation 
by non-sense mediated decay (Fan et al., 2003a; Fan et al., 2003b; Mori and 
Bruneau, 2004). In addition, there exists a subset of CHD-associated mutations 
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that lie in the C-terminus of TBX5, outside the T-box; the resulting mutant forms 
of TBX5 are stable, nuclear localized and bind DNA. The molecular basis for 
these CHD-associated mutations however, has been unknown. We found mis-
sense mutations that correspond to TBX5-associated CHD in the C-terminal 
region of TBX5 that fall within the TBX5NID including: TBX5S252I, TBX5S261C, 
TBX5V263M, TBX5K266R, and TBX5Q292R (Heinritz et al., 2005) (Figure 3.5A). We 
investigated the physical location of these TBX5 amino acids on the predicted 
NID structural domain and observed that the amino acids align along a single 
interaction surface of the TBX5NID α-Helix (Figure 3.5D). We hypothesized the 
CHD mis-sense mutations in the TBX5NID disrupt the TBX5-CHD4 interaction. 
 We tested the prediction that TBX5 mis-sense mutations in the TBX5NID 
alter the TBX5-NuRD association. Three single mis-sense mutations within the 
TBX5NID (TBX5S261C, TBX5V263M, and TBX5K266R) each abolished the interaction 
between TBX5 and both CHD4 and MTA1, and an additional two other CHD 
single mis-sense mutations (TBX5S252I and TBX5Q292R) reduced the interactions 
(Figure 3.5E). These results support the hypothesis that disruption of the TBX5-
NuRD complex in vivo leads to cardiac abnormalities associated with HOS.  
 
TBX5 represses a neural and cancer associated target gene in a NuRD 
dependent manner 
Having demonstrated that the TBX5-NuRD interaction is disrupted in 
CHD-associated mutations in the NID, we queried if repression of TBX5 target 
genes was NuRD dependent. We performed transcriptional assays and observed 
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that, of the 11 validated targets repressed by TBX5, Kctd16 and Mef2b fail to be 
repressed by TBX5 containing the CHD associated mutation TBX5S261C (Figure 
3.6A-B, S3.5). Moreover, TBX5S261C failed to repress transcription of multiple 
elements of the Mef2b gene (Figure 3.6B-D). Taken together, with results 
showing that we were able to ChIP CHD4 in the presence of TBX5 to these 
elements (Figure 3.6E-F), these results imply the TBX5-NuRD complex is 
required to repress inappropriate gene expression in the heart and further 
suggest a subset of CHD mutants leads to the mis-expression of genes including 
Mef2b in the developing heart. 
 
The TBX5-NuRD interaction arose concomitantly with the evolution of atrial 
septation 
Phylogenetic analysis of forty-eight TBX5 orthologues demonstrates there 
is a complete conservation of the TBX5NID amino acids mutated in TBX5-
associated CHD in animals with a septated heart (TBX5S261, TBX5V263, TBX5K266) 
(e.g. Xenopus to human) (Figure 3.7). In contrast, orthologues of TBX5 in 
vertebrates that lack a septated heart (e.g. zebrafish) have amino acid 
substitutions present in human CHD patients that we show ablate the TBX5-
NuRD interaction (Figure 3.5E).  We hypothesized that the Xenopus ortholog of 
Tbx5 would interact with the NuRD complex, but a Xenopus Tbx5 ortholog with 
zebrafish NID amino acid substitutions would fail to interact with the NuRD 
complex. To test this hypothesis we generated the K266R mutation in the 
Xenopus ortholog of Tbx5 (xTbx5K266R) and found that while mTBX5 and xTbx5 
 115	  
interact with the NuRD complex, xTbx5K266R has a disrupted interaction with 
CHD4 (Figure 3.7B). Thus, our data suggested that the TBX5-NuRD interaction 
arose coincidentally with the evolution of atrial septation and it is an essential 
component of an evolutionarily conserved mechanism for atrial septum 
formation. 
 
DISCUSSION 
Here we report the isolation and characterization of the first in vivo TBX5 
interactome. For over 20 years, studies have defined TBX5 as an activator of 
transcription. However, our analysis shows that TBX5 interacts biochemically and 
genetically with the transcriptional repression machinery of the NuRD complex. 
We further report that TBX5 acts to repress neural and cancer related genes in 
cardiac tissue. Our observation that only a subset of TBX5-repressed target 
genes failed to be repressed by the TBX5 HOS mutation TBX5S261C (Figure 3.6A-
D, S3.7) implies that TBX5-mediated repression occurs in both a NuRD-
dependent and NuRD-independent manner. We favor a model by which TBX5 
regulates growth and differentiation of cardiomyocytes in part through the 
repression of alternate lineage-specific gene regulatory networks, including 
neural and cancer networks. This model is consistent with the observation that 
Tbx5 null mice and human HOS patients display defects in atrial and ventricular 
septal growth, as well as cardiac conduction abnormalities.  
 We note we did not identify at statistical relevance (95% peptide identity 
and 99% protein identity) proteins previously shown to interact with TBX5 
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through in vitro studies (BRG1, NKX2.5, GATA4, TBX20, Myocardin, TAZ and 
BAF60C). However, if we relax the statistical cutoffs we were able to identify 
BRG1 (SMARCA4) in complex with TBX5 interaction partners (Takeuchi et al., 
2011). There are several reasons why we may not have identified these proteins. 
First, the proteins may not be soluble in the lysis buffer that was optimized for 
TBX5 and therefore lost. Second, they may not interact with TBX5 at the time 
points we performed the study. Third, although their interactions may be 
essential for TBX5 function, their kinetics may not allow the complex to be 
isolated by pulldown as we have performed. It remains a formal possibility that 
these proteins do not physically associate in vivo.  
 
TBX5 and atrial septation 
We have previously shown that Tbx5 is specifically required in second 
heart field (SHF) derivatives for atrio-ventricular septation (Xie et al., 2012).  A 
crucial aspect of atrio-ventricular septation is the development of the dorsal 
mesenchymal protrusion (DMP), a structure derived from the SHF. We observed 
DMP abnormalities in Tbx5+/- mice (Xie et al., 2012) and further observed 
absence of the DMP in Tbx5+/-; Mta1+/- compound heterozygotes. This suggests 
the AVSDs in Tbx5+/-; Mta1+/- compound heterozygotes may result from absence 
of a SHF-derived structure.  Taken together, our data suggest that the TBX5-
NuRD interaction arose coincidentally with cardiac atrial septation. This 
hypothesis is further supported by our observations that Tbx5+/-; Mta1+/- 
compound heterozygous mice have a higher frequency of AVSDs than either 
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single heterozygote (Figure S3.3D). AVSDs have been reported in 18 HOS 
patients, and 10 have been characterized to date (Baban et al., 2014). Of these, 
6 of the mutations lead to the introduction of a stop codon before the TBX5NID, 
and one mis-sense mutation maps within the TBX5NID and ablates the TBX5-
NuRD interaction (Figure 3.5E). Thus, we find a correlation between the 
phenotype of patients displaying AVSD and the genotype of those TBX5 patient 
mutations specifically lacking or altering the TBX5NID.   
 
CONCLUSIONS 
Our studies demonstrate that a proteomic-based approach coupled with 
protein modeling provides a powerful predictive strategy in prioritizing patient 
mutations. This type of approach should be broadly applicable to the analysis of 
protein complexes in any cell or tissue type. The power of such an approach is 
underscored by recent high-throughput sequencing studies that have led to the 
identification of a vast number of somatic mutations in coding regions of potential 
disease causing genes. Exploiting such large datasets has proved problematic 
because it has not been possible to determine which mutations are naturally 
occurring, non-disease associated variants and which are disease-causing. 
Results presented here demonstrate a novel proteomic-modeling based strategy 
that can serve to prioritize mis-sense mutations and, therefore, correlate disease 
associated phenotypes with specific mutations. 
The authors declare no financial interests. 
 118	  
 
FIGURES 
Figure 3.1. TBX5 interacts with the NuRD complex.  
(A) Overview of the isolation and characterization of the endogenous cardiac 
TBX5 interactome. (B) TBX5 transcriptional interaction network. Network nodes, 
labeled with mouse gene symbols, are candidate direct or indirect TBX5 protein 
interactions identified from affinity enrichment of biotinylated TBX5. Network 
edges represent known and/or predicted functional interactions in the STRING 
database. Edge thickness reflects the combined STRING evidence score for 
each binary relationship. Thicker edges represent increased interaction evidence. 
Selected transcriptional complexes within the network are highlighted in red 
dashed boxes. (C) Affinity isolation of endogenous TBX5Avi from 4 week cardiac 
nuclei confirms interaction of TBX5 with endogenous components of the NuRD 
complex. (D) Affinity isolation of TBX5 from E9.5 hearts further confirms 
interaction of TBX5 with the NuRD component CHD4 in the embryonic heart. 
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Figure 3.2. TBX5 and the NuRD complex genetically interact.  
Histology staining (Hematoxylin and Eosin) of heart tissue at E13.5 (A) Low 
magnification of a wild type heart. (B) High magnification of a wild type, (C) 
Mta1+/- , (D) Tbx5+/- and, (E) Tbx5+/-; Mta1+/ heart. Note that the Tbx5+/-; Mta1+/ 
hearts exhibited cardiac defects including ASD and AVSD (asterisk). Cardiac 
defects are characterized and quantified in Figure S3. as = atrial septum, ivs = 
intervectricular septum, la = left atrium, lv = left ventricle, ra = right atrium, rv = 
right ventricle. 
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Figure 3.3. TBX5 functions to repress neural and cancer genes in cardiac 
tissue. 
(A) Schematic overlay between genes upregulated in RNA-seq between wild 
type and Tbx5-/- heart tissue and TBX5 ChIP-seq data (He et al., 2011) reveals 
928 genes that are both upregulated in a Tbx5-/- null and bound by TBX5. (B) 
Summary of fold change (RNA-seq) and ChIP-seq peak values of the 15 top rank 
ordered genes. (C-M) Gene reporter elements cloned from potential TBX5 
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targets in the presence or absence of TBX5. Transcriptional assays of target 
genes show TBX5 acts as a transcriptional repressor in 11 of 15 elements tested 
(additional data in Figure S6). Genes defined as neural are shown in red, 
expressed in cancer as blue, or both as purple. Graphs are plotted as the mean 
luciferase value ± SEM. Student’s two tailed t-test was used to perform statistical 
analysis. * p< 0.05 *** p < 0.001. 
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Figure 3.4. Mapping the interaction domains of CHD4 and TBX5 
(A) Schematic of CHD4 deletion constructs. Phd= Plant homeo domain. CHD4 
FL = aa 1-1937, CHD4 N = aa 1-758, CHD4 C = aa 1183-1937, TBX5 FL = aa 1-
518, TBX5 N = aa 1-237, TBX5 C = aa 238-518. (B) Schematic of TBX5 deletion 
constructs. NLS = Nuclear Localization Signal. AD = Activation domain. (C-D) 
Affinity isolation of full-length TBX5-Avi-V5 with GFP-tagged CHD4 deletions 
reveals that CHD4 interacts with TBX5 via sequences in the N-terminus of 
CHD4, but that the Phd and chromo domains are not individually required for the 
TBX5-CHD4 interaction. (E-F) Affinity isolation of CHD4 with a TBX5-Avi-V5 
deletion series demonstrates TBX5 sequences aa 238-340 are both necessary 
and sufficient for interaction with CHD4. This region has been termed the NuRD 
interaction domain (NID).  
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Figure 3.5. Congenital heart disease associated mutations of TBX5 disrupt 
the TBX5-NuRD interaction. 
(A) Schematic of human TBX5 protein showing location of a subset of CHD 
associated mis-sense mutations. NID= NuRD interacting domain (aa 238-340). 
(B) Sequence alignment of the TBX5NID from 48 TBX5 ortholgues. Height of 
letters is relative conservation at that residue. (C) Structural prediction of the 
TBX5NID shows the TBX5NID is comprised of a coil region followed an α-helix. (D) 
CHD associated mis-sense mutations align along a single surface of the α-helix 
and are predicted to disrupt protein-protein interactions (representative residues 
TBX5S261, TBX5V263, and TBX5K266 shown in dark blue). (E) Immunoisolation of 
V5-tagged CHD associated mis-sense mutations of TBX5 probed for CHD4 and 
MTA1. 
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Figure 3.6. Congenital heart disease associated mutations of TBX5 disrupt 
TBX5-NuRD complex activity. 
(A-D) Transcription of the regulatory regions of TBX5 target genes in response to 
wild type TBX5 (second column) or TBX5S261C (third column). Additional gene 
targets shown in Figure S7. n= 9 per transcriptional assay. Graphs are plotted as 
the mean luciferase value ± SEM. Student’s two tailed t-test was used to perform 
statistical analysis. *** p < 0.001. (E) Schematic of ChIP primer location on 
Kctd16 element. The T-box binding element (asterisk) is noted. (c) ChIP of CHD4 
from cells co-transfected with Kctd16-Luciferase in the presence of absence of 
TBX5. 
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Figure 3.7. The TBX5-NuRD interaction evolved concurrently with atrial 
septation. (A) Phylogenetic comparison of TBX5 orthologues with boot-strap 
values. Dark green brackets represent animals with a septated heart. Light green 
brackets represent animals without a septated heart. Sequence of core amino 
acid residues required for the TBX5-NuRD interaction are shown to the right. 
Amino acid residues mutated in TBX5-associated CHD are bolded, and a K->R 
substitution from fish to frog is highlighted in pink. (B) Immunoisolation of V5-
tagged TBX5 orthologs probed for CHD4.  
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Figure S3.1, Related to Figure 3.1. Generation of a Tbx5Avi knock-in mouse  
(A) (Top) The Tbx5-Avi targeting cassette contains the biotin acceptor peptide 
(Avi) fused in frame to the terminal coding exon of Tbx5. Neo-neomycin 
resistance gene. PGK- phosphoglycerate kinase-1 promoter. Amp-Ampicillan 
resistance gene. Exons colored brown represent untranslated exons (5’ and 3’ 
UTR). Exons colored orange represent the T-box DNA binding domain. Exons 
colored green represent the nuclear localization signal. Exons colored pink 
represent the activation domain. (Middle) Schematic of the Tbx5 recombined 
locus (Tbx5Avi-Neo) upon homologous recombination. (Bottom) Schematic of the 
Tbx5 locus upon introduction of Cre (Tbx5Avi). (B) Southern blot of positive 
embryonic stem cell clone confirms homologous recombination. (C) Southern 
blot of F2 mice confirms removal of Neo cassette upon introduction of Cre. 
Samples were run on the same gel but were noncontiguous. (D) RT-PCR 
analysis of Tbx5Avi/+ adult hearts demonstrates presence of Tbx5Avi mRNA. 
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Figure S3.2, Related to Figure 3.1. The TBX5 transcription interaction 
network. 
(A) Sixty mouse genes corresponding to TBX5 candidate interactions as 
identified by the gene ontology function of transcription were uploaded to the 
STRING database (www.string-db.org). STRING functional relationships were 
evaluated with default settings with text mining disabled. Forty proteins were 
clustered in a single protein interaction network, reflecting a minimum combined 
STRING score of > 0.4 (medium confidence) between each binary relationship 
(left). This network was imported to Cytoscape for further processing (see Figure 
1). The remaining 20 nodes with scores < 0.4 are illustrated as disconnected 
(bottom). (B) RT-PCR analysis of all possible members of the NuRD complex 
demonstrates the NuRD complex is present in both the adult and embryonic 
heart. 
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Figure S3.3, Related to Figure 3.2. TBX5 and MTA1 and atrial septation. 
Histology staining (Hematoxylin and Eosin) of (A) Mta1+/-, (B) Tbx5+/- and, (C) 
Tbx5+/-; Mta1+/- mice at E13.5. (D) Quantification of cardiac defects seen in all 
mice. Both chi-squared and Fisher’s exact test show that the cardiac defects 
seen in Tbx5+/-; Mta1+/- are significant as compared to wild type and Tbx5+/-. (E-F) 
Measurements of left ventricular (LV) chamber width (E) and wall thickness (F) of 
wild type and Tbx5+/-; Mta1+/- embryonic hearts (n=11 per genotype) at E13.5 
from the 4-chamber view at the widest part. Data is reported as either chamber 
width or wall thickness in millimeters ± SEM.  P value was determined by 
Student’s T- test. (G-L) Histology staining at E13.5 through the entirety of one 
Tbx5+/-; Mta1+/- heart from superior to inferior orientation demonstrates that the 
inferior and superior cushions are present and appear normal in size. The 
cushions are normally populated by mesenchymal cells, and both AV valves are 
apparent. (M-N) Histology staining of (M) wild type and (N) Tbx5+/-; Mta1+/- mice 
at E14.5 demonstrates AVSD at this stage (asterisk). 
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Figure S3.4, Related to Figure 3.2. Mta1-/- embryos undergo normal heart 
chamber septation.  Histology staining (Hematoxylin and Eosin) of heart tissue 
at E13.5. Low magnification transverse section through (A) wild-type heart and 
(B) Mta1-/- heart. Asterisks denote region of higher magnification, arrows denote 
leaflets of venous valve of inferior vena cava, scale bar=310µm. High 
magnification of asterisk region in (C) wild-type heart and (D) Mta1-/- heart at 
point of chamber septation. Scale bar=130µm.  la = left atrium, lv = left ventricle, 
ra = right atrium, rv = right ventricle. 
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Figure S3.5, Related to Figure 3.3. Transcriptional targets not repressed by 
TBX5. 
(A-D) Gene reporter elements cloned from potential TBX5 targets in the 
presence or absence of TBX5. Data is reported as the mean ± SEM. Student’s T-
test was used to determine significance.  *** p < 0.001. 
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Figure S3.6, Related to Figure 3.3. Analysis of TBX5 binding motifs in 
activated vs repressed genes. (A) Schematic overlay between TBX5 peaks 
(He et al., 2011) and differentially expressed genes between wild-type and Tbx5 
null heart tissue.  2988 genes are differentially expressed and associated with a 
TBX5 peak.  Inset is number of up and downregulated genes. (B) 
Activating/Repressive function prediction of TBX5 peaks.  Red and purple lines 
represent up and down-regulated genes. Black dashed line represents 
background (static genes).  Genes are ranked from high to low based on their 
regulatory potential score (RPS) determined by BETA.  P values represent 
significance of up or down-regulated group relative to background (static genes) 
by Kolmogorov-Smirnov test. (C) Kegg Pathway enrichment of down-regulated 
genes associated with TBX5 binding ranked by –log10(pvalue). (D) TBX5 
consensus motif (top) and top motif from de novo identification (bottom) and its 
presence at ChIP-seq peaks associated with activated or repressed genes. 
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Figure S3.7, Related to Figure 3.6. Targets repressed by TBX5 in a NuRD 
independent manner. 
(A-I) TBX5-repressed gene reporter elements and in the co-transfected with wild 
type TBX5 or TBX5S261C. Genes sorted into neural (red), cancer (blue), or both 
(purple). Data is reported as the mean ± SEM. Student’s T-test was used to 
determine significance * p< 0.05 *** p < 0.001.
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Table S3.1. Spectral counts for TBX5 interacting proteins 
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Table S3.2.  Complete list of genes misregulated in Tbx5 null hearts 
This excel spreadsheet can be found on Frank Conlon’s lab website 
(http://www.unc.edu/~fconlon/index.htm) 
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Table S3.3.  Complete list of genes misregulated in Tbx5 null hearts 
This excel spreadsheet can be found on Frank Conlon’s lab website 
(http://www.unc.edu/~fconlon/index.htm) 
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Table S3.4. Ranked gene list of TBX5-mediated repressed genes for 
validation. Genes highlighted in orange were cloned and validated by 
transcriptional assay. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Generation of Tbx5Avi mice 
Genotyping primers for Tbx5Avi/Avi; Rosa26BirA/BirA mice. 
Genotyping Primers Sequence 
Wild type Tbx5 F: CGGCGTGCCCAGGACCCTGT 
R: GGCACAGGTCAGCCTTTAGC 
Tbx5Avi F: CGGCGTGCCCAGGACCCTGT 
R: GCGCGCCTTCGTGCCATTCGA 
Sox2-Cre F: GTCCCCTTCTCCATCTCCAG  
R: GCAAACGGACAGAAGCATTT 
Neo F: AGGATCTCCTGTCATCTCACCTT 
R: CTAGAGAATTGATCCCCTCAGAAG 
Presence of BirA F: TTACGCAAGCTGGGTGCAGA 
R: TTACGCAAGCTGGGTGCAGA 
Absence of BirA F: GTGTAACTGTGGACAGAGGAG 
R: GAACTTGATGTGTAGACCAGG 
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Transcriptional assays 
TBX5 target gene primers for transcriptional assays. 
ChIP cloning PCR Primers Sequence 
Casz1-1 F: ATCGGGTACCTGTCCCTTTCTTCTGTCCCA 
R: ATCGGGTACCAGGCATAAGATCGCTGGAAA 
Casz1-2 F: ATCGGGTACCACCATCCATCCTCGTGTAGC 
R: ATCGGCTAGCGCCAAAAACAGTGGCCTAAA 
Col20a1 F: ATCGGCTAGCATCGAGTGTGTCAGCTGTGG 
R: ATCGAAGCTTCCGTGGTGCTGTGTTCTTAC 
Fbxl20 F: GATCACGCGTGGCCCAAGGAATGGGTACT 
R: GATCACGCGTCCACAGTCGCCTCTATCGTC 
Fgf8 F: CGAGGCTAGCCCAGCTCCCTCCTTCCTTTA 
R: CGAGGGTACCGGCAGCTTTCTGTCTTGGTT 
Fgf11 F: 
GCACAGATCTGGGACTCCCTAACTGTCGTACC 
R: GCACACGCGTCCGCTGGAGCTAGTCAGG 
Gad1 F: CGAGGGTACCCACTGGAATTCCTACCGTGA 
R: CGAGGCTAGCCAAGGCGTTCTGGTCTAAGG 
Kcne3 F: CGCTACGCGTGTGCCACACAGCTACAATAA 
R: CGCTCTCGAGTCCGGTGAACACTGCAATAA 
Kcnn2 F: GATCGGTACCCTGGTCTCCCTGCAGCTTTA 
R: GATCGCTACGGTTGTCCTGGCTCTGTTGCT 
Kctd16 F: AGGACGCGTTGCTTGTGCAAACTCCAGAC 
R: GACCAGATCTAGGCAGGGCGACAGATAGAT 
Klf4 F: ATCGACGCGTCTTGGCGTGAGGAACTCTCT 
R: ATCGAGATCTCGCTCAAATGGGCCTCTA 
Mef2b-1 F: CGAGGTACCTCTTCTCTCGGACGGACCTA 
R: CGAGGCTAGCCACACACACTCACGGCTCTC 
Mef2b-2 F: CGAGGCTAGCCTGCACAGGGACCCACAG 
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R: CGAGGCTAGCCTGCACAGGGACCCACAG 
Mef2b-3 F: CGAGGGTACCGCGTGCGATCACCATAACT 
R: CGAGGCTAGCAGGGGCTGCGATGTAGGT 
Nxph-4 F: CGAGGGTACCGCTTGCAGAAGGGTATCTGG 
R: CGAGGCTAGCTAAGCCTCCAGGCATTCAAC 
Plekha2 F: GATCGGTACCTAACTTGGAACCGACCTACG 
R: GATCGCTAGCTTTCACACCTGAGCGAACTG 
Sncb F: CACGGGTACCTCCCTCCACTGCCTCCAC 
R: CAGCGCTAGCGCTCCAGGGTCCTCCTAGTC 
 
DNA constructs 
Site directed mutagenesis primer pairs. Amino acid changes are represented in 
bold. 
mTBX5S252I F: GATGTCTCGGATGCAAATTAAAGAGTATCCTGTGGTTC 
R: GAACCACAGGATACTCTTTAATTTGCATCCGAGACATC 
mTBX5S261C F: GTATCCTGTGGTTCCCAGGTCGACAGTGAGGCACAAAG 
R: CTTTGTGCCTCACTGTCGACCTGGGAACCACAGGATAC 
mTBX5V263M F: GGTTCCCAGGAGCACAATGAGGCACAAAGTCACCTCC 
R: GGAGGTGACTTTGTGCCTCATTGTGCTCCTGGGAACC 
mTBX5K266R F: GAGCACAGTGAGGCACAGAGTCACCTCCAACCACAGC 
R: GCTGTGGTTGGAGGTGACTCTGTGCCTCACTGTGCTC 
mTBX5Q292R F: CAATTTAGGGTCCCAGTACCGGTGTGAGAATGGTGTC 
R: GACACCATTCTCACACCGGTACTGGGACCCTAAATTG 
xTbx5K266R F: GTCCGTCAGAGGGTGTCCTCT 
R: TGTGCATCTTGGGACTAC 
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Chromatin IP 
Kctd16 intron 1 ChIP-PCR primer sequences 
Kctd16 intron 1 F: GTTTCTTGCCTGCACTGCT 
R: GAAGGAAAAGCAGCCGGGAA 
 
RT-PCR 
Primer sequences for NuRD complex members 
Chd3 F: AGAAGGAAAACAAGCCAGG 
R: TTGTGTCCCCCATCCCCTT 
Chd4 F: GGGTGAAATGAATCGTGGC 
R: TTGTGTAGGACTGCATTGGC 
Rbbp4 F: ACTGTTGCCTTGTGGGATCT 
R: AGATCCCAGACATTCAGCCT 
Rbbp7 F: GGTGGTTGCTCGAGTTCATA 
R: GTGGCAATGATGTGAGGATTC 
Mta1 F: AGAGCCCACTGGTGCTGAAG 
R: CATCTACCCCATTGTGCTGC 
Mta2 F: GCTCGATCCGACTTCCTAAG 
R: GTCTCATAGGAACGTTTCACC 
Mta3 F: TGAGAATTCCTCCAGCAACCC 
R: TTAGCATGCTTGTCGGCGAG 
Gatad2a F: GCCCAGTGCTGCCAATAATG 
R: CAGCGGCATGTGAAGTCTGT 
Gatad2b F: TTACAGCAGCAGGCAGCA 
R: GCCACCTGGCACAGACAATT 
Mbd2/3 F: GGAGAAGAACCCTGGTGTGT 
R: ACAGGCCTTGTCCAGTGGT 
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Hdac2 F: ATGAGGCTTCATGGGATGAC 
R: CATGGCGTACAGTCAAGGAG 
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CHAPTER 4 
DISCUSSION AND FUTURE DIRECTIONS 
TBX5 is required for heart development in a number of vertebrates from 
zebrafish humans (Basson et al., 1997; Bruneau et al., 1999; Bruneau et al., 2001; 
Garrity et al., 2002; Horb and Thomsen, 1999; Li et al., 1997; Liberatore et al., 
2000). TBX5 is one of the first cardiac transcription factors expressed in the 
developing heart (Basson et al., 1999; Brown et al., 2005; Horb and Thomsen, 
1999), and it interacts with other early-expressing cardiac transcription factors like 
TBX20, GATA4, and NKX2.5 to regulate cardiogenesis (Brown et al., 2005; Garg et 
al., 2003; Hiroi et al., 2001). TBX5 is required for proper cardiac looping to occur by 
E9.5 (Bruneau et al., 2001), cell proliferation and differentiation (Fijnvandraat et al., 
2003; Goetz et al., 2006; Misra et al., 2014), and subsequent chamber formation 
(Bruneau et al., 1999; Christoffels et al., 2000; Koshiba-Takeuchi et al., 2009; 
Liberatore et al., 2000; Rothschild et al., 2009). Later in development, TBX5 is 
required in the pSHF for the development of the atrial septum (Hoffmann et al., 
2014; Horb and Thomsen, 1999; Misra et al., 2014; Xie et al., 2012; Zhou et al., 
2015). However, the in vivo molecular mechanisms of TBX5 function are not yet 
established. This dissertation comprises a set of studies designed to understand the 
TBX5  in vivo protein interaction partners and how the TBX5 interactome leads to 
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HOS patient defects. These studies were performed in parallel in both Xenopus and 
mouse model systems. 
Generation of a TBX5Avi Xenopus line 
 In Chapter 2, I described our caracterization of a novel Tbx5 enhancer in 
Xenopus. We generated a line of frogs expressing TBX5Avi under the endogenous 
Tbx5 enhancer element. I designed a construct containing the Xenopus 5’ UTR, 
Tbx5Avi coding sequence, Tbx5 alternative exon 1b sequence and the Tbx5 intron 1 
sequence.  This construct with the enhancer sequence expressed EGFP at the time 
and place that TBX5 is endogenously expressed in Xenopus embryos. The TBX5Avi 
construct was injected into Xenopus embryos at the one cell stage by Restriction 
Enzyme Mediated Integration (REMI) transgenesis (Amaya and Kroll, 1999), and 
then the embryos were allowed to reach sexual maturity. Frogs that carried Tbx5Avi 
were backcrossed to wild-type frogs to demonstrate that the construct was 
transmissible through the germline.  
REMI transgenesis has been used extensively for promoter-enhancer 
analysis, because integration of the transgene into the Xenopus genome is random. 
Therefore, this is an ideal system to characterize enhancers and other cis-regulatory 
regions. Enhancers and regulatory regions have been identified for a number of 
cardiac factors, such as Anf, Cardiac α-actinin, Mlc2, Mlc1v, Nkx2-5, and Tbx20 
(Amaya and Kroll, 1999; Garriock et al., 2005; Latinkić  et al., 2004; Latinkić et al., 
2002; Mandel et al., 2010; Small and Krieg, 2003; Smith et al., 2005; Smith et al., 
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2006; Sparrow et al., 2000).  My in vivo studies add Tbx5 to this small list of cardiac 
factors with known enhancer/regulatory regions in Xenopus. 
By defining the endogenous enhancer of Tbx5 we are now able to express 
TBX5Avi under the control of this element. This tool provides us with a unique 
opportunity to isolate endogenous TBX5 protein in vivo. However, TBX5Avi is not 
currently biotinylated endogenously in this line of frogs. Instead, we can perform 
microinjections of BirA mRNA into developing embryos to biotinylate TBX5 in the 
current generation of frogs. We have since established a Xenopus line that 
ubiquitously expresses the BirA enzyme, and we will cross these lines together to 
generate a Tbx5Avi; BirA line with endogenously biotinylated TBX5.  
Having biotinylated TBX5 in vivo, we could isolate TBX5 protein complexes 
using steptavidin-coated beads (Chapter 3). We would then conduct similar 
proteomics experiments to answer a number of questions about the role of TBX5 in 
cardiogenesis. We could determine the TBX5 interactome in IP, identify novel TBX5 
target genes using ChIP, and determine a new mechanism for TBX5 in the 
developing heart.  More excitingly, we can use the Xenopus line to do a comparative 
analysis of the mouse and Xenopus proteomes to determine a role for TBX5 in 
ventricular septation. The developing mouse and Xenopus hearts have critical 
differences, and a comparative proteomics analysis could illuminate those 
differences. In both organisms, the heart begins as two bilateral patches of 
mesoderm that migrate to the ventral midline from the anterior of the embryo and 
fuse to form the cardiac crescent (Dale and Slack, 1987; Lawson et al., 1991; 
Moody, 1987; Parameswaran and Tam, 1995; Sater and Jacobson, 1989; Tam et 
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al., 1997). The cardiac crescent fuses to form a linear heart tube, which undergoes 
looping to form the developing chambers (de Boer et al., 2012; Kolker et al., 2000; 
Mohun et al., 2000; Moorman et al., 2003). However, the Xenopus heart only has 
three chambers (two atria and a ventricle) while the mouse heart has a four-
chambered heart (two atria and two ventricles)(Mohun et al., 2000; Moorman et al., 
2003). TBX5 is expressed predominantly in the left ventricle, and its expression 
pattern boundary with TBX20 has been shown to be required for formation of the 
ventricular septum in the four-chambered chick heart (Liberatore et al., 2000; 
Takeuchi et al., 2003). Therefore, we hypothesize that some differences in the TBX5 
proteome between the mouse and Xenopus may be proteins that are required for 
ventricular septation.  
We could further utilize this Xenopus line to determine the role of 
phosphorylation in TBX5 regulation. By isolating endogenous TBX5, we could 
determine whether TBX5 is phosphorylated in the adult heart. Furthermore, we could 
generate a T278 mutation in TBX5Avi using gene editing in the Tbx5Avi line. Our lab 
has generated mutations in Xenopus using Transcription Activator-like Effector 
nucleases (TALENs) (Boch et al., 2009; Moscou and Bogdanove, 2009). Classical 
genetic experiments are not normally performed in Xenopus because of the ploidy; 
Xenopus laevis is a pseudotetraploid. However, gene editing using TALENs can 
target multiple alleles. Assuming characterization of the number of transgene 
insertions, one could utilize gene editing to introduce the T278A point mutation by 
altering the sequence in the Tbx5Avi line and conduct quantitative proteomics 
analysis to determine the interactions that are ablated by this point mutation.  
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The TBX5-NuRD complex interaction 
 In Chapter 3 we established that TBX5 and the NuRD complex interact in 
both the adult and the E9.5 heart. We demonstrated that TBX5 acts to repress gene 
transcription in both a NuRD-dependent and NuRD-independent manner, providing 
a novel role for TBX5 in cardiogenesis. We show that the TBX5-NuRD interaction is 
required for septation, and correlate TBX5 genotypes that ablate the NuRD 
interaction to the AVSD phenotype. In light of these findings, several exciting future 
directions are described below.  
The roles of TBX5 and TBX5-NuRD in the adult heart 
 We conducted proteomics analysis of TBX5 complexes in the hearts of 4 
week old mice, but we characterized the role of the TBX5-NuRD complex in the 
developing heart at E9.5. It is likely that TBX5-NuRD acts via a different mechanism 
in the adult heart than in the developing heart. TBX5 is required for the formation of 
the cardiac conduction system (Bruneau et al., 2001; Moskowitz et al., 2007; 
Moskowitz et al., 2004), but GWAS studies of conduction system function have 
shown TBX5 to be associated with PR- and/or QRS- interval variation in humans, 
suggesting that TBX5 is required in the adult heart to maintain proper conduction 
system function (Holm et al., 2010; Pfeufer et al., 2010; Smith et al., 2011; 
Sotoodehnia et al., 2010). Furthermore, removal of TBX5 from the mature ventricular 
conduction system using the minKCreERT2 driver results in a slowing of conduction 
system activity, arrhythmia, and sudden death within 5 weeks. Arnolds et al 
demonstrated that TBX5 drives the expression of Scn5a to regulate the cardiac 
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conduction system function (Arnolds et al., 2012), but further analysis of the adult 
heart and adult conduction system could provide additional information about the 
mechanism of TBX5 function in the adult heart. As an example, we could utilize the 
Tbx5Avi mouse line to determine conduction system-specific interactors and targets 
of TBX5 by conducting proteomics and ChIP- experiments in dissected conduction 
system tissues.  
TBX5-NuRD in atrial/atrioventricular septation 
 We demonstrated that interaction between TBX5 and the NuRD complex 
(Mta1) is crucial for atrioventricular septation. Mice that are compound heterozygous 
for both Tbx5 and Mta1 expression display a significantly higher prevalence of AVSD 
than either heterozygote alone. Furthermore, human patients with mutations in TBX5 
that ablate the TBX5 NuRD-interacting domain are significantly more likely to have 
AVSD. These are the first data to show a correlation between TBX5 genotype and 
phenotype (Brassington et al., 2003), and the effect of the TBX5-NuRD interaction 
and septation should be expanded upon. 
 AVSD is caused by malformation of the AV septal complex. The most 
prominent structure in this complex is the DMP, which is derived from the SHF 
(Snarr et al., 2007). The DMP was notably absent in our compound heterozygous 
mice, suggesting that the interaction between TBX5 and the NuRD complex may 
occur in the SHF. To further address this question we would need to deplete both 
Tbx5 and Mta1 in the SHF using an Isl1-Cre (Yang et al., 2006), or, to look 
specifically at the posterior SHF, a Gli1-Cre (Ahn and Joyner, 2004). These 
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experiments would begin to define a requirement for the TBX5-NuRD interaction in 
the SHF as it relates to atrio-ventricular septation.  
 Phylogenetic analysis of 48 orthologs of TBX5 demonstrates conservation of 
the NuRD interaction domain in organisms with a septated heart (Xenopus to 
human). Zebrafish have the amino acid substitution K266R, which is a mutation 
seen in patients with AVSD. When Xenopus TBX5 K266 is mutated to arginine, 
TBX5 can no longer interact with CHD4. Therefore, we conclude that the TBX5-
NuRD interaction evolved concurrently with atrial septation. Now that gene editing is 
possible in Xenopus, it would be interesting to generate the K266R mutation to 
determine the effect on septation. This would further validate the importance of the 
TBX5-NuRD interaction and the requirement for this interaction in septation. 
The role of the NuRD complex in cardiac development 
 Our data demonstrate that the TBX5-NuRD complex is required for proper 
atrio-ventricular septation. Our lab has further demonstrated that a NuRD/Gro/TLE 
complex interacts with TBX20 and this interaction is important for cardiac 
development (Kaltenbrun et al., 2013). Recently, other labs have demonstrated that 
the NuRD complex interacts with other factors such as BAF250a (Singh and Archer, 
2014) and FOG2 (Garnatz et al., 2014; Roche et al., 2008) in the heart to regulate 
cardiogenesis.  However, the exact requirement of the NuRD complex in 
cardiogenesis remains unknown. 
Toward this end, I initiated a project to determine the role of Chd4 in the 
developing heart. I obtained a Chd4 floxed mouse (Williams et al., 2004) from Katia 
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Georgopaulos at Harvard University. Depletion of Chd4 using an Nkx2.5-Cre (Moses 
et al., 2001)  mouse results in formation of all four chambers, but the hearts are 
malformed and lethality occurs by E10.5 (data not shown). This project will be 
continued by graduate student Caralynn Wilczewski. Currently, she is investigating 
the cause of embryonic lethality in the myocardial depleted Chd4-/- mice. 
Furthermore, she seeks to determine the role of Chd4 in the second heart field by 
depleting Chd4 in the SHF using an Isl1-Cre driver (Yang et al., 2006). These 
studies will define a requirement for the NuRD complex in the developing heart. 
Furthremore, the combination of phenotypic and biochemical analyses (e.g. CHD4 
ChIP-seq and RNA-seq) will help to discern a mechanism for the NuRD complex in 
cardiogenesis.  
The repression activity of TBX5 and TBX5-NuRD 
 The overlay of ChIP-seq and RNA-seq data shows that TBX5 acts as both a 
transcriptional activator and a transcriptional repressor. We validated 11 
transcriptional targets that were repressed by TBX5.  Overall, these genes are 
genes misregulated in cancer, and genes required for the development of the neural 
lineage. It would be interesting to follow up on the role that TBX5 plays in repression 
of the neural program, potentially by promoting the proper propagation of electrical 
impulses through the developing heart. As a number of TBX5 repressed target 
genes (Kcne3, Kctd16) are potassium channels, and potassium signaling is required 
for repolarization of cell membranes after the heart beats (Hu et al., 2014), we 
hypothesize that misregulation of these channels leads to improper conduction 
system propagation, a phenotype of HOS patients.  
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Additionally, we had originally envisioned a model for TBX5 in the regulation 
of the proper growth and differentiation of cardiomyocytes through repression of 
those genes misregulated in cancer. TBX5 contributes to regulation of the cell cycle, 
and interacts with Osr1 to regulate pSHF cell cycle progression. Misregulation of this 
interaction leads to AVSD (Goetz et al., 2006; Zhou et al., 2015). We observe that 
about half of the TBX5 repressed target genes are misregulated in cancer, but most 
of these genes are also required for neurogenesis. As we do not observe 
misregulation of cell cycle genes (cyclins, Cdks, MCMs) in Tbx5-/- embryos, we do 
not believe that TBX5 represses genes required for proliferation. The two TBX5-
repressed “cancer” genes that are unrelated to neurogenesis are Col20a1 and 
Mef2b. The function of Col20a1 is currently unknown, but we hypothesize that Mef2b 
repression is important for the cooperative roles of the other MEF2 family members 
in cardiogenesis. Overexpression analysis of Mef2b can address this hypothesis. 
Therefore, we hypothesize that the role of TBX5 in proliferation, cell cycle, and 
cancer is likely unrelated to the role of TBX5-mediated repression.   
 Our data shows that TBX5 acts to repress transcription in combination with 
the NuRD complex. TBX5 represses the transcriptional targets Kctd16 and Mef2b. In 
contrast, the S261C HOS point mutant that ablates the TBX5/NuRD interaction, fails 
to repress these targets. We concluded that TBX5 represses these targets in a 
NuRD-dependent manner.  However, the other nine genes repressed by TBX5 were 
not repressed in a NuRD-dependent manner. It would be interesting to be able to 
separate genes repressed by TBX5 alone from those repressed by TBX5-NuRD. We 
have begun the experiments to answer this question by generating a mouse line that 
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is depleted of Chd4 and contains a biotinylated Tbx5 allele (Tbx5Avi/Avi; 
Rosa26BirA/BirA; Chd4fl/fl; Nkx2.5Cre/+). We will utilize the Tbx5Avi allele to perform 
TBX5 ChIP-seq experiments in both Chd4 wild-type and null embryonic hearts to 
determine the TBX5 targets that are regulated by NuRD dependent and NuRD 
independent mechanisms. 
TBX5 target gene activation versus repression 
 Given that TBX5 acts to both activate and repress target genes, our studies 
have created new avenues of research onTBX5. We would like to know how TBX5 
can repress certain genes and activate others. While the NuRD complex is generally 
considered to be a transcriptional repressor complex, NuRD has been found present 
at active promoters as well (Shimbo et al., 2013), and plays a role in the activating 
functions of factors like GATA1 and FOG1 (Miccio et al., 2010; Wade et al., 1998; 
Xue et al., 1998; Zhang et al., 1998). To address this question, we performed a 
genome-wide bioinformatics analysis of target genes both activated and repressed 
by TBX5. Pathway analysis of genes repressed by TBX5 implicates several 
pathways involved in cancer, which is consistent with our earlier findings.  We also 
performed a binding motif analysis of our activated and repressed gene sets. We 
found the TBX5 motif present in approximately 50% of the ChIP peaks for both gene 
sets. These data suggest that there may be an alternate motif or an alternate, 
indirect mechanism for TBX5-dependent regulation of genes that do not have a 
TBX5-binding motif.  
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 To uncover alternative motifs present in the TBX5 data sets we performed 
motif enrichment analysis (Figure 4.1.) We found multiple motifs present in genes 
activated by TBX5: Rela, a gene in the NFκB complex (NfκB3/NfκB-65) involved in 
cancer (Gannon et al., 2013; Gao and Zhang, 2015; Kochupurakkal et al., 2015; Koh 
et al., 2015; Liu and Brown, 2012; Pyo et al., 2013; Trecca et al., 1997), Egr3, a 
gene involved in muscle development and muscle innervation (Chen et al., 2002; Li 
et al., 2011; Tourtellotte et al., 2001; Tourtellotte and Milbrandt, 1998), Rhox11, a 
homeobox gene with no known function, and Ctcf, a gene responsible for chromatin 
looping (Guo et al., 2012; Junier et al., 2012; Rao et al., 2014; Sanyal et al., 2012; 
Splinter et al., 2006; Tark-Dame et al., 2014). We also found multiple motifs present 
in genes repressed by TBX5: Hic1, a gene involved in tumor suppression, 
methylation and cancer (Chen et al., 2005; Cheng et al., 2014; Dehennaut et al., 
2013; Lindsey et al., 2004; Svedlund et al., 2012; Yu et al., 2011; Zhang et al., 2010; 
Zheng et al., 2013), Uncx, a homeobox transcription factor involved in the 
proliferation of neural progenitor cells (Sammeta et al., 2010), Hnf4a, a liver-
expressed nuclear receptor and endoderm marker (Dean et al., 2010) and Pax7, a 
satellite cell marker in skeletal muscle development (Joung et al., 2014; Knappe et 
al., 2015; von Maltzahn et al., 2013; Zammit et al., 2006) and important factor for 
neural crest development (Murdoch et al., 2012; Vadasz et al., 2013). Figure 4.2 
depicts an example of these other binding motifs relative to the TBX5 motif in a 
TBX5-activated (Scn5a) (Figure 4.2A) and a TBX5-repressed (Kctd16) (Figure 4.2B) 
gene. 
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The presence of these other factors near TBX5 binding motifs may work in 
concert to activate or repress gene transcription (Figure 4.3A). However, it is also 
possible that the presence of TBX5 at its target genes may rearrange the chromatin 
structure so that these other factors cannot bind to the target genes (Figure 4.3B). 
We hypothesize that, while either possibility may be correct, it is specific to the 
binding factor. To address this question, we could overlay previously published 
ChIP-seq data from each of the other binding factors on the TBX5 ChIP-seq results 
and look for other binding factors that are present at the TBX5 target genes. Ideally, 
the ChIP-seq data should be from the same or comparable cell line (e.g. HL-1, E9.5 
heart). There are ChIP-seq data available for a number of these factors in several 
different cell types (Table 4.1).  
There are also available knockout mice for the genes whose binding sites are 
next to TBX5 binding sites (Table 4.2). We could breed the TBX5Avi mouse to one of 
these knockout mouse lines and conduct streptavidin ChIP-seq to determine the 
effect of TBX5 occupancy in the absence of the other binding protein. The reciprocal 
experiment could also be completed: ChIP-seq of the other binding protein in a Tbx5 
knockout mouse would determine the effect of gene occupancy in the absence of 
TBX5. This would begin to address the relationship between TBX5 and the other 
binding proteins. One could then utilize these knockout mice to determine the effect 
that this binding mechanism may have on the developing heart. This exciting finding 
is the beginning of a new project in our laboratory designed to test what makes 
TBX5 “choose” to activate or repress gene transcription. 
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Table 4.1. ChIP-seq data available for proteins with binding motifs enriched in 
TBX5-bound regions. 
Motifs in regions 
activated or 
repressed by TBX5? 
Protein Tissue Type Reference/ENCODE 
Activated RelA/p65 Lymphoblast cells (Kasowski et al., 
2010; Satoh, 2014; 
Zhao et al., 2014) 
Activated RelA/p65	   Smooth Muscle 
cells 
(Cookson et al., 
2015) 
Activated RelA/p65	   Airway epithelial 
cells 
(Yang et al., 2013) 
Activated RelA/p65	   HeLa cells (Rao et al., 2011) 
Activated RelA/p65	   TNF stimulated 
HeLa cells 
(Xing et al., 2013) 
Activated RelA/p65	   Dendritic cells (Garber et al., 2012) 
Activated  RelA/p65	   KB cells (Jurida et al., 2015) 
Activated RelA/p65 C26 cancer 
induced muscle 
(Cornwell et al., 
2014) 
Activated RelA/p65 HEK293 cells (Lu et al., 2013) 
Activated CTCF Primary 
cardiomyocyte 
ENCSR000DTI 
Activated CTCF Skeletal muscle 
myoblast 
ENCSR000ANE 
Activated CTCF Mouse embryonic 
fibroblasts (MEFs) 
ENCSR000CBW  
(Gerstein et al., 
2012) 
Activated CTCF Bone Marrow 
Macrophage 
ENCSR000CFJ 
Activated CTCF HeLa cells, 
immortalized 
lymphoblast cells, 
leukemia cells, 
ESCs, BMP4 
induced ESCs 
(Heintzman et al., 
2009) 
Activated CTCF Various tissues 
(mouse- 8 week): 
cortical plate, 
heart, thymus, 
lung, testis, 
olfactory bulb, 
cerebellum, 
kidney, small 
ENCSR000CBO, 
ENCSR000CBI, 
ENCSR000CDZ, 
ENCSR000CBV, 
ENCSR000CDX, 
ENCSR000CBN, 
ENCSR000CBY, 
ENCSR000CBU 
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intestine, spleen, 
liver, brain, limb 
ENCSR000CEH 
Activated CTCF MEL cells ENCSR000CFH, 
ENCSR000ETE 
Activated CTCF Neural cells ENCSR822CEA 
Activated CTCF C2C12 ENCSR000AIJ 
Activated CTCF 19 different cell 
types 
(Wang et al., 2012) 
Activated CTCF Liver (human, 
macaque, dog, 
mouse, rat, 
opossum) 
(Schmidt et al., 
2012) 
Repressed HNF4α HepG2 liver cells (Wallerman et al., 
2009) 
ENCSR000EEU 
ENCSR000BLF 
Repressed HNF4a Livers (human, 
mouse, dog) 
(Schmidt et al., 
2010) 
Repressed PAX7 Mouse skeletal 
muscle cell line 
(Soleimani et al., 
2012) 
Repressed PAX7 Pituitary 
corticotrope cells 
(AtT-20) 
(Budry et al., 2012) 
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Table 4.2. Mouse models available for genes that have binding motifs enriched 
in TBX5-bound regions. 
Motifs in regions 
activated or 
repressed by 
TBX5? 
Gene Mouse model 
available? 
Reference 
Activated RelA/p65 Yes (Gao et al., 2015), 
(Beg et al., 1995) 
Activated Egr3 Yes (Tourtellotte and 
Milbrandt, 1998) 
Activated Rhox11 No  
Activated Ctcf Yes (Heath et al., 2008) 
Repressed Hic1 Yes (Carter et al., 2000) 
Repressed Uncx Yes (Mansouri et al., 
2000) 
Repressed Hnf4α Yes (Hayhurst et al., 
2001; Walesky et 
al., 2013) 
Repressed Pax7 Yes  (Mansouri et al., 
1996) 
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Figure 4.1. Identification of differential motifs in TBX5 activated genes vs 
repressed genes. TBX5 peaks associated with differentially regulated genes were 
also analyzed for motif enrichment using HOMER (Heinz et al., 2010). Differential 
motif enrichment at regions associated with activated genes (left) and repressed 
genes (right).	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Figure 4.2. Presence of alternative binding motifs in TBX5 bound genes. (A) 
(Top) Schematic of the TBX5-activated target gene Scn5a ChIP-peak element. 
Binding sites for EGR3 (blue), CTCF (brown), TBX5 (orange), RHOX11 (green), and 
RELA (beige) are depicted. (Bottom) Sequence specific binding motifs in the Scn5a 
element. (B) (Top) Schematic of the TBX5-repressed target gene Kctd16 ChIP-peak 
element. Binding sites for HIC1 (light blue), PAX7 (purple), and TBX5 (orange) are 
depicted. (Bottom) Sequence specific binding motifs in the Kctd16 element. Motif 
sequences were identified using the Motif-based interval screener with PSSM 
Cistrome Analysis Pipeline (Liu et al., 2011) 
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Figure 4.3. Possible mechanisms of TBX5 regulation of target genes. (A) The 
presence of these other factors (EGR3 in this example) near TBX5 binding motifs 
may combinatorially activate or repress gene transcription. (B) It is also possible that 
the presence of TBX5 at its target genes may rearrange the chromatin structure so 
that these other factors cannot bind to the target genes.  
 
	   170	  
REFERENCES 
Ahn, S., and Joyner, A.L. (2004). Dynamic changes in the response of cells to 
positive hedgehog signaling during mouse limb patterning. Cell 118, 505-516. 
Amaya, E., and Kroll, K.L. (1999). A method for generating transgenic frog embryos. 
Methods Mol Biol 97, 393-414. 
Arnolds, D.E., Liu, F., Fahrenbach, J.P., Kim, G.H., Schillinger, K.J., Smemo, S., 
McNally, E.M., Nobrega, M.A., Patel, V.V., and Moskowitz, I.P. (2012). TBX5 drives 
Scn5a expression to regulate cardiac conduction system function. J Clin Invest 122, 
2509-2518. 
Basson, C.T., Bachinsky, D.R., Lin, R.C., Levi, T., Elkins, J.A., Soults, J., Grayzel, 
D., Kroumpouzou, E., Traill, T.A., Leblanc-Straceski, J., et al. (1997). Mutations in 
human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram 
syndrome. Nat Genet 15, 30-35. 
Basson, C.T., Huang, T., Lin, R.C., Bachinsky, D.R., Weremowicz, S., Vaglio, A., 
Bruzzone, R., Quadrelli, R., Lerone, M., Romeo, G., et al. (1999). Different TBX5 
interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl 
Acad Sci U S A 96, 2919-2924. 
Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., and Baltimore, D. (1995). 
Embryonic lethality and liver degeneration in mice lacking the RelA component of 
NF-kappa B. Nature 376, 167-170. 
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., 
Nickstadt, A., and Bonas, U. (2009). Breaking the code of DNA binding specificity of 
TAL-type III effectors. Science 326, 1509-1512. 
Brassington, A.M., Sung, S.S., Toydemir, R.M., Le, T., Roeder, A.D., Rutherford, 
A.E., Whitby, F.G., Jorde, L.B., and Bamshad, M.J. (2003). Expressivity of Holt-
Oram syndrome is not predicted by TBX5 genotype. Am J Hum Genet 73, 74-85. 
Brown, D.D., Martz, S.N., Binder, O., Goetz, S.C., Price, B.M., Smith, J.C., and 
Conlon, F.L. (2005). Tbx5 and Tbx20 act synergistically to control vertebrate heart 
morphogenesis. Development 132, 553-563. 
	   171	  
Bruneau, B.G., Logan, M., Davis, N., Levi, T., Tabin, C.J., Seidman, J.G., and 
Seidman, C.E. (1999). Chamber-specific cardiac expression of Tbx5 and heart 
defects in Holt-Oram syndrome. Dev Biol 211, 100-108. 
Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S., 
Conner, D.A., Gessler, M., Nemer, M., Seidman, C.E., et al. (2001). A murine model 
of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in 
cardiogenesis and disease. Cell 106, 709-721. 
Budry, L., Balsalobre, A., Gauthier, Y., Khetchoumian, K., L'Honore, A., Vallette, S., 
Brue, T., Figarella-Branger, D., Meij, B., and Drouin, J. (2012). The selector gene 
Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin 
remodeling. Genes Dev 26, 2299-2310. 
Carter, M.G., Johns, M.A., Zeng, X., Zhou, L., Zink, M.C., Mankowski, J.L., 
Donovan, D.M., and Baylin, S.B. (2000). Mice deficient in the candidate tumor 
suppressor gene Hic1 exhibit developmental defects of structures affected in the 
Miller-Dieker syndrome. Hum Mol Genet 9, 413-419. 
Chen, H.H., Tourtellotte, W.G., and Frank, E. (2002). Muscle spindle-derived 
neurotrophin 3 regulates synaptic connectivity between muscle sensory and motor 
neurons. J Neurosci 22, 3512-3519. 
Chen, W.Y., Wang, D.H., Yen, R.C., Luo, J., Gu, W., and Baylin, S.B. (2005). Tumor 
suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage 
responses. Cell 123, 437-448. 
Cheng, G., Sun, X., Wang, J., Xiao, G., Wang, X., Fan, X., Zu, L., Hao, M., Qu, Q., 
Mao, Y., et al. (2014). HIC1 silencing in triple-negative breast cancer drives 
progression through misregulation of LCN2. Cancer Res 74, 862-872. 
Christoffels, V.M., Habets, P.E., Franco, D., Campione, M., de Jong, F., Lamers, 
W.H., Bao, Z.Z., Palmer, S., Biben, C., Harvey, R.P., et al. (2000). Chamber 
formation and morphogenesis in the developing mammalian heart. Dev Biol 223, 
266-278. 
Cookson, V.J., Waite, S.L., Heath, P.R., Hurd, P.J., Gandhi, S.V., and Chapman, 
N.R. (2015). Binding loci of RelA-containing nuclear factor-kappaB dimers in 
promoter regions of PHM1-31 myometrial smooth muscle cells. Mol Hum Reprod 21, 
865-883. 
	   172	  
Cornwell, E.W., Mirbod, A., Wu, C.L., Kandarian, S.C., and Jackman, R.W. (2014). 
C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-
independent. PLoS One 9, e87776. 
Dale, L., and Slack, J.M. (1987). Fate map for the 32-cell stage of Xenopus laevis. 
Development 99, 527-551. 
de Boer, B.A., van den Berg, G., de Boer, P.A., Moorman, A.F., and Ruijter, J.M. 
(2012). Growth of the developing mouse heart: an interactive qualitative and 
quantitative 3D atlas. Dev Biol 368, 203-213. 
Dean, S., Tang, J.I., Seckl, J.R., and Nyirenda, M.J. (2010). Developmental and 
tissue-specific regulation of hepatocyte nuclear factor 4-alpha (HNF4-alpha) 
isoforms in rodents. Gene Expr 14, 337-344. 
Dehennaut, V., Loison, I., Boulay, G., Van Rechem, C., and Leprince, D. (2013). 
Identification of p21 (CIP1/WAF1) as a direct target gene of HIC1 (Hypermethylated 
In Cancer 1). Biochem Biophys Res Commun 430, 49-53. 
Fijnvandraat, A.C., Lekanne Deprez, R.H., Christoffels, V.M., Ruijter, J.M., and 
Moorman, A.F. (2003). TBX5 overexpression stimulates differentiation of chamber 
myocardium in P19C16 embryonic carcinoma cells. J Muscle Res Cell Motil 24, 211-
218. 
Gannon, P.O., Lessard, L., Stevens, L.M., Forest, V., Begin, L.R., Minner, S., 
Tennstedt, P., Schlomm, T., Mes-Masson, A.M., and Saad, F. (2013). Large-scale 
independent validation of the nuclear factor-kappa B p65 prognostic biomarker in 
prostate cancer. Eur J Cancer 49, 2441-2448. 
Gao, H., and Zhang, Z. (2015). Systematic Analysis of Endometrial Cancer-
Associated Hub Proteins Based on Text Mining. Biomed Res Int 2015, 615825. 
Gao, Z., Zhang, J., Henagan, T.M., Lee, J.H., Ye, X., Wang, H., and Ye, J. (2015). 
P65 inactivation in adipocytes and macrophages attenuates adipose inflammatory 
response in lean but not in obese mice. Am J Physiol Endocrinol Metab 308, E496-
505. 
Garber, M., Yosef, N., Goren, A., Raychowdhury, R., Thielke, A., Guttman, M., 
Robinson, J., Minie, B., Chevrier, N., Itzhaki, Z., et al. (2012). A high-throughput 
	   173	  
chromatin immunoprecipitation approach reveals principles of dynamic gene 
regulation in mammals. Mol Cell 47, 810-822. 
Garg, V., Kathiriya, I.S., Barnes, R., Schluterman, M.K., King, I.N., Butler, C.A., 
Rothrock, C.R., Eapen, R.S., Hirayama-Yamada, K., Joo, K., et al. (2003). GATA4 
mutations cause human congenital heart defects and reveal an interaction with 
TBX5. Nature 424, 443-447. 
Garnatz, A.S., Gao, Z., Broman, M., Martens, S., Earley, J.U., and Svensson, E.C. 
(2014). FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte 
proliferation during heart development. Dev Biol 395, 50-61. 
Garriock, R.J., Meadows, S.M., and Krieg, P.A. (2005). Developmental expression 
and comparative genomic analysis of Xenopus cardiac myosin heavy chain genes. 
Dev Dyn 233, 1287-1293. 
Garrity, D.M., Childs, S., and Fishman, M.C. (2002). The heartstrings mutation in 
zebrafish causes heart/fin Tbx5 deficiency syndrome. Development 129, 4635-4645. 
Gerstein, M.B., Kundaje, A., Hariharan, M., Landt, S.G., Yan, K.K., Cheng, C., Mu, 
X.J., Khurana, E., Rozowsky, J., Alexander, R., et al. (2012). Architecture of the 
human regulatory network derived from ENCODE data. Nature 489, 91-100. 
Goetz, S.C., Brown, D.D., and Conlon, F.L. (2006). TBX5 is required for embryonic 
cardiac cell cycle progression. Development 133, 2575-2584. 
Guo, Y., Monahan, K., Wu, H., Gertz, J., Varley, K.E., Li, W., Myers, R.M., Maniatis, 
T., and Wu, Q. (2012). CTCF/cohesin-mediated DNA looping is required for 
protocadherin alpha promoter choice. Proc Natl Acad Sci U S A 109, 21081-21086. 
Hayhurst, G.P., Lee, Y.H., Lambert, G., Ward, J.M., and Gonzalez, F.J. (2001). 
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for 
maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21, 
1393-1403. 
Heath, H., Ribeiro de Almeida, C., Sleutels, F., Dingjan, G., van de Nobelen, S., 
Jonkers, I., Ling, K.W., Gribnau, J., Renkawitz, R., Grosveld, F., et al. (2008). CTCF 
regulates cell cycle progression of alphabeta T cells in the thymus. EMBO J 27, 
2839-2850. 
	   174	  
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp, L.F., 
Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifications at 
human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-
112. 
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., 
Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-
determining transcription factors prime cis-regulatory elements required for 
macrophage and B cell identities. Mol Cell 38, 576-589. 
Hiroi, Y., Kudoh, S., Monzen, K., Ikeda, Y., Yazaki, Y., Nagai, R., and Komuro, I. 
(2001). Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte 
differentiation. Nat Genet 28, 276-280. 
Hoffmann, A.D., Yang, X.H., Burnicka-Turek, O., Bosman, J.D., Ren, X., Steimle, 
J.D., Vokes, S.A., McMahon, A.P., Kalinichenko, V.V., and Moskowitz, I.P. (2014). 
Foxf genes integrate tbx5 and hedgehog pathways in the second heart field for 
cardiac septation. PLoS Genet 10, e1004604. 
Holm, H., Gudbjartsson, D.F., Arnar, D.O., Thorleifsson, G., Thorgeirsson, G., 
Stefansdottir, H., Gudjonsson, S.A., Jonasdottir, A., Mathiesen, E.B., Njolstad, I., et 
al. (2010). Several common variants modulate heart rate, PR interval and QRS 
duration. Nat Genet 42, 117-122. 
Horb, M.E., and Thomsen, G.H. (1999). Tbx5 is essential for heart development. 
Development 126, 1739-1751. 
Hu, Z., Crump, S.M., Anand, M., Kant, R., Levi, R., and Abbott, G.W. (2014). Kcne3 
deletion initiates extracardiac arrhythmogenesis in mice. FASEB J 28, 935-945. 
Joung, H., Eom, G.H., Choe, N., Lee, H.M., Ko, J.H., Kwon, D.H., Nam, Y.S., Min, 
H., Shin, S., Kook, J., et al. (2014). Ret finger protein mediates Pax7-induced 
ubiquitination of MyoD in skeletal muscle atrophy. Cell Signal 26, 2240-2248. 
Junier, I., Dale, R.K., Hou, C., Kepes, F., and Dean, A. (2012). CTCF-mediated 
transcriptional regulation through cell type-specific chromosome organization in the 
beta-globin locus. Nucleic Acids Res 40, 7718-7727. 
Jurida, L., Soelch, J., Bartkuhn, M., Handschick, K., Muller, H., Newel, D., Weber, 
A., Dittrich-Breiholz, O., Schneider, H., Bhuju, S., et al. (2015). The Activation of IL-
	   175	  
1-Induced Enhancers Depends on TAK1 Kinase Activity and NF-kappaB p65. Cell 
Rep. 
Kaltenbrun, E., Greco, T.M., Slagle, C.E., Kennedy, L.M., Li, T., Cristea, I.M., and 
Conlon, F.L. (2013). A Gro/TLE-NuRD corepressor complex facilitates Tbx20-
dependent transcriptional repression. J Proteome Res 12, 5395-5409. 
Kasowski, M., Grubert, F., Heffelfinger, C., Hariharan, M., Asabere, A., Waszak, 
S.M., Habegger, L., Rozowsky, J., Shi, M., Urban, A.E., et al. (2010). Variation in 
transcription factor binding among humans. Science 328, 232-235. 
Knappe, S., Zammit, P.S., and Knight, R.D. (2015). A population of Pax7-expressing 
muscle progenitor cells show differential responses to muscle injury dependent on 
developmental stage and injury extent. Front Aging Neurosci 7, 161. 
Kochupurakkal, B.S., Wang, Z.C., Hua, T., Culhane, A.C., Rodig, S.J., Rajkovic-
Molek, K., Lazaro, J.B., Richardson, A.L., Biswas, D.K., and Iglehart, J.D. (2015). 
RelA-Induced Interferon Response Negatively Regulates Proliferation. PLoS One 
10, e0140243. 
Koh, D.I., An, H., Kim, M.Y., Jeon, B.N., Choi, S.H., Hur, S.S., and Hur, M.W. 
(2015). Transcriptional activation of APAF1 by KAISO (ZBTB33) and p53 is 
attenuated by RelA/p65. Biochim Biophys Acta 1849, 1170-1178. 
Kolker, S.J., Tajchman, U., and Weeks, D.L. (2000). Confocal imaging of early heart 
development in Xenopus laevis. Dev Biol 218, 64-73. 
Koshiba-Takeuchi, K., Mori, A.D., Kaynak, B.L., Cebra-Thomas, J., Sukonnik, T., 
Georges, R.O., Latham, S., Beck, L., Henkelman, R.M., Black, B.L., et al. (2009). 
Reptilian heart development and the molecular basis of cardiac chamber evolution. 
Nature 461, 95-98. 
Latinkić , B.V., Cooper, B., Smith, S., Kotecha, S., Towers, N., Sparrow, D., and 
Mohun, T.J. (2004). Transcriptional regulation of the cardiac-specific MLC2 gene 
during Xenopus embryonic development. Development 131, 669-679. 
Latinkić, B.V., Cooper, B., Towers, N., Sparrow, D., Kotecha, S., and Mohun, T.J. 
(2002). Distinct enhancers regulate skeletal and cardiac muscle-specific expression 
programs of the cardiac alpha-actin gene in Xenopus embryos. Dev Biol 245, 57-70. 
	   176	  
Lawson, K.A., Meneses, J.J., and Pedersen, R.A. (1991). Clonal analysis of epiblast 
fate during germ layer formation in the mouse embryo. Development 113, 891-911. 
Li, L., Eldredge, L.C., Quach, D.H., Honasoge, A., Gruner, K., and Tourtellotte, W.G. 
(2011). Egr3 dependent sympathetic target tissue innervation in the absence of 
neuron death. PLoS One 6, e25696. 
Li, Q.Y., Newbury-Ecob, R.A., Terrett, J.A., Wilson, D.I., Curtis, A.R., Yi, C.H., 
Gebuhr, T., Bullen, P.J., Robson, S.C., Strachan, T., et al. (1997). Holt-Oram 
syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene 
family. Nat Genet 15, 21-29. 
Liberatore, C.M., Searcy-Schrick, R.D., and Yutzey, K.E. (2000). Ventricular 
expression of tbx5 inhibits normal heart chamber development. Dev Biol 223, 169-
180. 
Lindsey, J.C., Lusher, M.E., Anderton, J.A., Bailey, S., Gilbertson, R.J., Pearson, 
A.D., Ellison, D.W., and Clifford, S.C. (2004). Identification of tumour-specific 
epigenetic events in medulloblastoma development by hypermethylation profiling. 
Carcinogenesis 25, 661-668. 
Liu, J., and Brown, R.E. (2012). Morphoproteomic confirmation of an activated 
nuclear factor-small ka, CyrillicBp65 pathway in follicular thyroid carcinoma. Int J 
Clin Exp Pathol 5, 216-223. 
Liu, T., Ortiz, J.A., Taing, L., Meyer, C.A., Lee, B., Zhang, Y., Shin, H., Wong, S.S., 
Ma, J., Lei, Y., et al. (2011). Cistrome: an integrative platform for transcriptional 
regulation studies. Genome Biol 12, R83. 
Lu, T., Yang, M., Huang, D.B., Wei, H., Ozer, G.H., Ghosh, G., and Stark, G.R. 
(2013). Role of lysine methylation of NF-kappaB in differential gene regulation. Proc 
Natl Acad Sci U S A 110, 13510-13515. 
Mandel, E.M., Kaltenbrun, E., Callis, T.E., Zeng, X.X., Marques, S.R., Yelon, D., 
Wang, D.Z., and Conlon, F.L. (2010). The BMP pathway acts to directly regulate 
Tbx20 in the developing heart. Development 137, 1919-1929. 
Mansouri, A., Stoykova, A., Torres, M., and Gruss, P. (1996). Dysgenesis of 
cephalic neural crest derivatives in Pax7-/- mutant mice. Development 122, 831-838. 
	   177	  
Mansouri, A., Voss, A.K., Thomas, T., Yokota, Y., and Gruss, P. (2000). Uncx4.1 is 
required for the formation of the pedicles and proximal ribs and acts upstream of 
Pax9. Development 127, 2251-2258. 
Miccio, A., Wang, Y., Hong, W., Gregory, G.D., Wang, H., Yu, X., Choi, J.K., Shelat, 
S., Tong, W., Poncz, M., et al. (2010). NuRD mediates activating and repressive 
functions of GATA-1 and FOG-1 during blood development. EMBO J 29, 442-456. 
Misra, C., Chang, S.W., Basu, M., Huang, N., and Garg, V. (2014). Disruption of 
myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and 
atrioventricular septation. Hum Mol Genet 23, 5025-5035. 
Mohun, T.J., Leong, L.M., Weninger, W.J., and Sparrow, D.B. (2000). The 
morphology of heart development in Xenopus laevis. Dev Biol 218, 74-88. 
Moody, S.A. (1987). Fates of the blastomeres of the 32-cell-stage Xenopus embryo. 
Dev Biol 122, 300-319. 
Moorman, A., Webb, S., Brown, N.A., Lamers, W., and Anderson, R.H. (2003). 
Development of the heart: (1) formation of the cardiac chambers and arterial trunks. 
Heart 89, 806-814. 
Moscou, M.J., and Bogdanove, A.J. (2009). A simple cipher governs DNA 
recognition by TAL effectors. Science 326, 1501. 
Moses, K.A., DeMayo, F., Braun, R.M., Reecy, J.L., and Schwartz, R.J. (2001). 
Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. Genesis 
31, 176-180. 
Moskowitz, I.P., Kim, J.B., Moore, M.L., Wolf, C.M., Peterson, M.A., Shendure, J., 
Nobrega, M.A., Yokota, Y., Berul, C., Izumo, S., et al. (2007). A molecular pathway 
including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system 
development. Cell 129, 1365-1376. 
Moskowitz, I.P., Pizard, A., Patel, V.V., Bruneau, B.G., Kim, J.B., Kupershmidt, S., 
Roden, D., Berul, C.I., Seidman, C.E., and Seidman, J.G. (2004). The T-Box 
transcription factor Tbx5 is required for the patterning and maturation of the murine 
cardiac conduction system. Development 131, 4107-4116. 
	   178	  
Murdoch, B., DelConte, C., and Garcia-Castro, M.I. (2012). Pax7 lineage 
contributions to the mammalian neural crest. PLoS One 7, e41089. 
Parameswaran, M., and Tam, P.P. (1995). Regionalisation of cell fate and 
morphogenetic movement of the mesoderm during mouse gastrulation. Dev Genet 
17, 16-28. 
Pfeufer, A., van Noord, C., Marciante, K.D., Arking, D.E., Larson, M.G., Smith, A.V., 
Tarasov, K.V., Muller, M., Sotoodehnia, N., Sinner, M.F., et al. (2010). Genome-wide 
association study of PR interval. Nat Genet 42, 153-159. 
Pyo, J.S., Kang, G., Kim, D.H., Chae, S.W., Park, C., Kim, K., Do, S.I., Lee, H.J., 
Kim, J.H., and Sohn, J.H. (2013). Activation of nuclear factor-kappaB contributes to 
growth and aggressiveness of papillary thyroid carcinoma. Pathol Res Pract 209, 
228-232. 
Rao, N.A., McCalman, M.T., Moulos, P., Francoijs, K.J., Chatziioannou, A., Kolisis, 
F.N., Alexis, M.N., Mitsiou, D.J., and Stunnenberg, H.G. (2011). Coactivation of GR 
and NFKB alters the repertoire of their binding sites and target genes. Genome Res 
21, 1404-1416. 
Rao, S.S., Huntley, M.H., Durand, N.C., Stamenova, E.K., Bochkov, I.D., Robinson, 
J.T., Sanborn, A.L., Machol, I., Omer, A.D., Lander, E.S., et al. (2014). A 3D map of 
the human genome at kilobase resolution reveals principles of chromatin looping. 
Cell 159, 1665-1680. 
Roche, A.E., Bassett, B.J., Samant, S.A., Hong, W., Blobel, G.A., and Svensson, 
E.C. (2008). The zinc finger and C-terminal domains of MTA proteins are required 
for FOG-2-mediated transcriptional repression via the NuRD complex. J Mol Cell 
Cardiol 44, 352-360. 
Rothschild, S.C., Easley, C.A.t., Francescatto, L., Lister, J.A., Garrity, D.M., and 
Tombes, R.M. (2009). Tbx5-mediated expression of Ca(2+)/calmodulin-dependent 
protein kinase II is necessary for zebrafish cardiac and pectoral fin morphogenesis. 
Dev Biol 330, 175-184. 
Sammeta, N., Hardin, D.L., and McClintock, T.S. (2010). Uncx regulates proliferation 
of neural progenitor cells and neuronal survival in the olfactory epithelium. Mol Cell 
Neurosci 45, 398-407. 
	   179	  
Sanyal, A., Lajoie, B.R., Jain, G., and Dekker, J. (2012). The long-range interaction 
landscape of gene promoters. Nature 489, 109-113. 
Sater, A.K., and Jacobson, A.G. (1989). The specification of heart mesoderm occurs 
during gastrulation in Xenopus laevis. Development 105, 821-830. 
Satoh, J. (2014). Molecular network of ChIP-Seq-based NF-kappaB p65 target 
genes involves diverse immune functions relevant to the immunopathogenesis of 
multiple sclerosis. Mult Scler Relat Disord 3, 94-106. 
Schmidt, D., Schwalie, P.C., Wilson, M.D., Ballester, B., Goncalves, A., Kutter, C., 
Brown, G.D., Marshall, A., Flicek, P., and Odom, D.T. (2012). Waves of 
retrotransposon expansion remodel genome organization and CTCF binding in 
multiple mammalian lineages. Cell 148, 335-348. 
Schmidt, D., Wilson, M.D., Ballester, B., Schwalie, P.C., Brown, G.D., Marshall, A., 
Kutter, C., Watt, S., Martinez-Jimenez, C.P., Mackay, S., et al. (2010). Five-
vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor 
binding. Science 328, 1036-1040. 
Shimbo, T., Du, Y., Grimm, S.A., Dhasarathy, A., Mav, D., Shah, R.R., Shi, H., and 
Wade, P.A. (2013). MBD3 localizes at promoters, gene bodies and enhancers of 
active genes. PLoS Genet 9, e1004028. 
Singh, A.P., and Archer, T.K. (2014). Analysis of the SWI/SNF chromatin-remodeling 
complex during early heart development and BAF250a repression cardiac gene 
transcription during P19 cell differentiation. Nucleic Acids Res 42, 2958-2975. 
Small, E.M., and Krieg, P.A. (2003). Transgenic analysis of the atrialnatriuretic factor 
(ANF) promoter: Nkx2-5 and GATA-4 binding sites are required for atrial specific 
expression of ANF. Dev Biol 261, 116-131. 
Smith, J.G., Magnani, J.W., Palmer, C., Meng, Y.A., Soliman, E.Z., Musani, S.K., 
Kerr, K.F., Schnabel, R.B., Lubitz, S.A., Sotoodehnia, N., et al. (2011). Genome-
wide association studies of the PR interval in African Americans. PLoS Genet 7, 
e1001304. 
Smith, S.J., Ataliotis, P., Kotecha, S., Towers, N., Sparrow, D.B., and Mohun, T.J. 
(2005). The MLC1v gene provides a transgenic marker of myocardium formation 
within developing chambers of the Xenopus heart. Dev Dyn 232, 1003-1012. 
	   180	  
Smith, S.J., Fairclough, L., Latinkic, B.V., Sparrow, D.B., and Mohun, T.J. (2006). 
Xenopus laevis transgenesis by sperm nuclear injection. Nat Protoc 1, 2195-2203. 
Snarr, B.S., O'Neal, J.L., Chintalapudi, M.R., Wirrig, E.E., Phelps, A.L., Kubalak, 
S.W., and Wessels, A. (2007). Isl1 expression at the venous pole identifies a novel 
role for the second heart field in cardiac development. Circ Res 101, 971-974. 
Soleimani, V.D., Punch, V.G., Kawabe, Y., Jones, A.E., Palidwor, G.A., Porter, C.J., 
Cross, J.W., Carvajal, J.J., Kockx, C.E., van, I.W.F., et al. (2012). Transcriptional 
dominance of Pax7 in adult myogenesis is due to high-affinity recognition of 
homeodomain motifs. Dev Cell 22, 1208-1220. 
Sotoodehnia, N., Isaacs, A., de Bakker, P.I., Dorr, M., Newton-Cheh, C., Nolte, I.M., 
van der Harst, P., Muller, M., Eijgelsheim, M., Alonso, A., et al. (2010). Common 
variants in 22 loci are associated with QRS duration and cardiac ventricular 
conduction. Nat Genet 42, 1068-1076. 
Sparrow, D.B., Cai, C., Kotecha, S., Latinkic, B., Cooper, B., Towers, N., Evans, 
S.M., and Mohun, T.J. (2000). Regulation of the tinman homologues in Xenopus 
embryos. Dev Biol 227, 65-79. 
Splinter, E., Heath, H., Kooren, J., Palstra, R.J., Klous, P., Grosveld, F., Galjart, N., 
and de Laat, W. (2006). CTCF mediates long-range chromatin looping and local 
histone modification in the beta-globin locus. Genes Dev 20, 2349-2354. 
Svedlund, J., Koskinen Edblom, S., Marquez, V.E., Akerstrom, G., Bjorklund, P., and 
Westin, G. (2012). Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene 
epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine 
modification. J Clin Endocrinol Metab 97, E1307-1315. 
Takeuchi, J.K., Ohgi, M., Koshiba-Takeuchi, K., Shiratori, H., Sakaki, I., Ogura, K., 
Saijoh, Y., and Ogura, T. (2003). Tbx5 specifies the left/right ventricles and 
ventricular septum position during cardiogenesis. Development 130, 5953-5964. 
Tam, P.P., Parameswaran, M., Kinder, S.J., and Weinberger, R.P. (1997). The 
allocation of epiblast cells to the embryonic heart and other mesodermal lineages: 
the role of ingression and tissue movement during gastrulation. Development 124, 
1631-1642. 
	   181	  
Tark-Dame, M., Jerabek, H., Manders, E.M., Heermann, D.W., and van Driel, R. 
(2014). Depletion of the chromatin looping proteins CTCF and cohesin causes 
chromatin compaction: insight into chromatin folding by polymer modelling. PLoS 
Comput Biol 10, e1003877. 
Tourtellotte, W.G., Keller-Peck, C., Milbrandt, J., and Kucera, J. (2001). The 
transcription factor Egr3 modulates sensory axon-myotube interactions during 
muscle spindle morphogenesis. Dev Biol 232, 388-399. 
Tourtellotte, W.G., and Milbrandt, J. (1998). Sensory ataxia and muscle spindle 
agenesis in mice lacking the transcription factor Egr3. Nat Genet 20, 87-91. 
Trecca, D., Guerrini, L., Fracchiolla, N.S., Pomati, M., Baldini, L., Maiolo, A.T., and 
Neri, A. (1997). Identification of a tumor-associated mutant form of the NF-kappaB 
RelA gene with reduced DNA-binding and transactivating activities. Oncogene 14, 
791-799. 
Vadasz, S., Marquez, J., Tulloch, M., Shylo, N.A., and Garcia-Castro, M.I. (2013). 
Pax7 is regulated by cMyb during early neural crest development through a novel 
enhancer. Development 140, 3691-3702. 
von Maltzahn, J., Jones, A.E., Parks, R.J., and Rudnicki, M.A. (2013). Pax7 is critical 
for the normal function of satellite cells in adult skeletal muscle. Proc Natl Acad Sci 
U S A 110, 16474-16479. 
Wade, P.A., Jones, P.L., Vermaak, D., and Wolffe, A.P. (1998). A multiple subunit 
Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated 
Snf2 superfamily ATPase. Curr Biol 8, 843-846. 
Walesky, C., Edwards, G., Borude, P., Gunewardena, S., O'Neil, M., Yoo, B., and 
Apte, U. (2013). Hepatocyte nuclear factor 4 alpha deletion promotes 
diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology 57, 
2480-2490. 
Wallerman, O., Motallebipour, M., Enroth, S., Patra, K., Bysani, M.S., Komorowski, 
J., and Wadelius, C. (2009). Molecular interactions between HNF4a, FOXA2 and 
GABP identified at regulatory DNA elements through ChIP-sequencing. Nucleic 
Acids Res 37, 7498-7508. 
	   182	  
Wang, H., Maurano, M.T., Qu, H., Varley, K.E., Gertz, J., Pauli, F., Lee, K., Canfield, 
T., Weaver, M., Sandstrom, R., et al. (2012). Widespread plasticity in CTCF 
occupancy linked to DNA methylation. Genome Res 22, 1680-1688. 
Williams, C.J., Naito, T., Arco, P.G., Seavitt, J.R., Cashman, S.M., De Souza, B., Qi, 
X., Keables, P., Von Andrian, U.H., and Georgopoulos, K. (2004). The chromatin 
remodeler Mi-2beta is required for CD4 expression and T cell development. 
Immunity 20, 719-733. 
Xie, L., Hoffmann, A.D., Burnicka-Turek, O., Friedland-Little, J.M., Zhang, K., and 
Moskowitz, I.P. (2012). Tbx5-hedgehog molecular networks are essential in the 
second heart field for atrial septation. Dev Cell 23, 280-291. 
Xing, Y., Yang, Y., Zhou, F., and Wang, J. (2013). Characterization of genome-wide 
binding of NF-kappaB in TNFalpha-stimulated HeLa cells. Gene 526, 142-149. 
Xue, Y., Wong, J., Moreno, G.T., Young, M.K., Cote, J., and Wang, W. (1998). 
NURD, a novel complex with both ATP-dependent chromatin-remodeling and 
histone deacetylase activities. Mol Cell 2, 851-861. 
Yang, J., Mitra, A., Dojer, N., Fu, S., Rowicka, M., and Brasier, A.R. (2013). A 
probabilistic approach to learn chromatin architecture and accurate inference of the 
NF-kappaB/RelA regulatory network using ChIP-Seq. Nucleic Acids Res 41, 7240-
7259. 
Yang, L., Cai, C.L., Lin, L., Qyang, Y., Chung, C., Monteiro, R.M., Mummery, C.L., 
Fishman, G.I., Cogen, A., and Evans, S. (2006). Isl1Cre reveals a common Bmp 
pathway in heart and limb development. Development 133, 1575-1585. 
Yu, J., Liu, P., Cui, X., Sui, Y., Ji, G., Guan, R., Sun, D., Ji, W., Liu, F., Liu, A., et al. 
(2011). Identification of novel subregions of LOH in gastric cancer and analysis of 
the HIC1 and TOB1 tumor suppressor genes in these subregions. Mol Cells 32, 47-
55. 
Zammit, P.S., Relaix, F., Nagata, Y., Ruiz, A.P., Collins, C.A., Partridge, T.A., and 
Beauchamp, J.R. (2006). Pax7 and myogenic progression in skeletal muscle 
satellite cells. J Cell Sci 119, 1824-1832. 
Zhang, W., Zeng, X., Briggs, K.J., Beaty, R., Simons, B., Chiu Yen, R.W., Tyler, 
M.A., Tsai, H.C., Ye, Y., Gesell, G.S., et al. (2010). A potential tumor suppressor role 
	   183	  
for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 
29, 2467-2476. 
Zhang, Y., LeRoy, G., Seelig, H.P., Lane, W.S., and Reinberg, D. (1998). The 
dermatomyositis-specific autoantigen Mi2 is a component of a complex containing 
histone deacetylase and nucleosome remodeling activities. Cell 95, 279-289. 
Zhao, B., Barrera, L.A., Ersing, I., Willox, B., Schmidt, S.C., Greenfeld, H., Zhou, H., 
Mollo, S.B., Shi, T.T., Takasaki, K., et al. (2014). The NF-kappaB genomic 
landscape in lymphoblastoid B cells. Cell Rep 8, 1595-1606. 
Zheng, J., Wang, J., Sun, X., Hao, M., Ding, T., Xiong, D., Wang, X., Zhu, Y., Xiao, 
G., Cheng, G., et al. (2013). HIC1 modulates prostate cancer progression by 
epigenetic modification. Clin Cancer Res 19, 1400-1410. 
Zhou, L., Liu, J., Olson, P., Zhang, K., Wynne, J., and Xie, L. (2015). Tbx5 and Osr1 
interact to regulate posterior second heart field cell cycle progression for cardiac 
septation. J Mol Cell Cardiol 85, 1-12. 
 
 
  184	  
 
 
 
Appendix 1 
Xenopus: An emerging model for studying congenital heart disease 
 
Overview 
 This work was published as a review article in the journal Birth Defects 
Research A: Clinical and Molecular Teratology. I wrote sections on Tbx5 and Holt-
Oram Syndrome as well as utilizing Xenopus transgenesis to study congenital heart 
disease. The manuscript was written primarily by Erin Kaltenbrun and finalized by 
Frank Conlon and Chris Showell. 
 
Kaltenbrun E.,Tandon P., Amin N.M., Waldron L. Showell C., and Conlon F.L. 
Xenopus: An emerging model for studing congenital heart disease (2011) Birth 
Defects Res A Clin Mol Teratol. Jun;91(6):495-510. 
 
Congenital heart defects affect nearly 1% of all newborns and are a 
significant cause of infant death. Clinical studies have identified a number of 
congenital heart syndromes associated with mutations in genes that are involved in 
the complex process of cardiogenesis. The African clawed frog, Xenopus, has been 
instrumental in studies of vertebrate heart development and provides a valuable tool 
to investigate the molecular mechanisms underlying human congenital heart 
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diseases. In this review, we discuss the methodologies that make Xenopus an ideal 
model system to investigate heart development and disease. We also outline 
congenital heart conditions linked to cardiac genes that have been well-studied in 
Xenopus and describe some emerging technologies that will further aid in the study 
of these complex syndromes.   
 
INTRODUCTION 
Xenopus as a Model System for Human Congenital Heart Disease  
It is becoming increasingly clear that many forms of human disease are 
associated with defects in genes required for early steps in embryonic development. 
The African clawed frog, Xenopus shares surprising similarities with humans both 
genetically and anatomically. Thus, the molecular and cellular pathways through 
which these genes function can be elucidated using Xenopus to model vertebrate 
heart development and disease. Xenopus has numerous advantages as a model 
system in which to identify and characterize cellular and developmental processes. 
Unlike the mouse, the Xenopus embryo develops externally, and its early patterning 
and morphogenesis have been extensively studied. The Xenopus embryo is 
relatively large and is amenable to surgical manipulations, allowing defined regions 
to be excised and cultured in simple salt solutions in which the developmental and 
downstream transcriptional effects of exogenous growth factors can be determined. 
These classical approaches are complemented by molecular techniques that allow 
the overexpression or knockdown of specific gene products in the early embryo 
(Harvey and Melton, 1988; Heasman et al., 2000). In addition, transgenesis 
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techniques are well established and technologies are continually being optimized 
(Chesneau et al., 2008). Moreover, recent sequence annotation and assembly of the 
Xenopus tropicalis genome has demonstrated that it has long regions in which 
genes exhibit remarkably similar synteny relationships to those found in the human 
genome (Showell and Conlon, 2007; Hellsten et al., 2010). Specifically, regarding 
human congenital heart disease (CHD), Xenopus has unique advantages for 
studying cardiovascular development (Warkman and Krieg, 2006; Bartlett and 
Weeks, 2008; Evans et al., 2010). First, early Xenopus development can proceed in 
the absence of a functional circulation system, allowing defects to be extensively 
analyzed in living embryos. Second, Xenopus has a pulmonary system and a two-
chambered atrium. Third, Xenopus has a well-established fate map that is not 
confounded by extensive cell mixing (Dale and Slack, 1987; Moody, 1987). Only 
three hours after fertilization, it is possible to identify the blastomeres that will give 
rise to the adult heart. Collectively, this unique set of attributes places Xenopus as 
an ideal model system for studying congenital heart defects and in this review we 
will describe the experimental tools available to researchers, together with the 
existing Xenopus models of human CHDs (Table A1.1). 
 
METHODS FOR STUDYING HEART DEVELOPMENT AND DISEASE IN 
XENOPUS 
Protein Depletion and Overexpression 
The advent of effective antisense techniques has enabled researchers to 
associate developmental processes with the genes that control them. The most 
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extensively used of these techniques are the use of morpholino oligonucleotides (MOs), 
which inhibit the function of specific genes by preventing translation or splicing of 
messenger RNA (mRNA). This technique has resulted in the publication of many 
studies of heart development in Xenopus that have advanced our understanding of this 
process in vertebrates (Brown et al., 2005; Garriock et al., 2005a; Small et al., 2005; 
Zhang et al., 2005; Inui et al., 2006; Kumano et al., 2006; Brown et al., 2007; Hilton et 
al., 2007; Bartlett and Weeks, 2008; Christine and Conlon, 2008; Movassagh and 
Philpott, 2008; Nagao et al., 2008). MO antisense oligonucleotides are neutrally 
charged synthetic nucleic acid analogs that are stable, soluble, and bind to RNA with 
high affinity (Heasman et al., 2000; Moulton, 2007). In addition, they are resistant to 
nuclease degradation and have limited interaction with proteins (Summerton, 2007; 
Eisen and Smith, 2008; Bill et al., 2009). MOs are designed to reduce gene function in 
two ways. First, the MO can be designed to target sequences in the 5′ untranslated 
region close to the translation initiation codon of the gene to sterically block the 
attachment of the ribosomal machinery and inhibit protein translation (Heasman et al., 
2000). Alternatively, MOs can be designed to target the splice junctions in the pre-
mRNA strand, resulting in the incorporation of intron-encoded amino acids and, in many 
cases, early termination of translation via premature stop codons or by a shift in the 
reading frame of the subsequent sequence (Morcos, 2007).  
Strategies other than MOs have been employed to inhibit gene function. These 
include antisense RNA injection (Harland and Weintraub, 1985; Melton, 1985; Dagle 
and Weeks, 2001), RNA interference in which the RNA is targeted for degradation by 
the binding of small inhibitory RNA molecules and recruitment of the RNA-induced 
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silencing complex (Zhou and others, 2002; Summerton, 2007), DNA with chemically 
modified phosphate linkages that employs cellular RNase H to cleave the target RNA 
strand (Summerton, 2007), and peptide nucleic acid nucleotides which sterically block 
RNA translation in a similar way to MOs (Harland and Weintraub, 1985; Melton, 1985; 
Dagle and Weeks, 2001; Zhou et al., 2002; Summerton, 2007). However, due to few 
off-target effects, their binding success and their commercial availability, MOs have 
become a favored tool for studying gene function in vertebrate models (Knudsen and 
Nielsen, 1996; Summerton, 2007).  
Protein overexpression can be as valuable a technique as protein depletion to 
determine the role of a particular gene in development. The microinjection of capped 
mRNA into the Xenopus embryo has commonly been used to study heart development 
in the context of globally increased function of the protein under investigation, the 
effects of lateral- and lineage-specific overexpression, and to study isoform-specific 
phenotypes (Campione et al., 1999; Kitaguchi et al., 2000; Stennard et al., 2003; Goetz 
et al., 2006). Overexpression of truncated or mutated proteins can also be utilized to 
reproduce and investigate phenotypes caused by mutations identified in human patients 
with CHD (Ataliotis et al., 2005; Bartlett et al., 2007). Furthermore, protein function can 
be manipulated in a spatio-temporal manner by injecting hormone-inducible constructs 
with timed dexamethasone application (Kitaguchi et al., 2000; Afouda et al., 2008). 
 
Xenopus Explants for Cardiogenic Assays 
The Xenopus embryo is particularly amenable to tissue explant assays due to 
its unique ability to heal after microsurgery. In addition, Xenopus embryonic tissue 
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can survive in the absence of added nutrients (due to the yolk contained in 
embryonic cells) allowing culture of tissue explants in a simple saline solution. The 
first use of Xenopus explants in a cardiogenic assay was performed by Horst Grunz 
in 1992 (Grunz, 1992) who demonstrated that the isolated blastopore lip, fated to 
give rise to notochord and somites but not the heart, gives rise to differentiated 
cardiac tissue when cultured in the presence of the growth factor-blocking 
compound suramin. This demonstrated the importance of growth factor signaling in 
negatively regulating the induction of cardiac cell fate in the dorsal marginal zone 
(DMZ), which restricts cardiac cell fate to two bilateral groups of cells in the 
dorsoanterior mesoderm of the gastrula. Similar experiments by Schneider and 
Mercola have shown that Wnt signaling can antagonize cardiac specification in DMZ 
explants. When an arc of dorsal marginal zone mesoderm containing the heart 
progenitors is excised from the equatorial region of the gastrula and cultured in 
isolation it gives rise to differentiated, beating cardiac tissue. However, 
overexpression of wnt3A and wnt8 in these DMZ explants by injection of plasmid 
DNA into dorsal blastomeres results in a downregulation of cardiac marker 
expression, suggesting that inhibition of endogenous Wnt signaling might be 
required for proper heart induction (Schneider and Mercola, 2001). Indeed, when the 
Wnt inhibitors dickkopf1 or crescent are expressed ectopically in non-cardiogenic 
ventral marginal zone (VMZ) explants, cardiac terminal differentiation can be 
induced. This results in the striking observation of beating cardiac tissue within the 
cultured explants (Schneider and Mercola, 2001). A role has also been identified for 
wnt11, encoding a non-canonical Wnt antagonist, in the induction of heart formation 
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by the observation that it is sufficient to induce expression of cardiac markers and 
differentiation of contractile cardiac tissue in VMZ explants (Pandur et al., 2002). As 
WNT11 both inhibits β-catenin through the canonical pathway and activates JNKAs 
WNT11 also inhibits β-catenin through the canonical pathway, Pandur et al. injected 
mRNA encoding a dominant negative LEF-1 and observed that disruption of β-
catenin signaling alone fails to induce a contractile phenotype in VMZ explants. s. 
This result indicates that heart induction may require both 1) low levels of Wnt/β-
catenin activity and, 2) activation of non-canonical Wnt/JNK signaling through 
WNT11 activation of the non-canonical Wnt signaling cascade through WNT11 is 
required for cardiac differentiation in this assay (Pandur et al., 2002). Alternately, it 
could reflect activity differences between TCF and LEF factors in β-catenin inhibition 
as another group demonstrated that injection of a dominant negative TCF3 was 
indeed sufficient to induce cardiogenesis in Xenopus animal caps.  
Explants have also been used to investigate factors required for induction of 
cardiogenesis via a loss-of-function approach. For example, MO knockdown of hex 
(a transcription factor induced by antagonists of the canonical Wnt pathway) in DMZ 
explants resulted in loss of cardiac markers, indicating that heart induction by Wnt 
antagonists relies upon activation of hex (Foley and Mercola, 2005).  
The Xenopus animal cap also serves as a useful tissue for cardiogenic 
assays and can be used to examine the ability of various molecules to affect cardiac 
gene expression and differentiation. The animal cap consists of prospective 
ectoderm at the animal pole of a blastula embryo and is fated to become epidermal 
and neural tissues. Because the ectodermal cells of the animal pole are pluripotent, 
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they can be induced to give rise to alternate cell lineages, including mesodermal 
derivatives such as the heart. Logan and Mohun demonstrated that cardiac muscle 
is induced in animal caps treated with high concentrations of the mesoderm-inducing 
factor activin (Logan and Mohun, 1993). A more recent protocol involving the 
dissociation and reaggregation of animal caps in the presence of activin results in 
beating animal cap explants that can form ectopic hearts in Xenopus adults following 
transplantation into the hosts at embryonic stages (Ariizumi et al., 2003). As with 
DMZ and VMZ explants, animal caps have been used to advance our understanding 
of the role of WNT signaling during cardiogenesis. Activin-induced expression of 
GATA factors in animal caps is abolished upon injection of an inducible form of β-
catenin, suggesting that Wnt signaling may act to repress gata gene expression to 
restrict cardiogenesis (Afouda et al., 2008). In addition, inhibition of gata4 and gata6 
by MO injection in animal cap explants results in decreased wnt11 expression, 
whereas injection of inducible versions of Gata4 and Gata6 results in upregulation of 
wnt11 expression, placing GATA factors in a regulatory pathway that links canonical 
and non-canonical Wnt signaling during cardiogenesis (Pandur et al., 2002; Afouda 
et al., 2008). 
Finally, prospective cardiac tissue itself can be explanted from the embryo 
and used for cardiogenic assays in the absence of the rest of the embryo. This 
technique is particularly useful when it is necessary to bypass an early embryonic 
requirement for a gene to assess its later role in the developing heart. In short, 
tissue posterior to the cement gland including the heart field can be excised starting 
at stage 22 when the cardiac precursor populations form a ridge of tissue on top of 
  192	  
underlying endoderm. In isolation, these explants will go on to form beating hearts in 
culture (Raffin et al., 2000; Langdon et al., 2007). Using this assay, a recent study 
identified a role for SHP-2, a protein tyrosine phosphatase that is disrupted in human 
CHD, in the maintenance of cardiac progenitors (Langdon et al., 2007). 
 
Xenopus Transgenesis 
The development of transgenesis in Xenopus has allowed investigators to 
introduce heritable genetic modifications into the frog genome, propelling Xenopus 
forward as both a genetic and developmental model. Transgenic procedures in 
Xenopus have primarily been used for promoter/enhancer analyses and for 
expressing transgenes in a tissue-specific manner with defined promoters. Early 
experiments involving microinjection of circular or linear DNA demonstrated that 
integration into the genome occurred in a significant number of injected embryos 
(Rusconi and Schaffner, 1981; Etkin and Roberts, 1983; Andres et al., 1984; Bendig 
and Williams, 1984; Etkin et al., 1984). The first characterization of transgenic frogs 
produced by this method showed that the resulting animals were mosaic and that 
the copy number was highly variable, even within cells from the same animal (Etkin 
and Pearman, 1987). It was not until the development of the Restriction Enzyme 
Mediated Integration (REMI) strategy that the problem of mosaicism was overcome 
(Kroll and Amaya, 1996b). Using this method, sperm nuclei are incubated with 
linearized DNA and a restriction enzyme along with egg extracts which promote 
DNA decondensation. The modified sperm nuclei are then injected into unfertilized 
eggs, where the foreign DNA is believed to integrate randomly into the genomic 
  193	  
DNA during the DNA repair process prior to the first cell division (Amaya and Kroll, 
1999; Smith et al., 2006). 
Other methods of transgenesis that utilize different core insertion techniques 
have been used with varying success. Transposable elements such as Sleeping 
Beauty or the Tol2 transposon have been used as an alternative to REMI to facilitate 
transgene integration in Xenopus (Kawakami et al., 2000; Kawakami et al., 2004; 
Parinov et al., 2004; Choo et al., 2006; Hamlet et al., 2006; Sinzelle et al., 2006; 
Yergeau and Mead, 2007; Yergeau et al., 2009). The more commonly used 
transposon Tol2 is an active and autonomous transposable element that can 
integrate into one or multiple sites in the genome and has been used successfully in 
zebrafish for insertional mutagenesis, although this method of transgenesis in 
Xenopus has not been as efficient as expected. Other groups have optimized the 
use of integrase-mediated transgenesis utilizing the bacteriophage ΦC31 and the 
more frequently used I-SceI meganuclease (Allen and Weeks, 2005; Allen and 
Weeks, 2009). The I-SceI meganuclease, originally isolated from Saccharomyces 
cerevisiae, is used to digest transgene DNA containing I-SceI 18-bp recognition sites 
and this reaction mixture is injected into unfertilized eggs where it integrates 
randomly into the host genome. Copy number of integrated transgenes is relatively 
low, ranging from one to four, compared to the REMI method which typically results 
in the integration of transgene concatemers (two to six copies) at four to eight sites 
in the genome (Kroll and Amaya, 1996a). (Jacquier and Dujon, 1985; Ogino et al., 
2006; Pan et al., 2006). 
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The developmental regulation of several cardiac genes has been 
characterized with Xenopus transgenesis, leading to a clearer picture of the complex 
gene regulatory networks that guide heart development. This commonly involves in 
vivo analysis of cis-regulatory regions that drive cardiac expression in the heart and 
is accomplished by inserting the promoter of interest upstream of a reporter 
transgene, such as green fluorescent protein (GFP), to follow transgene expression 
in the live embryo. This approach has been used to identify cardiac-specific 
regulatory elements for atrial natriuretic factor (anf), cardiac α-Actin, myosin Light 
Chain 2 (mlc2), myosin light chain 1v (mlc1v), nkx2-5, alpha myosin heavy chain (α-
mhc), and tbx20 (Sparrow et al., 2000; Latinkić et al., 2002; Small and Krieg, 2003; 
Latinkić  et al., 2004; Garriock et al., 2005b; Smith et al., 2005; Mandel et al., 2010). 
Additional studies examining the mechanisms of regulating these cardiac elements 
have revealed much about the signaling pathways that act on cardiac genes during 
development. Importantly, many of these regulatory elements are evolutionarily 
conserved as they are sufficient for cardiac-specific expression in other vertebrates 
including mice.     
One of the benefits of transgenesis is the ability to tightly control the spatial 
and temporal expression of a transgene during development with tissue-specific 
promoters. Several cardiac promoters that drive expression throughout the 
developing heart have been used with great success to misexpress a gene of 
interest specifically in the heart-forming region. Using transgenic embryos 
expressing bmp4 under the control of the mlc2 promoter, Breckenridge et al. 
demonstrated that ectopic expression throughout the developing heart results in 
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randomization of the direction of cardiac looping, indicating that asymmetric BMP4 
signaling is required for proper cardiac looping (Breckenridge et al., 2001). 
 
CONGENITAL HEART DISEASE 
Atrial Septal Defects: Nkx2.5 and Gata4 
Atrial Septal Defects (ASD) are relatively common and account for 10% of all 
human congenital heart defects (Hoffman and Kaplan, 2002). ASD refers to a failure 
of the atrial septum to fully separate the right and left atrial chambers after birth and 
is often accompanied by other forms of CHD including cardiac conduction system 
abnormalities. The cardiac transcription factor Nkx2.5 is mutated in a number of 
patients with non-syndromic ASD, suggesting a critical function for this gene in the 
septogenesis process (Schott et al., 1998; Benson et al., 1999).  
Nkx2.5 encodes a homeodomain protein that is highly conserved from 
Drosophila to human. Nkx2.5 is expressed early in development, and in combination 
with other cardiac transcription factors, helps define the cardiogenic field in which it 
plays an essential role in the specification of cardiac progenitors from the 
cardiogenic mesoderm. Cardiac expression of Nkx2.5 persists into adulthood, 
however, a complete understanding of the role NKX2.5 plays during the later stages 
of heart formation has been complicated by the fact that targeted disruption of 
murine Nkx2.5 results in embryonic lethality at E9-E10, prior to heart looping (Lyons, 
1995). Interestingly, a recent study in Xenopus demonstrated that injection of two 
truncated forms of Xenopus laevis NKX2.5, corresponding to two human NKX2.5 
point mutations identified in patients with cardiac defects including ASD and 
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atrioventricular conduction delays, results in atrial septal and conduction system 
defects (Schott et al., 1998; Bartlett et al., 2007). Significantly, this study focused on 
the effects of injecting mutant forms of nkx2.5on internal changes to the hearts of 
stage 46 embryos when the Xenopus heart is fully looped with chambers, septae, 
valves, and a functional conduction system (Bartlett et al., 2007). The results 
suggest that early expression of mutant nkx2.5 in the frog can lead to a late 
phenotype that includes cardiac defects consistent with those seen in human 
disease.  
NKX2.5 has also been shown to physically interact with the cardiac zinc finger 
transcription factor GATA4, an additional gene mutated in in patients with ASD 
(Durocher et al., 1997; Lee et al., 1998; Sepulveda et al., 1998; Pehlivan et al., 
1999; Garg et al., 2003). The NKX2.5-GATA4 interaction synergistically activates 
cardiac promoters during the cardiogenic program, suggesting that deficiencies in 
either member of this transcriptional complex can result in ASDs (Durocher et al., 
1997; Lee et al., 1998; Sepulveda et al., 1998). Studies utilizing the embryonic 
carcinoma P19 cell line have shown Gata4 to be essential for cardiac differentiation. 
However, Gata4 null mice can generate differentiated cardiac myocytes that express 
contractile proteins but are deficient in ventral morphogenesis, resulting in a failure 
of cardiomyocytes to form a linear heart tube at the ventral midline (cardia bifida) 
(Grepin et al., 1995; Grepin et al., 1997; Kuo et al., 1997; Molkentin et al., 1997). 
Recent studies in Xenopus complement the mouse work and demonstrate with MOs 
that gata4 is dispensable for cardiac specification but essential for proper heart 
morphogenesis downstream of the induction of the myocardium (Haworth et al., 
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2008). Interestingly, when GATA4, GATA5, and GATA6 are all depleted from 
Xenopus embryos, myosin heavy chain expression is completely lost from most 
morphant embryos, suggesting that there is GATA factor redundancy in the 
regulation of myocardial differentiation, providing a possible explanation for the 
persistent presence of differentiated cardiomyocytes in Gata4-/- mice (Peterkin et al., 
2007). 
 
DiGeorge Syndrome: Tbx1 
DiGeorge syndrome (DGS) is a congenital disorder that has many 
overlapping characteristics with velo-cardio-facial syndrome and conotruncal 
anomaly face syndrome due to shared deletions within chromosome band 22q11.2 
(Yamagishi and Srivastava, 2003; Baldini, 2004). For this reason, these syndromes 
are collectively known as 22q11 deletion syndrome (del22q11DS). Approximately 
80% of neonates displaying del22q11DS have congenital heart defects that include 
Tetralogy of Fallot, persistent truncus arterious, and cardio-facial abnormalities 
(Epstein, 2001; Yamagishi and Srivastava, 2003; Baldini, 2004; Di Felice and 
Zummo, 2009; Momma, 2010; Starr, 2010).  
 
DGS is one of the most prevalent chromosomal microdeletion genetic 
disorders. The region of chromosome 22q11.2 that is deleted in DGS encompasses 
1.5 to 3 Mb and includes 24-30 genes (Epstein, 2001; Yamagishi and Srivastava, 
2003; Baldini, 2004). A heterozygous mouse genetic model in which the orthologous 
chromosomal region affected in DGS is deleted displays similar phenotypes as 
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those in human patients (Lindsay et al., 1999; Lindsay and Baldini, 2001). The 
deleted region frequently includes the locus encoding the T-box transcription factor 
Tbx1. In a genetic analysis screen, five patients were identified who exhibited DGS 
phenotypes and had Tbx1 mutations but not chromosomal microdeletions, 
suggesting that Tbx1 may be contributing to the DGS phenotype in these individuals 
(Yagi et al., 2003). DGS abnormalities have been correlated with disrupted 
pharyngeal and neural crest patterning during development. Subsequently, Tbx1 
was shown to be expressed in the pharyngeal arches, and mouse genetic models 
have demonstrated that Tbx1 haplo-insufficiency disrupts the development of the 
fourth pharyngeal arch arteries, possibly in conjunction with FGF8 signaling 
(Chapman et al., 1996; Lindsay et al., 2001b; Merscher et al., 2001; Kochilas et al., 
2002; Sauka-Spengler et al., 2002; Vitelli et al., 2002; Kochilas et al., 2003; Baldini, 
2004; Ataliotis et al., 2005; Showell et al., 2006). In addition, Tbx1 plays a role in 
growth and septation of the outflow tract (OFT). Conditionally ablating Tbx1 in the 
Nkx2.5 domain of the secondary heart field results in mild pharyngeal defects and a 
severe defect in aorto-pulmonary septation of the OFT that is associated with neural 
crest migration defects and reduced proliferation of cells in the secondary heart field 
(Waldo et al., 2001; Xu et al., 2004). FGF signaling may be involved in the latter 
event as there is a reduction in Fgf10 expression in the secondary heart field in 
Tbx1-null mice. Further, Fgf10 is a direct transcriptional target of Tbx1 in vitro 
(Waldo et al., 2001; Xu et al., 2004). Interestingly, the defect in OFT septation 
suggests a dose-dependent role for Tbx1 because this phenotype can be partially 
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rescued upon reestablishing Tbx1 expression (Jerome and Papaioannou, 2001; 
Lindsay et al., 2001a; Xu et al., 2004).  
Tbx1 has been identified in many vertebrates including Xenopus laevis and 
Xenopus tropicalis. In these model systems, the expression domains of tbx1 
replicate those seen in other vertebrates, namely the pharyngeal arches, otic 
vesicle, and mesenchyme surrounding the OFT (Chapman et al., 1996; Sauka-
Spengler et al., 2002; Kochilas et al., 2003; Ataliotis et al., 2005; Showell et al., 
2006). A dominant interfering mutant of tbx1 injected into Xenopus embryos results 
in very similar phenotypes to those of mice deficient in Tbx1, including pharyngeal 
defects, unlooped heart, pericardial edema, and a reduction in anterior structures. 
These defects can be rescued by co-injecting wild-type tbx1 mRNA. To lineage trace 
the fate of TBX1-deficient cells, Ataliotis et al. co-injected β-galactosidase mRNA 
and the dominant interfering mutant tbx1 mRNA into Xenopus embryos and 
identified a requirement for TBX1 in cells that contribute to pharyngeal mesoderm 
(Ataliotis et al., 2005). Additionally, recent advances in Xenopus transgenesis have 
enabled researchers to analyze cardiac and craniofacial phenotypes in embryos with 
reduced functions of specific genes, effectively generating models of CHD such as 
DGS. Using the active promoter of mlc1v to drive GFP, craniofacial and cardiac 
muscle formation was followed in Xenopus embryos injected with the dominant 
interfering mutant of tbx1, enabling real-time visualization of cardiac structural 
defects in developing embryos (Smith et al., 2005). 
Holt-Oram Syndrome: Tbx5 
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Holt-Oram Syndrome (HOS), also known as heart-hand syndrome, is a 
congenital autosomal dominant disorder that primarily affects the heart and upper 
limbs (Holt and Oram, 1960). HOS is the most common heart-hand syndrome, 
affecting nearly 1 in 100,000 total births (Basson et al., 1994). Approximately 75% of 
patients with HOS experience cardiac defects, most commonly ASD, ventricular 
septal defects (VSD), and/or defects in the cardiac conduction system (Basson et 
al., 1994; Benson et al., 1996; Newbury-Ecob et al., 1996; Cross et al., 2000; 
McDermott et al., 2005). Atypical phenotypes have also been discovered and 
characterized, and phenotypic expression is variable even within families (Newbury-
Ecob et al., 1996; Sletten and Pierpont, 1996; Brassington et al., 2003; Lehner et al., 
2003; McDermott et al., 2005; Garavelli et al., 2008). HOS is often caused by 
mutations in the coding region of the T-box transcription factor Tbx5 on chromosome 
12q.24.1 (Basson et al., 1997; Li et al., 1997; Basson et al., 1999). More than 70% 
of patients with HOS have a mutation in the Tbx5 coding exons, and 85% of these 
mutations are de novo (McDermott et al., 2005). Most HOS mutations are predicted 
to result in haploinsufficiency of Tbx5 (Li et al., 1997; Basson et al., 1999).   
Mice lacking Tbx5 do not survive past E10.5 due to arrested cardiac 
development caused by impaired cardiac differentiation (Bruneau et al., 2001). 
Heterozygous Tbx5del/+ mice display subtle defects in the paw and wrist, enlarged 
hearts with ASD, cardiac conduction defects, and a variety of additional complex 
cardiac defects reminiscent of patients with HOS. The expression of several cardiac 
genes is reduced in mice lacking Tbx5. Two of these genes, ANF and Cx40, are also 
reduced in mice expressing 50% of the normal TBX5 levels (Moskowitz et al., 2004). 
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Similar heart and limb defects are observed in the orthologous Tbx5 zebrafish 
mutant heartstrings, suggesting that both the expression domain and protein 
function of Tbx5 are conserved among vertebrates (Garrity et al., 2002). In Xenopus, 
tbx5 is first expressed in the migrating heart primordia and eye anlage of the late 
neurula embryo. Its expression is maintained in the primitive heart tube, although its 
expression becomes more graded after looping of the heart, with higher expression 
in the ventricle than the atria (Horb and Thomsen, 1999; Showell et al., 2006). 
Consistent with work in other organisms, Tbx5 was demonstrated to be critical for 
proper heart morphogenesis in Xenopus (Horb and Thomsen, 1999; Brown et al., 
2005). Overexpression of a dominant negative hormone-inducible form of TBX5 
blocks heart tube formation, whereas knockdown of tbx5 expression by MO results 
in reduced cardiac cell number and an unlooped heart tube (Horb and Thomsen, 
1999; Brown et al., 2005). The decrease in cardiac cell number in the tbx5 morphant 
embryos was demonstrated to result from a proliferation defect caused by a delay or 
arrest in the G1/S phase of the cell cycle, implicating a role for TBX5 in cardiac cell 
cycle control (Goetz et al., 2006). These results from Xenopus as well as those from 
human studies (Hatcher et al., 2001), suggest that HOS defects may in part arise 
from a decrease in cell cycle progression and cardiac cell proliferation in Tbx5-
expressing regions. In addition, work in a number of model systems has 
demonstrated a conserved role for Tbx5 in the regulation of cardiac-specific gene 
expression (Liberatore et al., 2000; Bruneau et al., 2001; Hatcher et al., 2001; Hiroi 
et al., 2001; Garrity et al., 2002; Plageman and Yutzey, 2004; Brown et al., 2005). 
 
  202	  
Spectrum of Congenital Heart Defects: Tbx20 
Tbx20 is a member of the T-box family of transcription factors and is one of 
the first genes to be expressed in the cardiac lineage along with Nkx2.5, Gata4, and 
Tbx5. In all species examined, expression of Tbx20 is maintained throughout the 
primary heart field, in both myocardium and endocardium, as development proceeds 
and persists in the adult heart. Kirk et al. were the first group to identify mutations in 
human Tbx20 in patients with familial CHD (Kirk et al., 2007). The two mutations 
identified are both in the T-box DNA binding domain and segregate with a spectrum 
of cardiac pathologies including ASD, VSD, valve disease, pulmonary hypertension, 
and cardiomyopathy. Loss-of-function mutations were the first to be identified. 
However, several other groups have since identified new Tbx20 mutations with both 
loss- and gain-of-function that are associated with CHD (Posch et al.; Liu et al., 
2008; Qian et al., 2008). In addition, upregulation of Tbx20 expression has been 
noted in patients with Tetralogy of Fallot (Hammer et al., 2008). The wide range of 
defects associated with mutant or misregulated Tbx20 may be the result of the 
expression of Tbx20 in both myocardium and endocardium, where endocardial 
cushions give rise to valves and the interventricular septum.  
Although the early expression of Tbx20 in cardiogenic mesoderm suggests a 
role in the specification, migration, and/or differentiation of cardiac progenitors, a 
requirement for TBX20 is not evident until the early stages of heart morphogenesis, 
as shown by studies in fish and frogs (Szeto et al., 2002; Brown et al., 2005). Upon 
MO knockdown of Tbx20 in zebrafish and Xenopus embryos, morphant embryos 
display unlooped heart tubes and pericardial edema, but express markers of cardiac 
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specification and differentiation, indicating an essential role for TBX20 in cardiac 
morphogenesis. In addition, TBX20-depleted Xenopus hearts have reduced 
cardiomyocyte cell numbers and fail to properly form chambers (Brown et al., 2005). 
Likewise, mice lacking Tbx20 undergo normal cardiac specification and 
differentiation, but development is arrested in the primary linear heart tube stage, 
and chamber differentiation is not initiated (Cai et al., 2005; Singh et al., 2005; 
Stennard et al., 2005; Takeuchi et al., 2005). There also appears to be a proliferation 
defect in Tbx20 null hearts that is thought to be mediated by a loss of repression of 
Tbx2, thereby allowing aberrant repression of the cell cycle gene N-Myc in chamber 
myocardium (Cai et al., 2005; Singh et al., 2005). The misregulation of Tbx2 in 
Tbx20 mutant hearts may partially explain the loss of cardiomyocytes seen in 
Xenopus and mouse Tbx20 mutants. 
The frequent occurrence of cardiac defects resulting from perturbations in the 
complex regulatory network guiding the cardiomyogenic program highlights the 
importance of understanding the interactions that occur between members of this 
network. Xenopus embryos co-injected with MOs against tbx20 and tbx5 display a 
more severe cardiac phenotype than single mutants, indicating that TBX20 and 
TBX5 cooperate to regulate cardiac morphogenesis (Brown et al., 2005). TBX20 
physically interacts with the cardiac transcription factors NKX2.5, GATA4, GATA5, 
and TBX5 and, in transcription assays, TBX20 synergistically activates cardiac 
promoters in the presence of NKX2.5, GATA4, and ISLET1 (Stennard et al., 2003; 
Brown et al., 2005; Takeuchi et al., 2005). Surprisingly, in transient transcription 
assays, the shorter TBX20b isoform, which is terminated shortly after the T-box 
  204	  
domain, is more effective at activating reporter gene expression than the longer 
TBX20a that is the predominant isoform expressed in the heart during development 
(Stennard et al., 2003). To determine which TBX20 isoform promotes changes in 
morphogenesis and gene expression in vivo, Tbx20a and Tbx20b mRNAs were 
injected into Xenopus embryos . Overexpression of Tbx20a, but not Tbx20b, results 
in multiple developmental defects, including shortening of the anterior/posterior axis 
and secondary axis formation (Stennard and others, 2003). Tbx20 mRNAs were also 
injected into explanted Xenopus animal pole caps resulting in an upregulation of the 
early mesoderm marker Xbra and the cardiac marker Nkx2.5 in the Tbx20a-injected, 
but not Tbx20b-injected, caps (Stennard and others, 2003). These studies suggest 
that the C-terminal domain of TBX20a is essential for TBX20 activity in the embryo 
and highlight the utility of Xenopus embryo assays for investigating the biological 
relevance of in vitro findings.  
 
Noonan Syndrome: Shp-2 
Noonan syndrome is one of the most common forms of CHD. The disorder 
leads to several cardiac developmental abnormalities including ASD, VSD, 
pulmonary stenosis, and hypertrophic cardiomyopathy (Noonan, 1968; Noonan, 
1994). Noonan syndrome was shown to be associated with mis-sense mutations in 
SHP-2 in approximately half of affected individuals (Tartaglia et al., 2001; Kosaki et 
al., 2002; Maheshwari et al., 2002; Tartaglia et al., 2002). Shp-2 mis-sense 
mutations are associated with a gain-of-function and are thought to result in 
prolonged downstream activation of several growth factors including epidermal 
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growth factors (EGFs), fibroblast growth factors (FGFs), and platelet-derived growth 
factor (Feng et al., 1994; Van Vactor et al., 1998; Feng, 1999; Qu, 2000; Zhang et 
al., 2000; Tartaglia et al., 2001). Interestingly, patients with acute myelogenous 
leukemia (AML), acute lymphoblastic leukemia (ALL), and juvenile myelomonocytic 
leukemia (JMML) carry a second, mostly mutually exclusive, somatically introduced 
subset of mis-sense mutations in Shp-2, strongly suggesting a genotype-phenotype 
relationship between Shp-2 mis-sense mutations and disease (Musante et al., 2003; 
Tartaglia et al., 2003; Bentires-Alj et al., 2004; Loh et al., 2004; Kratz et al., 2005). 
However, the cellular and biochemical basis for the role of SHP-2 in Noonan 
syndrome, AML, ALL, and JMML is unknown.  
Shp-2 is a widely expressed non-receptor tyrosine phosphatase comprised of 
two tandemly arranged SH2 domains and a protein tyrosine phosphatase (PTP) 
domain. Shp-2, also known as Sh-Ptp2, Ptpn11, Ptp1d, and Ptp2c, is the vertebrate 
homologue of the Drosophila gene corkscrew (csw). The sequence, expression 
pattern, and function of Shp-2 are highly conserved throughout evolution. For 
example, Xenopus and human orthologues display 94% sequence identity, and as in 
fly and mouse, Xenopus shp-2 is believed to be ubiquitously expressed (Tang et al., 
1995; Langdon et al., 2007). Moreover, several animal models have suggested a 
critical role for Shp-2 in vertebrate development. For example, mice expressing an 
internal deletion of the amino-terminal (N-SH2) domain of Shp-2 die at late 
gastrulation and display several mesodermal abnormalities including heart and 
vascular defects (Saxton et al., 1997; Saxton and Pawson, 1999; Yang et al., 2006). 
In addition Shp-2 mutant cells derived from homozygous mutant embryos show that 
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Shp-2 is required for full and sustained activation of the MAPK pathway in response 
to FGF, thus demonstrating that SHP-2 functions downstream of the FGF/MAPK 
pathway in vivo (Saxton et al., 1997; Saxton and Pawson, 1999). Consistent with 
these findings, studies in Xenopus have shown that a dominant negative form of 
Xenopus Shp-2 can completely block mesoderm formation in response to both 
MAPK and FGF (Tang et al., 1995). Furthermore, in vitro and tissue culture studies 
have shown that csw/Shp-2 interacts directly with the FGF inhibitor SPROUTY, 
leading to SPROUTY phosphorylation and inactivation (Hanafusa et al., 2004; Jarvis 
et al., 2006).  
In the mouse and chick, SHP-2 is required in the EGF pathway for formation 
of cardiac valves. However, because approximately one-third of patients with 
Noonan-associated heart defects appear to undergo normal valvulogenesis (Chen et 
al., 2000; Krenz et al., 2005), it remains unclear if SHP-2 is required downstream of 
other receptor tyrosine kinase receptors for other aspects of heart development. To 
address whether SHP-2 functions in cardiac pathways in addition to EGF and 
valvulogenesis and to bypass the early embryonic requirements for SHP-2, Langdon 
et al. (2007) used a Xenopus cardiac explant assay and chemical SHP-2 inhibitors 
to demonstrate that SHP-2 is required for the survival of actively proliferating cardiac 
progenitor populations but not those that have exited the cell cycle. It was further 
demonstrated that SHP-2 is directly phosphorylated on specific residues in vivo in 
response to FGF signaling, that SHP-2 co-immunoprecipitates with the FGF receptor 
adaptor, and that a constitutively active Noonan-associated Shp-2 mutation can 
rescue cardiac defects induced by FGF inhibition. Collectively, these studies imply 
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that SHP-2 functions in the FGF/MAPK pathway to maintain survival of proliferating 
populations of cardiac progenitor cells. However, it remains to be determined why 
mis-sense mutations in Shp-2 lead to a tissue-specific effect in animals and humans. 
 
Heterotaxy and Cardiac Looping Defects: Zic3 
Heterotaxy (situs ambiguus) is a spectrum disorder in which the position of 
thoracic and abdominal organs is abnormal. Heterotaxy malformations are thought 
to arise from defective left-right patterning during embryonic development.  
Establishing laterality in the embryo is a complex process involving a 
multitude of spatio-temporal signaling events (Mercola, 1999; Boorman and Shimeld, 
2002). Initially, cells in the left-right coordinator (posterior notochord in mammals, 
gastrocoel roof plate in Xenopus, and Kupffer’s vesicle in zebrafish) adjacent to the 
organizing node develop specialized motile cilia that generate a leftward fluid flow 
and an asymmetrical morphogen gradient (Tabin and Vogan, 2003; Blum et al., 
2009; Sutherland and Ware, 2009). The subsequent lateralized expression of nodal, 
a member of the transforming growth factor β (TGFβ) family, is then thought to be 
involved in specifying left-right asymmetry via the notch signaling pathway (Krebs et 
al., 2003; Raya et al., 2003). Pitx2, a paired homeobox transcription factor, also 
plays a crucial role in organ symmetry, particularly in heart looping, downstream of 
nodal signaling (Ryan et al., 1998).  
One of the first major morphological symmetry-breaking events in vertebrates 
occurs when the relatively symmetrical heart tube undergoes a rightward (dextral) 
bend, after which a complex process of looping and septation results in the mature 
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multi-chambered heart (Mercola, 1999; Manner, 2000; Boorman and Shimeld, 2002; 
Manner, 2009). Cardiac looping defects are commonly observed in cases of 
heterotaxy, and these defects account for approximately 3% of all CHDs. Other 
common heart phenotypes seen in heterotaxic patients include ASD, VSD, 
transposition of the great arteries, double outlet right ventricle, single ventricle, and 
aortic arch defects (Bowers et al., 1996; Lin et al., 2000; Belmont et al., 2004; 
Sutherland and Ware, 2009). Numerous cases of familial clustering of heterotaxy 
have been identified, suggesting autosomal inheritance of the disorder. However, X-
linked inheritance has also been shown, involving mutations in the conserved zinc-
finger transcription factor gene, Zic3 (Gebbia et al., 1997; Ware et al., 2004). Heart 
defects and altered nodal expression are observed in Zic3 mutant mice (Purandare 
et al., 2002). In Xenopus embryos, zic3 is expressed in the mesoderm of the 
gastrulating embryo in a left-right (L-R) symmetrical fashion, however, unilateral 
right-sided overexpression of zic3 is sufficient to disturb the L-R axis, resulting in 
abnormal heart and gut looping and affecting the lateral expression of pitx2 and 
nodal related 1 (XnrI) (Kitaguchi and others, 2000). Xenopus zic3 is therefore 
considered to have a conserved early role in transducing signals from the left-right 
organizer and establishing asymmetry (Kitaguchi et al., 2000; Kitaguchi et al., 2002).  
The amphibian model system has historically been used to study left-right 
patterning since the early 1900s by Spemann and colleagues. Subsequently, the 
Xenopus model was established, and has proven ideally suited to study the role of 
left-right laterality, using well-accepted techniques such as lineage tracing and fate 
mapping, in the process of heart development (Gormley and Nascone-Yoder, 2003; 
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Blum et al., 2009). One of the first events in Xenopus embryonic development is 
cleavage at the one-cell stage to form two blastomeres, the descendents of which 
will contribute almost exclusively to either the left or the right side of the embryo. 
This feature enables researchers to independently alter signaling events or gene 
expression unilaterally to determine their effect on asymmetry and to conduct left-
right lineage tracing experiments, particularly of the heart region (Branford et al., 
2000; Kitaguchi et al., 2000; Kitaguchi et al., 2002; Dagle et al., 2003; Chen et al., 
2004; Ramsdell et al., 2006; Toyoizumi et al., 2006; Jahr et al., 2008). Recent work 
in Xenopus has demonstrated that cell lineages in the heart display a high degree of 
asymmetry, and that defects in left-right patterning alter cardiomyocyte allocation 
and differentiation in the heart, leading to cardiac malformations (Chen et al., 2004; 
Ramsdell et al., 2006). The Xenopus model is therefore an optimal organism to 
study the fate of cardiac cell populations and to determine how specific genes such 
as Zic3 may be involved in establishing laterality in the heart and their roles in 
heterotaxic phenotypes.  
Axenfeld-Reiger Syndrome: Pitx2 and FoxC1 
Axenfeld-Rieger syndrome (ARS) is a complex autosomal dominant disorder 
primarily characterized by anomalies of the anterior segment of the eye, face, teeth, 
and umbilical stump.  Congenital heart defects, including ASD, pseudotruncus 
arteriosus, and mitral valve and intraventricular septal defects have also been 
reported in a number of patients with ARS (Cunningham et al., 1998; Mammi et al., 
1998; Davies et al., 1999; Bekir and Gungor, 2000; Baruch and Erickson, 2001; 
Grosso et al., 2002; Maclean et al., 2005; Calcagni et al., 2006; Aysenur Pac et al., 
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2008; Weisschuh et al., 2008; Antevil et al., 2009; Akkus and Argin, 2010).  Linkage 
analyses have identified four different loci in humans, 4q25, 6p25, 13q14, and 
16q24, each of which has been independently associated with ARS. Further 
analyses of 4q25 and 6p25 in patients with ARS have uncovered mutations in two 
genes, Pitx2 and Foxc1, respectively (Amendt et al., 2000; Hjalt and Semina, 2005; 
Maclean et al., 2005). 
Pitx2 is a highly conserved homeodomain transcription factor that is 
expressed asymmetrically in the left lateral plate mesoderm in chick, zebrafish, 
Xenopus, and mouse embryos (Ryan et al., 1998; Campione et al., 1999). At heart-
forming stages, pitx2 expression continues to be restricted to the left half of the heart 
tube in Xenopus embryos. In mouse, Pitx2 is expressed in the left side of the heart 
tube and in the left ventricle, OFT, and atrium during heart looping (Ryan et al., 
1998). The defects observed in Pitx2 null and hypomorphic mice, such as altered 
looping of the heart, absence of atrial septation, and dysmorphic ventricular 
septation, recapitulate the defects observed in human ARS patients with Pitx2 
dysfunction (Gage et al., 1999; Lin et al., 1999; Lu et al., 1999).  
The use of Xenopus has been instrumental in understanding the dual role of 
Pitx2 in heart development, firstly in directing the looping of the heart tube and 
secondly in controlling the morphogenesis of the cardiac chambers. Misexpression 
of pitx2 by injection of its mRNA on the right side of the Xenopus embryo results in a 
reversal of heart looping, showing the conserved role of pitx2 in directing this event. 
The restricted expression of pitx2 is likely to be downstream of the TGFβ signaling 
family, as bilateral injections of mRNA encoding nodal or activin results in bilateral 
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expression of the gene (Campione et al., 1999). Further, injection of a dominant 
negative form of the activin type II receptor into Xenopus embryos alters pitx2 
expression levels and subsequent heart looping. These findings are supported by 
similar experiments in chick (Ryan et al., 1998). Of the three isoforms of Pitx2 
present during development, experiments in Xenopus, zebrafish, and mouse 
demonstrate that Pitx2c is the isoform that is specifically expressed in heart (Essner 
et al., 2000; Schweickert et al., 2000). The injection of modified antisense 
oligonucleotides that mediate degradation of pitx2c mRNA in Xenopus embryos 
results in cardiac defects that are very similar to phenotypes observed in Pitx2 
mutant mice, including abnormal atrial septation, extracellular matrix restriction, 
abnormal positioning of the atrial and ventricular chambers, and restriction of 
ventricular development. These tadpoles also exhibit dramatic straightening of the 
OFT, followed by a rightward migration (Dagle et al., 2003). This study demonstrates 
the conservation of pitx2 function in Xenopus cardiac development and its 
relationship to ARS. It has recently been shown that Pitx2 patterns the second heart 
field and is required to specify the left versus right atrium (Liu et al., 2002; Ai et al., 
2006; Galli et al., 2008). It will be interesting to determine if Xenopus can be 
exploited as a useful model for testing the effects of various ARS-derived mutations 
on Pitx2 function during second heart field development and for further identifying 
the mechanisms by which Pitx2 functions.  
Foxc1 is a member of the forkhead family of transcription factors and is 
expressed in endothelial and mesenchymal cells of the developing heart as well as 
in endocardial cushions derived from cardiac neural crest cells (Iida et al., 1997; 
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Winnier et al., 1999; Kume et al., 2001; Seo et al., 2006). Foxc1 transcripts have 
also been detected in the second heart field and in the proepicardium (Seo and 
Kume, 2006). In the newly formed heart, Foxc1 is expressed in the atrial septum, the 
venous, aortic and pulmonary valves, and the mitral and tricuspid valves (Swiderski 
et al., 1999).  Consistent with its widespread expression in the heart, FOXC1 plays a 
critical role in heart valve formation and atrial septation as suggested by the cardiac 
defects noted in mice mutant for Foxc1. Specifically, Foxc1 homozygous mutants 
display interruption or coarctation of the aortic arch, VSD, and pulmonary and aortic 
valve dysplasia (Winnier et al., 1999). Mice lacking both Foxc1 and the closely 
related Fox transcription factor Foxc2 have even more severe cardiac abnormalities 
consisting of hypoplasia or lack of the OFT and right ventricle as well as the inflow 
tract, and dysplasia of the OFT and atrioventricular cushions. These mice also have 
an abnormally formed epicardium, reduced cell proliferation, and increased 
apoptosis of neural crest cells (Winnier et al., 1999; Kume et al., 2001; Seo and 
Kume, 2006).  
Foxc1 has been identified in Xenopus and is present in cardiac lineages 
(Koster et al., 1998; Gessert and Kuhl, 2009). Depletion of foxc1 during early 
Xenopus development results in downregulation of adhesion molecules involved in 
mesoderm development and increased apoptosis, correlating with the phenotypes 
observed in the mouse mutants (Cha et al., 2007). It remains to be determined if 
reduction of FOXC1 levels in Xenopus has similar effects on cardiac morphology to 
those observed in mouse knockouts and patients with ARS.  However, the early 
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phenotypes of FOXC1 depletion during Xenopus development provide a model in 
which to investigate the phenotypic changes that result from Foxc1 disruption. 
 
CHARGE Syndrome: Chd7 
CHARGE syndrome (Coloboma, Heart defects, choanal Atresia, Retarded 
growth and development, Genital abnormalities, and Ear anomalies) is a complex 
disease associated with a number of cardiac abnormalities including Tetralogy of 
Fallot, atrioventricular canal defects, and aortic arch anomalies (Davenport et al., 
1986). The majority of individuals with CHARGE syndrome have mutations in the 
coding region of chromodomain helicase DNA binding protein 7 (Chd7) (Vissers et 
al., 2004; Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al., 2006; Delahaye 
et al., 2007; Wincent et al., 2008; Kaliakatsos et al., 2010; Wessels et al., 2010).  
Chd7 expression has been characterized in the chick and mouse, where it 
has been found to be expressed mainly in the neural ectoderm and branchial arches 
(Bosman et al., 2005; Aramaki et al., 2007; Hurd et al., 2007). Mutant Chd7 mice 
display defects in neural stem cell proliferation, olfaction, and some cardiac defects, 
including formation of the interventricular septum (Bosman et al., 2005; Adams et al., 
2007; Hurd et al., 2007; Layman et al., 2009). It has been proposed that the multiple 
phenotypes in CHARGE syndrome are caused by defects in neural crest cell (NCC) 
migration (Siebert et al., 1985). Recently, Chd7 was found to be expressed in 
Xenopus NCCs as well as in human NC-like cells. MO knockdown of chd7 in 
Xenopus perturbs the migration of NCCs to the pharyngeal arches. This phenotype 
is partially rescued by injecting human Chd7 mRNA, suggesting that the molecular 
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function of CHD7 is well-conserved. In addition, overexpression of human Chd7 with 
a substitution of a conserved lysine residue in its ATPase domain results in a 
dominant-negative effect (Bajpai et al., 2010). This dominant negative effect 
recapitulates the major features of CHARGE syndrome described above, including 
abnormal positioning of the truncus arteriosus and OFT. Analysis of markers 
associated with NCCs reveal that chd7 is not required for the induction or survival of 
NCCs, but for their specification. The expression of sox9, twist, and slug, genes that 
mark multipotent, migrating NCCs, is severely perturbed in chd7 downregulated 
embryos (Sauka-Spengler and Bronner-Fraser, 2008; Bajpai et al., 2010). These 
studies in Xenopus have provided a powerful in vivo model in which to study the role 
of NCCs in heart development and the CHDs that result from improper NCC 
migration and specification. More recently, the chromatin remodeling factors CHD8 
and BRG1 have been shown to physically interact with CHD7 (Bajpai et al., 2010; 
Batsukh et al., 2010) and Brg1 was demonstrated to play a role in regulating cardiac 
growth and differentiation (Hang et al., 2010). The roles of Chd8 and Brg1 in a 
Xenopus model of CHARGE syndrome could aid in the understanding of this 
complex syndrome. 
 
FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES IN XENOPUS 
Investigating a Role for the Epicardium in Congenital Heart Disease  
The epicardium is a mesothelial sheet of cells surrounding the myocardium of 
the developing looped heart in many vertebrate organisms (Ho and Shimada, 1978; 
Viragh and Challice, 1981; Hirakow, 1992; Manner et al., 2001; Jahr et al., 2008; 
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Pombal et al., 2008; Serluca, 2008). The epicardial structure arises from the pro-
epicardial organ (PEO), which is situated on the sinus venosus. These mesothelial 
cells cluster and bridge over towards the ventricular surface of the heart and migrate 
onto the myocardial surface as an epithelial-like sheet. Subsequently, subsets of 
epicardial cells undergo epithelial-mesenchymal transition (EMT) and migrate into 
the sub-epicardial space and myocardium where they differentiate into various cell 
populations including fibroblasts and smooth muscle cells of the coronary 
vasculature (Manner et al., 2001; Lie-Venema et al., 2007; Winter and Gittenberger-
de Groot, 2007). The epicardium is thought to play a mitogenic role in cardiomyocyte 
growth and has been shown to be important for cardiac repair in adult zebrafish 
(Lepilina et al., 2006). Recently, adult human epicardium-derived cells (EPDCs) 
were demonstrated to have a paracrine role in improving mammalian cardiac 
function when co-transfected with cardiomyocytes into an infarcted murine heart 
(Winter et al., 2007; Winter et al., 2009). Thus, the epicardium may have the 
potential to stimulate cardiac repair and regeneration, given the right conditions. 
Various congenital heart diseases display abnormalities that may arise from 
improper epicardium formation or differentiation of EPDCs. In avian embryos in 
which either the pro-epicardial organ is ablated or the epithelial-mesenchymal 
transition of EPDCs is disrupted, defects are seen in the compact layer of the 
myocardium, while the inner curvature of the heart is wider and often displays a 
double outlet right ventricle, indicative of a heart looping defect (Gittenberger-de 
Groot et al., 2000; Lie-Venema et al., 2005; Manner et al., 2005). Ventricular non-
compaction is also seen when genes involved in epicardium formation, e.g., Wt1 and 
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RXRα, are knocked out in the mouse (Moore et al., 1998; Merki et al., 2005). In 
addition to their roles in regulating the development of the compact ventricular and 
atrial myocardia, EPDCs are involved in the development of cardiac structures 
associated with the conduction system. The annulus fibrosus, which plays an 
important insulating role in the cardiac conduction system, is derived from the 
epicardium, and EPDCs also influence the formation of the peripheral Purkinje fiber 
network from ventricular cardiomyocytes (Eralp et al., 2006; Zhou et al., 2010). 
Electrophysiological cardiac defects, such as Wolff-Parkinson-White syndrome and 
Mahaim tachycardia, may therefore have an origin in improper epicardium or EPDC 
formation. 
EPDCs also contribute cells to the atrioventricular cushions and valves, and 
disrupting epicardium formation can lead to aberrant valve formation (Gittenberger-
de Groot et al., 1998; Gittenberger-de Groot et al., 2000; Perez-Pomares et al., 
2002; Manner et al., 2005). It is conceivable that disorders in which the valve leaflet 
has not fully delaminated - for example, Ebstein’s anomaly (tricuspid valve leaflet) - 
might result from defects in epicardial patterning or signaling (Attenhofer Jost et al., 
2005; Lie-Venema et al., 2007). Ventricular non-compaction may also be indicative 
of an epicardial defect as shown by mouse knockout models of genes involved in 
epicardium formation, e.g., Wt1 and RXRα, or in PEO ablation studies in chick 
(Moore et al., 1998; Manner et al., 2005; Merki et al., 2005; Sucov et al., 2009). 
Interestingly, the Fog-2 knockout mouse, which has an epicardial defect phenotype, 
displays many of the anomalies described above - including tricuspid atresia, thin 
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myocardium, double outlet right ventricles, and VSD (Svensson et al., 2000; 
Tevosian et al., 2000; Clark et al., 2006). 
To date, little is known about how the epicardium develops and functions in 
Xenopus embryos. Scanning electron microscopy has demonstrated the presence of 
the PEO on the right side of the septum transversum in Xenopus embryos, similar to 
other vertebrates (Jahr et al., 2008). Furthermore, genes characteristic of the 
vertebrate PEO and epicardium are conserved in Xenopus (Jahr et al., 2008). The 
Xenopus model lends itself to studying the epicardium and potential defects in valve 
formation and conduction systems due to the ease of manipulating gene function 
and the established techniques of tissue explanting, antisense MO microinjection, 
lineage tracing, and transgenics. Recent advances in live imaging have enabled 
researchers to utilize the Xenopus model to visualize cardiac development in real 
time and to use non-invasive electrical recording, Doppler optical cardiograms, and 
optical coherence tomography to study heart structure, conduction, and blood flow to 
determine the role of the epicardium in these processes (Bartlett et al., 2004; 
Mariampillai et al., 2007; Yelin et al., 2007; Kieserman et al., 2010).  
 
In Vivo Imaging of the Developing Xenopus Heart  
Xenopus embryos are very well-suited for live imaging of dynamic 
developmental processes due to their large size and external development. Because 
of the large size of the embryos, individual cells in the embryo are larger, which 
allows visualization of the subcellular localization and dynamics of a given 
fluorescent fusion protein. For example, live confocal imaging has been successfully 
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used to demonstrate the dispersal of individual fluorescent myeloid cells throughout 
the Xenopus embryo (Kieserman et al., 2010). A combination of transgenesis and 
advanced imaging tools makes this type of approach feasible in the living animal. 
Yolk opacity in the early Xenopus embryo presents a challenge for imaging of 
deeper tissues. However, cells and/or deep tissues can be visualized easily after 
microsurgery and subsequent culture of tissue explants. High resolution imaging of 
the structure and function of the developing myocardium will be critical to complete 
our understanding of how the heart develops in three and four dimensions, and thus 
how developmental defects can arise in this system. 
Historically, the morphology of the Xenopus embryonic heart has been 
studied in fixed embryos with a combination of confocal microscopy and 3D 
reconstruction of serial sections through the heart (Kolker et al., 2000; Mohun, 
2000). As even slight morphological or dynamic changes in the heart can result in 
myocardial dysfunction, it is of vital importance to examine these changes in vivo in 
the developing embryo. One area in which this is particularly relevant is in the 
characterization of defects in the cardiac conduction system. Human CHD is often 
complicated by atrioventricular conduction abnormalities. However, a thorough 
understanding of the defects in embryonic heart contraction as they result from a 
genetic or morphological abnormality is lacking due to the difficulty of examining 
these defects in vivo. It has recently been demonstrated that the Xenopus embryo is 
amenable to noninvasive live video analysis of the conduction system, allowing one 
to examine the properties of chamber contraction in vivo (Bartlett et al., 2004). 
Moreover, Xenopus cardiac electrophysiology shares many characteristics with the 
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human conduction system, making it an ideal model in which to analyze the 
physiology of cardiac conduction defects. As a proof of principle, this methodology 
has been used to examine the microscopic timing of heart contraction in embryos 
injected with two human Nkx2.5 mutants and resulted in the identification of a 
number of conduction defects including a delay in the AV interval and a distinct 
tachycardia (Bartlett et al., 2007). This type of study, when applied to other human 
mutations such as those in Tbx5 that cause Holt-Oram Syndrome, can improve our 
understanding of these complex human pathologies. 
 
Protein Interactions and Biochemical Function 
As discussed previously, transgenesis has primarily been used to study the 
regulation of gene expression and has revealed much about the transcriptional 
regulation of cardiac development. However, it has been used relatively little as a 
tool for isolating protein complexes. Because protein complexes mediate the 
majority of cellular processes, knowledge of the composition and function of cardiac-
specific protein complexes will provide key insights into their tissue-specific activity 
in the heart. With the advent of proteomics-based approaches to identify 
endogenous protein complexes, there are a variety of convenient in vivo tags such 
as GFP that can be used to genomically label any protein of interest. Thus, the 
generation of transgenic Xenopus lines that express tagged versions of proteins will 
provide virtually unlimited material for applications such as mass spectrometry and 
protein localization studies.  Additionally, tagged proteins carrying known CHD-
causing mutations could be utilized to characterize changes in their ability to form 
  220	  
complexes with other cardiac proteins. As discussed previously, deficiencies in 
members of cardiac transcriptional complexes often lead to congenital heart 
malformations, illuminating the need to investigate the functional role of these 
complexes during cardiac development. 
 
Genetic Approaches in Xenopus tropicalis 
To date, most studies that have used Xenopus as a model system to examine 
cardiac development have used the pseudotetraploid species Xenopus laevis and 
have relied upon well-established nucleic acid microinjection techniques for 
depletion or over-expression of proteins in the developing embryo. As our 
understanding of the genetic basis of inherited cardiac disease increases, there will 
be a greater need to use genetic approaches in Xenopus. Genetic techniques 
enable precise experimental manipulation that can be used to gain a deeper 
understanding not just of individual gene functions, but also of the interconnectivity 
between genes in genetic networks (through enhancer/suppressor gene interaction 
studies, for example). These interconnections, coupled with variation in the genetic 
background, may ultimately explain the range of disease type and severity often 
observed in patients with particular CHDs (Basson et al., 1994; Newbury-Ecob et al., 
1996; Sznajer et al., 2007). The use of loss-of-function or gain-of-function alleles of 
endogenous genes that are generated by mutagenesis also circumvents the 
undesirable features of MO-based inhibition and mRNA-based expression that result 
from the inherent limitations in controlling where and when MOs or mRNAs are 
active in the embryo. Specifically, the role of mutations that affect the biochemical 
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function of a protein can be examined without inappropriately expressing the mutant 
protein in cells in which the native protein is not expressed, or at times at which it 
would not normally be present. 
 
 The diploid Xenopus tropicalis is much more amenable to genetic analysis 
than the pseudotetraploid X. laevis. Fortunately, the vast majority of reagents and 
techniques developed by researchers for X. laevis can be adapted for use with X. 
tropicalis, primarily due to the extremely close similarities between the two species 
at the genetic and embryonic levels. Even complex reagents such as microarrays 
developed in one Xenopus species have been shown to be usable in both, although 
species-specific reagents are becoming increasingly available (Chalmers et al., 
2005). A key factor encouraging researchers to adopt X. tropicalis is the availability 
of a high-quality genome sequence and the resources that have stemmed from it, 
including a simple-sequence repeat map of more than 1,500 polymorphic markers 
that allows mutations to be mapped to relatively small regions of the genome 
following their isolation in forward genetic screens (Xu et al., 2008; Hellsten et al., 
2010) (http://tropmap.biology.uh.edu/index.html). The first two mutations mapped in 
X. tropicalis, Muzak and Dicky Ticker, both affect cardiac function and are located in 
the myosin heavy chain gene myh6 and the muscle-specific chaperone gene 
unc45b, respectively (Abu-Daya et al., 2009; Geach and Zimmerman, 2010). These 
early successes validate X. tropicalis as a model in which novel cardiac genes can 
be identified through phenotype-based forward genetic screens. The primary 
importance of this work will be to gain a better understanding of the developmental 
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genetics of cardiac cell type differentiation and morphogenesis. However, studying 
the effects of mutations in disease-associated genes is also likely to advance our 
understanding of the etiology of congenital heart abnormalities. 
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Table A1.1. Xenopus models of human congenital heart disease. 
Gene 
Name 
Disease 
Cardiovascular 
Manifestations 
Xenopus 
Model 
Xenopus 
Cardiac 
Phenotype 
Refs 
Tbx1 DiGeorge 
Syndrome 
TOF, persistent 
truncus 
arteriosus 
overexpression 
of dominant 
negative  
unlooped 
heart, 
pericardial 
edema 
(Ataliotis et 
al., 2005) 
Tbx5 Holt-Oram 
Syndrome 
ASD, VSD, 
cardiac 
conduction 
system defects 
overexpression 
of dominant 
negative 
 
protein 
depletion 
unlooped heart 
 
 
unlooped 
heart, loss of 
cardiac cells 
(Horb and 
Thomsen, 
1999) 
 
(Brown et 
al., 2005) 
Tbx20 NA ASD, VSD, valve 
disease, 
pulmonary 
hypertension, 
cardiomyopathy, 
TOF 
protein 
depletion 
unlooped 
heart, 
pericardial 
edema, loss of 
cardiac cells 
(Brown et 
al., 2005) 
Nkx2.5 NA ASD, cardiac 
conduction 
system defects 
overexpression 
 
overexpression 
of dominant 
negative  
 
overexpression 
of mutant 
mRNA 
enlarged heart 
 
reduced heart 
 
 
ASD, cardiac 
conduction 
system defects 
(Cleaver, 
1996) 
 
(Fu, 1998; 
Grow and 
Krieg, 
1998) 
 
(Bartlett et 
al., 2007) 
Gata4 NA ASD protein 
depletion 
partial fusion of 
heart fields, 
cardiac bifida, 
abnormal 
cardiac looping 
(Haworth 
et al., 
2008) 
Shp2 Noonan 
Syndrome 
ASD, VSD, 
pulmonary 
stenosis, 
hypertrophic 
cardiomyopathy 
chemical 
inhibition 
unfused heart 
fields, loss of 
cardiac cells 
(Langdon 
et al., 
2007) 
Zic3 Heterotaxy cardiac looping 
defects, ASD, 
VSD, 
transposition of 
the great arteries, 
overexpression abnormal 
cardiac looping 
(Kitaguchi 
et al., 
2000; 
Kitaguchi 
et al., 
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double outlet 
right ventricle, 
ventricle and 
aortic arch 
defects 
2002) 
Pitx2 Axonfeld-
Reiger 
Syndrome 
ASD, 
pseudotruncus 
arteriosus, mitral 
valve and 
intraventricular 
septal defects 
overexpression 
 
overexpression 
of dominant 
negative  
 
protein 
depletion 
abnormal 
cardiac looping 
 
abnormal 
cardiac looping 
 
 
abnormal atrial 
septation, 
defects in atrial 
and ventricular 
chamber 
position, 
restriction of 
ventricular 
development 
(Campione 
et al., 
1999) 
(Campione 
et al., 
1999) 
 
(Dagle et 
al., 2003) 
Chd7 CHARGE 
Syndrome 
TOF, 
atrioventricular 
canal defects, 
aortic arch 
defects 
protein 
depletion 
 
 
overexpression 
of mutant 
mRNA 
defects in 
neural crest 
cell migration 
 
abnormal 
positioning of 
truncus 
arteriosus and 
OFT 
(Bajpai et 
al., 2010) 
 
(Bajpai et 
al., 2010) 
TOF, Tetralogy of Fallot; ASD, atrial septal defects; VSD, ventricular septal defects; 
NA, Not Applicable; OFT, outflow tract 
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Appendix 2 
Immunoisolation of protein complexes from Xenopus 
 
Overview 
 This work was published as an in-depth technical article as part of the series 
Xenopus Protocols: Post-Genomic Approaches (ed. Stefan Hoppler and Peter D. 
Vize) in the journal Methods in Molecular Biology. It is based on an ongoing 
collaboration between our laboratory and Ileana Cristea’s lab at Princeton University 
to optimize the isolation of protein complexes from Xenopus embryonic tissue. I 
contributed an IP-western blot demonstrating assessment of isolation efficiency of 
an endogenous protein (Shp2) and to the writing of the manuscript itself. The article 
was conceived and finalized by Frank Conlon and Ileana Cristea. 
 
Conlon F.L., Miteva Y., Kaltenbrun E., Waldron L., Greco T.M., and Cristea I.M. 
(2012) Immunoisolation of protein complexes from Xenopus. Methods in Molecular 
Biology, vol 917: 369-390. 
 
The immunoaffinity isolation of protein complexes is an essential technique 
for the purification and concentration of protein complexes from cells and tissues. In 
this chapter we present the methodologies for the purification of proteins and protein 
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complexes from Xenopus laevis and Xenopus tropicalis. Specific to this protocol are 
the techniques for the cryolysis of Xenopus cells and tissues, a procedure that limits 
contamination from yolk proteins while preserving endogenous protein complexes, 
the methodologies for immunoaffinity purification of proteins using magnetic beads, 
and the protocols for western blot analysis. In addition, the procedures in this 
chapter can be extended to use with proteomic analysis of protein complexes as 
presented in the following chapter. 
 
INTRODUCTION 
It is becoming increasingly clear that many forms of human disease are 
associated with defects in genes that are required for early steps in embryonic 
development. Moreover, the molecular and cellular pathways through which these 
genes function can be elucidated using established model systems such as the 
African clawed frog, Xenopus. Xenopus has numerous advantages as a model 
system in which to identify and characterize cellular and developmental processes 
particularly in regards to proteomic-based approaches. Most critically, unlike the 
mouse, the Xenopus embryo develops externally and the embryo is relatively large 
and is amenable to surgical manipulations, allowing defined regions to be excised 
and cultured in simple salt solutions. These classical approaches are complemented 
by molecular techniques that allow the ectopic expression, overexpression, or 
knock-down of specific gene transcripts in the early embryo, and transgenic 
technologies.  
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Complementary to these approaches are emerging biochemical approaches. 
In this regard, Xenopus offers a unique model system for the identification and 
characterization of protein complexes in vivo. However, the use of these approaches 
has been limited due to the lack of optimized protocols for isolation of early stage 
Xenopus tissues and the large abundance of yolk proteins. As shown in Figure A2.1, 
this chapter describes methods for conducting immuno-precipitation of endogenous 
protein complexes in Xenopus laevis and Xenopus tropicalis which combines the 
cryogenic lysis of tissues with immunoisolation on magnetic beads. An overview of 
the approach is shown in Figure A2.1. Collectively, these approaches function to 
preserve endogenous protein complexes, limit problems associated with yolk 
platelets, and proved a specific isolation of a given protein. 
 
METHODS AND EQUIPMENT 
Obtaining Xenopus laevis embryonic tissue 
1. Fine watchmaker’s forceps such as Dumont number 5 forceps. 
2. X. laevis embryos cultured to desired stage of development (Nieuwkoop, 1994) 
3. 10X Modified Barth’s Saline (MBS), pH 7.8: 880 mM NaCl, 10 mM KCl, 10 mM 
MgSO4, 50 mM HEPES pH 7.8, 25 mM NaHCO3. 1X MBS is made by mixing 
100 mL of 10X stock solution with 700 µL 1 M CaCl2 and adjusting the volume 
to 1 L with dH2O. Store at room temperature. 
4. 1% agarose plates for dissections: Weigh 1 g agarose and transfer to 250 mL 
Erlenmeyer flask containing 100 mL dH2O. Heat flask in microwave until 
agarose has completely dissolved. Cool molten agarose until cool enough to 
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hold flask. Pour a layer of agarose into small plastic petri dishes (5 cm). Allow 
agarose to set. Store plates at 4°C. 
5. Plastic transfer pipettes 
6. Liquid nitrogen 
7. Syringe needle (19G1½) 
8. 50 mL conical tubes 
9. A dissecting microcope (e.g. Leica MZ6) 
 
Tissue lysis and protein extraction 
1. Retsch MM 301 Mixer Mill with 2 X 25 mL jars and 2 X 20 mm (tungsten 
carbide or stainless steel) grinding balls (Retsch, Newtown, PA). 
2. Liquid nitrogen, Styrofoam container and a pair of long forceps 
3. Windex 
4. Methanol 
5. 50 mL conical tubes 
6. Ultrapure water   
 
Immunoaffinity purification of protein complexes 
Conjugation of magnetic beads 
Unless otherwise stated all solutions can be stored at room temperature 
1. Dynabeads M-270 Epoxy (Invitrogen).  
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2. Affinity purified antibodies against a protein of interest or tag (e.g., anti-GFP 
antibodies as shown below for the isolation of GFP-tagged proteins), or 
Immunoglobulin G (for isolation of Protein A-tagged proteins).   
3. 0.1 M Sodium Phosphate buffer, pH 7.4:  Prepare as 19 mM NaH2PO4, 81 mM 
Na2HPO4 in water and adjust pH to 7.4, if necessary. Filter sterilize (0.2 µm 
filter (Millipore)). Store at 4°C.   
4. 3 M Ammonium Sulfate: Prepare in 0.1 M Sodium Phosphate buffer, pH 7.4. 
Filter sterilize (0.2 µm filter (Millipore)).   
5. 100 mM Glycine-HCl, pH 2.5: Prepare in water. Adjust pH to 2.5 with HCl. Filter 
sterilize (0.2 µm filter (Millipore)). Store at 4°C.    
6. 10 mM Tris, pH 8.8: Prepare in water. Adjust pH to 8.8 with HCl. Filter sterilize 
(0.2 µm filter (Millipore)). 
7. 100 mM Triethylamine: Prepare fresh in water. CAUTION: toxic and extremely 
flammable. Must handle in a chemical hood and dispose of appropriately.   
8. DPBS, pH 7.4 (Dulbecco's Phosphate-Buffered Saline (1X), liquid), (Invitrogen): 
Store at 4°C. 
9. 0.5% Triton X-100: Prepare in DPBS. Store at 4°C. 
10. 0.02% Sodium azide (NaN3): Prepare in DPBS. Store at 4°C. CAUTION: NaN3 
is a toxic solid compound. Must handle in a chemical hood and dispose of 
appropriately.   
11. Rotator (at 30°C)   
12. Magnetic separation tube rack (Invitrogen) 
13. Tube shaker (Tomy shaker) 
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14. Round bottom 2 mL Safe-Lock tubes (Eppendorf) 
15. Ultrapure water (e.g., from a Milli-Q Integral Water Purification System) 
 
Immunoaffinity purification 
1. Frozen tissue powder (see section Obtaining Xenopus laevis embryonic tissue) 
2. Optimized lysis buffer (See section Tissue lysis and protein extraction) 
prepared fresh prior to each experiment.  
3. Magnetic beads conjugated with antibodies (see section Conjugation of 
magnetic beads) 
4. 50 mL conical tubes 
5. Polytron for tissue homogenization (e.g., PT 10-35 Polytron from Kinematica) 
6. Centrifuge and rotor, compatible with 50 mL conical tubes and capable of 8000 
x g at 4°C 
7. Tube rotator at 4°C 
8. Ultrapure dH2O 
9. Round bottom eppendorf tubes (Fisher) 
10. Axygen Maxymum Recovery microcentrifuge tubes, 1.5 mL (VWR)  
11. Bar magnets (for conical tubes) and magnetic separation rack (for eppendorf 
tubes) (Invitrogen) 
12. Ammonium hydroxide, 14.8 M (Sigma). Store at 4°C. 
13. Base elution buffer: Mix 4.826 mL of ultrapure H2O, 5 µL of 0.5 M EDTA, pH 
8.0, and 169 µL of ammonium hydroxide. Prepare fresh before use. 
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14. 4X LDS elution buffer: Dissolve 0.666 g of Tris-HCl, 0.682 g of Tris-Base, 0.8 g 
of LDS, and 0.006 g of EDTA (free acid) in ultrapure dH2O to a final volume of 
10 mL.  Aliquot and store at -20°C. 
15. 10X Reducing Agent (Invitrogen) 
16. 1M iodoacetamide (IAA) (Sigma): Dissolve 0.185 g of iodoacetamide in 1 mL 
HPLC grade water. Dispense into 50 x 20 ml aliquots and store at -20°C 
17. Heat block at 70°C 
 
Assessment of immunoaffinity purification: Sample preparation 
1. Reserved fractions (from section Basic elution of immunoisolates) 
a. Cell pellet (step 7) 
b. Input Supernatant (step 7)  
c. Flow-through (step 11) 
d. Primary eluate (step 21)  
e. Secondary eluate (step 18) 
2. Ultrapure dH2O 
3. Acetone (-20°C) 
4. 1.7 mL eppendorf tubes (Fisher) 
5. Microcentrifuge 
6. NuPAGE 4-12% Bis-Tris pre-cast SDS-PAGE gel, 10 well (Invitrogen) 
7. Xcell SureLock Mini-Cell electrophoresis system (Invitrogen) 
1. 20X NuPAGE MOPS SDS Running Buffer (Invitrogen) 
8. 4X NuPAGE LDS Sample Buffer (Invitrogen) 
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9. 10X Reducing Agent (Invitrogen) 
10. Heat block at 70°C 
 
Assessment of immunoaffinity purification: SDS-PAGE and western blot analysis 
1. Prepared fractions (from section Assessment of immunoaffinity purification: 
Sample preparation) 
a. Cell pellet (step 1) 
b. Input supernatant (step 2)  
c. Flow-through (step 3) 
d. Secondary eluate (step 4)  
e. Primary eluate (step 5) 
2. NuPAGE 4-12% Bis-Tris gel, 10 well (Invitrogen) 
3. Xcell SureLock Mini-Cell electrophoresis system (Invitrogen) 
4. 20X NuPAGE MOPS SDS Running Buffer (Invitrogen) 
5. 1X Running Buffer: Dilute 20X NuPAGE MOPS SDS Running Buffer in 700 mL 
of ultrapure water. 
6. Precision Plus Protein Dual Color Molecular Weight Standards (BioRad) 
7. 4X NuPAGE LDS Sample Buffer (Invitrogen) 
8. 10X Reducing Reagent (Invitrogen) 
9. PVDF membrane (BioRad) 
10. Methanol 
11. Transfer apparatus (e.g. Mini Trans-blot Cell from BioRad) 
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12. 10X Transfer Buffer: Dissolve 144 g glycine and 30.3 g Tris base in final 
volume of 1 L dH2O. Prepare 1L of 1X Transfer Buffer containing 20% 
methanol. Chill at 4°C for 30min before use. 
13. 2 x Whatman filter paper and 2 x sponges for transfer 
14. 20X TBST: 200 mM Tris-HCl pH 8, 3 M NaCl, 2% Tween-20 in dH20. Dilute to 
1X with dH20 for use. 
15. Blocking Buffer: 5% non-fat dry milk powder in 1X TBST. 
16. Appropriate primary and secondary antibodies, diluted in Blocking Buffer 
17. Autoradiography cassette (FisherBiotech Cat# FBCA 57) 
18. ECL chemiluminescent substrate kit (Thermo Scientific) 
19. Autoradiography film (Kodak) 
 
METHODS AND PROCEDURES 
Obtaining Xenopus laevis embryonic tissue 
 Of all the proteins in X. laevis embryonic tissue, yolk proteins are among the 
most abundant, especially at earlier developmental stages when the embryo is still 
dependent on yolk for nutrients. The abundance of yolk proteins can be problematic 
when performing immunoaffinity purifications, as these proteins can nonspecifically 
react with antibodies and mask a less abundant interaction. For this reason, it is 
desirable to remove as much of the yolk from the embryo as possible. 
 
1. Fill a 1% agarose plate with cold 1X MBS. Transfer X. laevis embryos to MBS in 
agarose plate. 
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2. Using fine forceps and a dissecting microscope, remove as much of the yolk as 
possible from the rest of the embryo. Using a plastic transfer pipette, transfer the 
embryo to a new agarose plate containing fresh 1X MBS. Keep tissue on ice 
until all dissections are completed. Collect appropriate number of embryos for 
each immunopurification to be performed (See Note 1). 
3. Using a syringe needle, poke 4 holes in the cap of a 50 mL conical tube. 
Remove cap and secure tube into a rack in a styrofoam cooler. Fill cooler and 
tube with liquid nitrogen. 
4. Using a plastic transfer pipette, drop embryos one by one into liquid nitrogen in 
conical tube (see Note 4). When finished, replace the cap and screw on tightly. 
Remove the tube from the cooler (using a paper towel for protection) and invert 
to remove the liquid nitrogen. Store frozen tissue at -80°C. 
 
Tissue lysis and protein extraction 
 Tissue lysis can be carried out utilizing several approaches, including 
homogenization in a detergent-containing lysis buffer, passage through a needle 
(different needle gauges can be tested for efficiency of lysis), and cryogenic tissue 
disruption using traditional mortar and pestle or a Mixer Mill. While the procedures 
described below for immunoaffinity purification of protein complexes utilize as 
starting material tissue disrupted cryogenically using a Mixer Mill, the other types of 
tissue lysis can also be incorporated. We prefer the type of cryogenic disruption 
described below as it leads to an increased efficiency of extraction (i.e., isolation of 
the targeted protein) and decreased level of non-specific associations. This method 
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has provided us with a reliable and effective means of cell lysis for isolating varied 
protein complexes (Cristea et al., 2005; Cristea et al., 2006; Carabetta et al., 2010; 
Goldberg et al., 2010; Moorman et al., 2010; Greco et al., 2011). In circumstances 
that require a mild tissue lysis, such as the maintenance of intact organelles or large 
structures, e.g postsynaptic densities (Selimi et al., 2009), cryogenic disruption may 
not be the method of choice.  
 
Cryogenic tissue disruption 
1. Clean one spatula, the Retsch Mixer Mill jars, and the grinding balls 
sequentially with ultrapure dH2O, Windex, ultrapure dH2O, and 100% methanol. 
Allow all parts to dry completely in a chemical hood. 
2. Cool the jars and balls in liquid nitrogen (e.g., using a Styrofoam container filled 
with liquid nitrogen). Once cooled (i.e., liquid nitrogen no longer appears to be 
bubbling) remove them from the liquid nitrogen container using a pair of long 
forceps and place the frozen tissue into the jar. The tissue can fill up to a 
maximum of one third of the total volume of the jar for optimal cryogenic 
grinding (e.g., ~7 g frozen tissue pellets per 25 mL jar). Add the chilled ball on 
top of the tissue (use one ball per jar), close the jar, and place it back into the 
liquid nitrogen container to cool. 
3. Place the filled jars in the Retsch Mixer Mill holders. If only one jar contains 
frozen tissue for grinding, then use the other empty jar (without a ball) as a 
balance. Grind the tissue using 20 cycles of 2 minutes 30 seconds each at a 
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frequency of 30 Hz. Place the jars in liquid nitrogen in between cycles to cool, 
and ensure that the jars are still tightly closed.  
4. Open the jar and use a chilled spatula to transfer the frozen tissue powder to a 
50 mL conical tube kept on dry ice. Work as quickly as possible to avoid 
thawing of the ground sample. Periodically chill the spatula in liquid nitrogen. 
Store the powder at -80°C until immunopurification is to be performed. 
 
Optimization of lysis buffer and isolation conditions 
Successful isolation of a protein of interest and its interacting partners is 
dependent on several criteria including protein abundance and subcellular 
localization, sample amount, affinity of the antibody used for immunoaffinity 
purification, efficiency of bead conjugation, and lysis buffer conditions for 
immunoaffinity purification. During the cell lysis and protein isolation steps it is 
crucial to extract and preserve the targeted protein with its interactions in a soluble 
fraction. Therefore, the lysis buffer conditions utilized prior and during the affinity 
purification have to be optimized for each protein of interest before proceeding with 
larger scale immunoaffinity purifications for proteomics studies.  This can be done by 
performing small scale experiments (i.e., 20 embryos per immunopurification) that 
use western blotting to assess 1) the efficiency of protein solubilization (see 
procedure below) and 2) efficiency of isolation (see section Assessment of 
immunoaffinity purification). It is recommended to compare at least three lysis buffer 
conditions with varied levels of stringency. Generally, the stringency of a lysis buffer 
is determined by the concentrations and combinations of detergents and salts. Table 
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A2.1 provides examples of frequently used detergents, and Table A2.2 lists several 
lysis buffers that differ slightly in their compositions and were successfully utilized in 
immunoaffinity purifications of protein complexes from varied species.  
 
1. Split cryogenically ground tissue into equal small aliquots (e.g., 0.1 g) (see Note 
2). Ensure that the tissue power does not thaw during the weighing. 
2. Place the small aliquots on ice (4°C) and add a different lysis buffer (5 mL 
buffer per 1 g cells) to each sample.  
3. Homogenize the tissue powder in the buffer by vortexing for 1 min with 
intermittent cooling. This step is different than the usual homogenization for 
immunoaffinity purifications, which uses a polytron and a larger volume for the 
starting material. 
4. Separate the soluble and insoluble fractions by centrifugation at 8000 x g at 
4°C for 10 minutes. Recover soluble fraction and label “supernatant” 
5. Wash the pellet in water and discard supernatant. Extract pellet by sequential 
sonication then boiling at 95°C for 5 min in 50 mM Tris-HCl, pH 7.4, containing 
2% SDS.  Centrifuge at 20,000 x g for 10 min.  Recover supernatant and label 
“Pellet”. 
6. Assess the levels of bait protein in the supernatant and pellet fractions (5 – 
10% aliquots) using western blotting and antibodies against either the affinity 
tag (if present) or the endogenous protein. 
7. To proceed with a larger scale immunoaffinity purification for proteomics 
analyses, select the lysis buffer condition that provides the highest proportion of 
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bait protein in the soluble fraction, at the lowest necessary stringency. This will 
allow for a balance between an efficient extraction of the protein of interest and 
maintenance of interacting partners (see Note 3). 
 
Immunoaffinity purification of protein complexes 
Conjugation of magnetic beads 
This protocol has been optimized for conjugation of Dynabeads M-270 Epoxy, 
however it can also be applied for conjugation of other types of magnetic beads with 
larger or smaller diameters. In such cases, it is important to adjust the amount of 
antibody used for conjugation, depending on the bead capacity of binding. This 
protocol can be utilized for conjugating beads with high-affinity purified in-house 
developed antibodies as well as commercially available ones, provided their storage 
buffer doesn’t hinder covalent conjugation to Epoxy.   
 
It is best to start this protocol in the late afternoon and perform all washing 
steps (Step 7-10) in the morning of the following day. Unless otherwise stated all 
steps should be performed at room temperature. Do not allow the beads to dry out 
(i.e., do not keep the beads without a washing solution in between the steps).  
 
1. Weigh out the necessary amount of magnetic Dynabeads in a round-bottom 
tube.  
a. Round-bottom tubes are preferred to avoid the trapping of beads in conical-
shape tubes during the conjugation.  
 264	  
b. The necessary amount of beads is dependent on the purpose of the 
experiment and the abundance of the protein that will be immunoaffinity 
purified. An approximate guidance: 1-2 mg beads are appropriate for small-
scale optimization experiments, 5-7 mg beads are usually sufficient for 
performing single immunoaffinity purifications, and 10-20 mg beads are 
suitable for highly abundant proteins. 
2. Add 1 mL Sodium Phosphate buffer pH 7.4 to the beads; mix by vortexing for 
30 sec, followed by 15 min on a tube shaker (vigorous setting).  
3. Place the tube on a magnetic rack. After all the beads settle towards the 
magnetic side, discard the buffer.  
4. Remove the tube from the rack. Add 1 mL Sodium Phosphate buffer pH 7.4. 
Mix by vortexing for 30 sec and remove the buffer in the same manner as 
above. 
5. Remove the tube from the rack. Add, in this order, the necessary amount of 
antibodies, Sodium Phosphate buffer, and Ammonium Sulfate solution.  
a. The optimal total volume during the beads conjugation (that includes the 
antibody, Sodium Phosphate buffer, and Ammonium Sulfate solution) is ~ 20 
µl/mg beads  
b. As a guideline of amounts of antibodies or IgG that we routinely use: 8-10 µg 
Ab/mg beads for commercially available antibodies and IgG, and 3-5 µg 
Ab/mg beads for purified high-affinity antibodies (e.g., in-house developed 
anti-GFP antibodies).  
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c. The 3 M Ammonium Sulfate solution is added last and will be one third of total 
volume to give a final concentration of 1 M. 
d. For example, to conjugate 18 mg beads, use a total volume of 360 µL. For 
this, add 54 µg antibody to beads (if using 3 µg Ab/mg beads), then add 0.1 
M Sodium Phosphate Buffer (volume 0.1 M Sodium Phosphate Buffer = 360 
µL – volume of antibody used – 66.7 µL 3M Ammonium Sulfate), then add 
66.7 µL of 3 M Ammonium Sulfate. 
6. Secure the tube with parafilm and rotate bead slurry overnight on rotator at 
30°C. 
7. The next morning, place the tube with bead slurry on a magnetic rack. Remove 
and reserve the supernatant to assess the efficiency of bead conjugation by 
SDS-PAGE (See Note 4).  
8. Wash the beads sequentially with the following buffers. For each wash, gently 
resuspend the beads in 1 mL of the buffer, then place the tube on the magnet 
and remove buffer. “FAST” indicates that buffer should not be in contact with 
beads for longer than it takes to resuspend them:  
a. 1 mL of Sodium Phosphate buffer 
b. 1 mL 100 mM Glycine-HCl, pH 2.5 (FAST) 
c. 1 mL 10 mM Tris-HCl pH 8.8 
d. 1 mL 100 mM Triethylamine solution (FAST) 
e. 4 x 1 mL DPBS 
f. 1 mL DPBS containing 0.5% Triton X-100. Leave the tube on a Tomy 
shaker (gentle setting) for 15 min.  
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g. 1 mL DPBS 
9. Beads can be used immediately or stored at 4°C in DPBS containing 0.02% 
NaN3. For beads stored for future use, measure the final volume of the bead 
slurry (the bead size will contribute to the final volume) and make a note of the 
volume required for one mg beads as this will permit known aliquots of beads to 
be removed for multiple immunoaffinity purifications. Beads should be used 
within 2 weeks of conjugation. After 1 month of storage, their efficiency for 
isolation decreases by approximately 40%. 
 
Immunoaffinity purification: Basic elution of immunoisolates 
It is important to prepare all necessary reagents beforehand. Carry out all 
procedures on ice unless otherwise noted. At several steps during the protocol 
aliquots of samples (indicated with “RESERVE”) are taken to assess bait protein 
extraction and isolation efficiency (see section Assessment of immunoaffinity 
purification). 
 
Day 1 
1. Prepare appropriate volume of optimized lysis buffer as determined in section 
3.2.2. Pre-cool to 4°C. Add protease inhibitors just before use. Prepare 10 mL 
of wash buffer per sample (used in steps 6, 11 – 13), which is usually identical 
in composition to the optimized lysis buffer, except protease and phosphatase 
inhibitors cocktails are not included. 
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2. Incubate the frozen tissue powder on ice for 1 - 2 min, but do not thaw. Proceed 
immediately to step 3.  
3. Resuspend the frozen tissue powder in appropriate volume of lysis buffer by 
first adding a small amount of lysis buffer and swirling homogenate to solubilize 
pellet. Continue to add lysis buffer and gently mixing by hand until tissue 
powder has been completely solubilized (see Note 5).  
4. Run Polytron 10 sec in ultrapure dH2O to wash. Ensure that the tissue 
homogenate occupies ≤ 1/3 of the conical tube volume. Subject tissue lysates 
to Polytron homogenization for 2 x 15 second (speed = 22.5k), resting the 
sample on ice for a few minutes between homogenizations. If processing 
additional samples, rinse and run Polytron in ultrapure dH2O to wash out 
excess lysate.  When finished, perform a final rinse with methanol.  
5. Centrifuge the lysate at 8000 x g at 4°C for 10 minutes.  
6. During centrifugation, place tube containing antibody-conjugated magnetic 
beads on a magnetic rack for 30 – 60 secs. Discard the storage buffer and 
wash with 3 x 1 mL wash buffer by gently pipeting up and down to resuspend 
the beads. Do not vortex antibody-conjugated beads. Suspend beads in 100 – 
200 mL of wash buffer. 
7. Carefully pour the clarified lysates (supernatant) into new 50 mL conical tubes 
(see Note 6). RESERVE (i) the cell pellet and (ii) 40 mL of the input 
supernatant (See section Assessment of immunoaffinity purification for 
analysis).   
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8. Gently flick tube of antibody-conjugated beads to mix beads in solution.  Pipet 
the appropriate amount of beads into the clarified lysates. 
9. Rotate the lysates with beads on a rotator at 4°C for 1 hour. Do not use longer 
incubation times as this promotes the accumulation of non-specific binding and 
loss of weak interacting partners. 
10. During incubation, prepare base elution buffer and 1X LDS elution buffer (see 
Note 7). 
11. Attach a bar magnet to the lysates/bead suspension tube using a rubber band. 
Incubate on ice for 5 min. RESERVE the flow-through (unbound) fraction by 
pouring the supernatant into a clean conical tube (see section Assessment of 
immunoaffinity purification for analysis) 
12. Resuspend the beads in 1 mL of wash buffer and transfer the bead slurry to a 
round-bottom eppendorf tube.  
13. Place on a magnetic rack for 30 sec to pellet the beads and discard wash 
buffer.  Perform this procedure between all subsequent wash steps. 
14. Wash the beads 3 x 1 mL wash buffer. On the third wash, transfer the bead 
slurry to a clean round-bottom eppendorf tube, then pellet beads and discard 
wash buffer. 
15. Wash the beads 2 x 1 mL with wash buffer.  
16. Add 1 mL DPBS to beads and transfer slurry to clean round-bottom eppendorf 
tube. Repeat wash once with 1 mL of DPBS to remove residual detergent. 
Quantitatively remove DPBS wash. 
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17. Add 750 ml of base elution buffer. Incubate at RT for 20 min while shaking (see 
Note 8).  
18. Place the tube on the magnetic rack and transfer the eluate to an Axygen 
microcentrifuge tube. Freeze primary eluate in liquid nitrogen and evaporate to 
dryness overnight by vacuum centrifugation. 
19. Perform a second elution from the beads by suspending the beads in 40 µL of 
1X LDS elution buffer containing 50 mM DTT, incubating at 70°C for 10 min, 
and then at RT for 10 min while shaking. Place the tube on a magnetic rack and 
transfer the eluate to a clean microcentrifuge tube. RESERVE 10% (4 µl) of the 
secondary eluate in a clean microcentrifuge tube (see section Assessment of 
immunoaffinity purification for analysis). Freeze remaining 90% of secondary 
eluate in liquid nitrogen and store at -20°C. 
20. Proceed to Assessment of immunoaffinity purification to prepare reserved 
samples for Western blot analysis.  Continue with step 21 the following day. 
 
Day 2 
21. Remove dried eluate from the Speedvac.  
a. If performing SDS-PAGE-in-gel digestion (see Note 4), suspend dried eluate 
in 40 mL of 1X NuPAGE sample buffer containing 1X reducing agent and 
heat at 70°C for 10 min. RESERVE 10% (4 µl) of the eluate in a clean 
microcentrifuge tube. Add 4 ml of 1 M iodoacetamide to remaining 90% of 
primary eluate and incubate 30 min at RT protected from light. Freeze in 
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liquid nitrogen and store at -20°C or proceed immediately to proteomic 
analysis (see (Greco et al., 2012) 
b. If in-solution digestion is to be performed (see Note 4), suspend dried eluate 
in 40 mL of 1X LDS elution buffer containing 50 mM DTT and heat at 70°C 
for 10 min. RESERVE 10% (4 µl) of the eluate in a clean microcentrifuge 
tube. Freeze remaining 90% of primary eluate in liquid nitrogen and store at -
20°C or proceed immediately to proteomic analysis (see (Greco et al., 2012). 
 
Immunoaffinity purification: Alternate procedure (detergent elution of 
immunoisolates; see Note 7) 
Day 1 
1. Perform steps 1 – 16 as described above, except preparation of base elution 
buffer can be omitted (step 10). 
2. Add 40 µl of 1X LDS elution buffer to beads. Incubate 10 min at 70°C, then 10 
min at RT while shaking. 
3. Pellet beads on magnetic rack and transfer primary eluate to an Axygen 
microcentrifuge tube.  
4. Repeat Steps 2 and 3, transferring secondary eluate to an Axygen 
microcentrifuge tube.  
5. Add 2.0 mL of 1 M DTT to primary and secondary eluates. Heat at 70°C for 10 
min.  RESERVE 10% (4 µl) of eluates in clean microcentrifuge tubes.  
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6. If performing in-gel digestion (see Note 8), add 4 µl of 1 M iodoacetamide to 
remaining 90% of eluates and incubate at RT for 30 min protected from light. If 
performing in-solution digestion (see Note 8), proceed directly to step 7. 
7. Freeze remaining 90% of eluates in liquid nitrogen and store at -20°C or 
proceed immediately to proteomic analysis (see (Greco et al., 2012). 
 
Assessment of immunoaffinity purification: Sample preparation 
Reserved sample aliquots from section Immunoaffinity purification are 
prepared for SDS-PAGE and Western blot analysis. The recommended amount of 
each aliquot analyzed is provided as a starting point, and may need further 
optimization for differences in input material and bait protein abundance.  
 
1. Cell Pellet  
a. Wash the cell pellet with 1.0 mL dH2O. Homogenize washed cell pellet in 
1.0 mL of 2% SDS, transfer to microcentrifuge tube, and heat at 70°C for 10 
min. Centrifuge at maximum speed for 5 minutes at RT (see Note 9). 
b. Remove aliquot of SDS-soluble pellet fraction that corresponds to an 
identical percent of the input supernatant. For example, assuming a 40 µL 
aliquot of input supernatant was reserved from a total lysis volume of 10 mL, 
a 4 µL aliquot of the pellet sample should be removed.  
c. Dilute aliquot of SDS-soluble pellet fraction to a final volume of 60 µL 
containing 1X NuPAGE LDS Sample Buffer/1X Reducing Agent. 
2. Input Supernatant 
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a. Dilute 40 µL of reserved input supernatant to a final volume of 60 µL 
containing 1X NuPAGE LDS Sample Buffer/1X Reducing Agent. 
3. Flow-through (see Note 10) 
a. Transfer 10% of flow-through to clean tube. Slowly add 4 volumes of -20°C 
acetone. Vortex briefly. Incubate at -20°C for at least 1 hr. 
b. Centrifuge at 3000 x g at 4°C for 10 min. Pour off supernatant 
c. Briefly wash pellet with 4 volumes of 80% acetone/20% dH2O and discard. 
d. Air dry pellet for 5 min, then partially solubilize in 40 µL of 1X NuPAGE LDS 
Sampler Buffer/1X Reducing Agent by gentle agitation. 
4. Secondary Eluate 
a. Dilute 4 µL (10%) of the secondary eluate into a final volume of 40 µL 1x 
NuPAGE LDS Sample Buffer/1X Reducing Agent. 
5. Primary Eluate (prepared the following day, see Note 11) 
a. Dilute 4 µL (10%) of the primary eluate into a final volume of 40 µL 1x 
NuPAGE LDS Sample Buffer/1X Reducing Agent. 
6. Heat all samples at 70°C for 10 minutes. Freeze the samples at -20°C until 
ready to proceed with SDS-PAGE and western blot analysis. 
 
Assessment of immunoaffinity purification: SDS-PAGE and western blot analysis 
In this protocol the efficiency of immunoaffinity isolation of the bait protein is 
assessed by comparing 5 samples reserved at progressing stages of the 
immunoaffinity purification procedure: 1) cell pellet, 2) input supernatant, 3) flow-
through, 4) secondary eluate, and 5) primary eluate (see section Immunoaffinity 
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purification). While the amount of sample prepared (see section Sample preparation) 
is sufficient for duplicates analyses, the protocol below details a single experiment. A 
representative western blot is shown below (Figure A2.2A) indicating efficient 
isolation (no protein remaining in the flow-through) and recovery of the intended 
GFP-tagged bait protein (a majority of the protein was in the primary eluate). 
 
1. Set up the Xcell SureLock Mini-Cell electrophoresis system:  
a. Remove the white strip and the upper comb from the NuPAGE 4-12% Bis-
Tris pre-cast SDS-PAGE gel and rinse wells with ultrapure dH20. Place the 
gel in the apparatus, using a buffer dam for the opposing side, then lock the 
assembly in place.  
b. Fill the inner chamber with 200 mL and the outer chamber with 500 mL of 
1X Running Buffer. 
2. Thaw fractions if previously frozen and load into wells as follows: Lane 2, 10 µL 
Molecular Weight Standards; Lane 3, 30 µl of input supernatant; Lane 4, 30 µl 
of cell pellet; Lane 5, 20 µl of primary eluate; Lane 6, 20 µl of secondary eluate; 
Lane 8, 20 µl of flow-through; Empty lanes, 20 µL of 1X LDS Sample Buffer. 
3. Electrophorese for 5 min at 100 V, then 45 - 50 min at 200 V, or until the dye 
front has migrated all the way down the gel. 
4. While the gel is running, cut 2 pieces of Whatman filter paper and one PVDF 
membrane to the appropriate gel size. Always handle the membrane with 
tweezers.   
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5. Pre-wet PVDF in methanol and soak along with 2 transfer sponges, 2 filter 
papers, in pre-cooled 1X Transfer Buffer at least 15 min at 4°C. 
6. Open gel cassette to expose gel and discard the wells.  Working with wet 
gloves, transfer gel (by the thick ridge at the bottom) into a plastic tray 
containing 1X Transfer buffer.  Remove bottom ridge.   
7. Assemble a WB “sandwich” in the tray with pre-soaked items. Layer them in a 
transfer cassette as follows, starting from the clear side of the cassette: 
sponge, filter paper, PVDF membrane, SDS-PAGE gel, filter paper (gently roll 
out any bubbles using a 15ml conical tube), sponge. Close the sandwich and 
place into transfer apparatus with black side of cassette (gel side) facing black 
(anode) side transfer core. Place ice tray and stir bar into apparatus. Pour ice-
cold 1X Transfer Buffer into the apparatus until it covers fully the cassette.   
8. Transfer at 100 V for 1.5 hrs at 4°C while stirring. 
9. Open transfer cassette and discard the filter papers and gel. Verify the pre-
stained Molecular Weight Standards transferred to the membrane.  
10. Wash PVDF membrane with 1X TBST, discard, then add Blocking Buffer and 
incubate for 1 hour at RT on a rocking platform. Do not let the membrane dry. 
11. Discard Blocking Buffer and add the primary antibody diluted in Blocking Buffer. 
Incubate for 1-2 hours at RT or overnight at 4°C.    
12. Wash the membrane 3 x 20 mL in 1X TBST for 5 min while rocking at RT. 
13. Add the secondary horseradish peroxidase-conjugated antibody diluted in 
Blocking Buffer. Incubate for 1 hour at RT.  
14. Wash the membrane 4 x 20 mL in 1X TBST for 5 min while rocking at RT.   
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15. Mix ECL chemiluminescence substrates in 1:1 ratio (a total volume of 1 mL is 
usually sufficient to cover the membrane). Using tweezers, place the 
membrane on a dry plastic surface and apply the ECL solution, incubating for 1 
minute. Blot off the excess substrate and place the membrane between a sheet 
protector or Saran-wrap and tape into a film cassette. 
16. Carefully place a piece of autoradiography film on top of the membrane and 
close the cassette avoiding any film shifts as this will result in smeared bands. 
An initial exposure of 30 sec will indicate whether subsequent exposures of 
longer or shorter duration are required.  
 
Appropriate controls 
To assess the specificity of immunoaffinity isolation it is critical to have a 
control sample analyzed in parallel, beginning from tissue lysis through the isolation 
of the target protein. The controls described below account for non-specific binding 
of proteins to magnetic beads, antibody, and affinity tag (when present).   
 
GFP-tagged 
Often the bait protein is expressed as a GFP fusion protein. Here, parallel 
isolations of the GFP-tagged protein and GFP alone are highly desirable. If the GFP-
tagged protein is stably overexpressed by mRNA injection into embryos, it is 
necessary to generate a GFP-only tissue/animal in the same manner as the GFP 
fusion protein, i.e. mRNA injection of a GFP-only expression construct. Moreover, all 
treatment conditions and experimental variables, such as lysis buffer composition, 
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should be identical between the two isolations. Thus both the tag alone and the 
fusion protein can be immunoaffinity purified using identical preparations of 
antibody-conjugated magnetic beads. If lysis buffer conditions or other isolation 
variables are altered, such as incubation time of sample with antibody, an additional 
control should be performed. 
 
FLAG-tagged 
 If the bait protein is tagged with FLAG, then a more appropriate control 
(compared to the GFP tag), is the respective cell/tissue/animal but under wild type 
conditions. For both FLAG-tagged and wild-type conditions, magnetic beads 
conjugated with an antibody against the FLAG tag should be utilized. Although this 
doesn’t control for proteins that bind non-specifically to FLAG itself, non-specificity 
due to the antibody and beads can be determined.    
 
Endogenous, non-tagged protein 
In many experiments it is essential to immunoaffinity purify the bait protein at 
an endogenous level of expression (under its native promoter). Here, the control 
sample will use the identical cell/tissue/animal as for the experimental condition. In 
contrast to an affinity tag, the beads for the negative control are conjugated with 
either non-specific IgG or an IgG that lacks reactivity towards the endogenous bait 
protein. The control protein isolation will reveal interactions that bind non-specifically 
to the antibody and magnetic beads. A representative western blot from an 
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immunoisolation of endogenous Shp2 from X. tropicalis embryos is shown in Figure 
A2.2B.   
 
NOTES      
1. The number of embryos needed for each immunopurification is dependent on a 
number of criteria including protein abundance and solubility as well as the 
affinity of the antibody used for immunoisolation. For this reason, the optimal 
number of embryos and resulting amount of tissue must be optimized 
individually for each protein studied. Generally, 20-50 embryos per 
immunoisolation is a good starting point for small-scale experiments and may be 
scaled up for larger immunoaffinity purifications for proteomics studies. 
 
2. If starting directly with a small amount of tissue, the sample could be ground 
using round-bottom eppendorf tubes or used directly for incubation with the 
various lysis buffers. While performing the cryogenic grinding is preferred to 
mimic the conditions that will be utilized for protein isolation, direct resuspension 
in lysis buffer is an alternative that can adequately guide selection of an optimal 
buffer composition. 
 
3. The balance between extraction efficiency and maintenance of interacting 
partners can be further optimized by increasing the stringency of the buffer 
used to wash the magnetic beads relative to the buffer used for tissue 
homogenization. 
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4. To test the efficiency of bead conjugation, prepare the following samples for 
SDS-PAGE analysis: 1) Dilute >1 µg neat antibody with 2.5 µL 10x Reducing 
Agent and 6.25 µL 4x NuPAGE LDS Sample Buffer. Bring the sample to 25 µL 
total volume with dH2O. 2) Calculate the amount of bead supernatant that is 
equivalent to the amount of neat antibody in the previous sample, assuming that 
no antibody successfully conjugated to the beads. Dilute this amount with 2.5 µL 
10X Reducing Agent and 6.25 µL 4X NuPAGE LDS Sample Buffer. Bring 
sample to 25 µL with ultrapure H2O. Heat samples for 10 minutes at 70°C. 
Centrifuge the samples at 20,000 x g for 3 minutes at room temperature and 
load onto an SDS-PAGE gel. Stain the gel with SimplyBlue SafeStain and look 
for a reduction in the amount of antibody in the lane containing the bead 
supernatant. Refer to Cristea et al. 2005 (Cristea et al., 2005) for the expected 
amount of unbound antibody resulting from differing amounts of antibody used 
in the conjugation. 
 
5. After suspending tissue powder in lysis buffer, the solution may be slightly 
turbid, but should be devoid of tissue “clumps”.  Do not proceed to Polytron 
(step 4) until a homogenous suspension is observed. If necessary, additional 
rotation for 10 – 20 min at 4°C can be performed.  
 
6. If insoluble particles are present in supernatant after centrifugation, a pipet can 
be used to selectively transfer supernatant to clean 50 mL conical tube. 
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7. The base elution buffer is preferred as significantly less background protein 
contamination is observed under these elution conditions. However, if low 
recovery of bait protein is observed, e.g. when a high affinity antibody is used, 
an “Alternate Procedure” can be followed that uses a harsher detergent-based 
elution buffer (see above). 
 
8. The selection of an in-gel or in-solution digestion approach depends largely on 
the properties and nature of the proteins within the samples, e.g. pI, molecular 
weight, hydrophobicity, complexity, dynamic range, and total yield. In general, 
for high complexity and large yield and/or dynamic range of protein abundances, 
an in-gel approach is often desired. For further discussion, see (Greco et al., 
2012). 
 
9. For viscous samples, brief sonication can be used to aid solubilization of cell 
pellet. 
 
10. As the flow-through fraction often has higher protein concentration, the percent 
of material analyzed may need to be adjusted to prevent overloading of the SDS 
gel.  For NuPAGE gels of 1.0 mm thickness, between 100 – 150 mg is 
recommended.  
 
 280	  
11. If base elution buffer is used, processing of the primary eluate and its reserved 
fraction is not performed until the day after the immunoisolation was started (see 
section Immunoaffinity purification: Base elution, step 20).  
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Figure A2.1. Immunoisolation of protein complexes from Xenopus. 
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Figure A2.2. Assessment of isolation efficiency and specificity of 
immunoaffinity purification. (A) A GFP-tagged bait protein was isolated and eluted 
with the alternate detergent-based procedure. 10% of the following fractions were 
analyzed to assess the efficiency of isolation: FT, flow-through; PE, primary eluate; 
SE, secondary eluate. The majority of bait protein was found in the primary eluate. 
(B) Immunoaffinity purification of endogenous Shp2 protein from 100 stage 40 
Xenopus tropicalis whole embryos. As a control for the specificity of the Shp2 
antibody, a second immunopurification was performed using anti-V5 antibody-
conjugated beads. 
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Table A2.1. Examples of detergents commonly used for cell lysis and their 
properties. 
Detergent Properties Notes 
Triton X-100 • Nonionic detergent  
• pH 6.0 to 8.0 (5% aqueous 
solution)  
• Critical micelle concentration 
(CMC): 0.22-24 mM  
• Soluble at 25°C in all 
proportions; Soluble in water, 
benzene, toluene, xylene, 
trichloroethylene, ethylene 
glycol, ethyl ether, ethanol, 
isopropanol, ethylene 
dichloride  
• Depending on the 
utilized 
concentration, 
Triton is 
considered a 
relatively mild, 
non-denaturing 
detergent. Many 
enzymes remain 
active in 0.1%-
0.5% Triton X-100 
solution (e.g. 
Proteinase K is 
still active in 1% 
solution).  
• Can be used to 
preserve protein-
lipid interactions 
Sodium 
deoxycholate 
(DOC) 
• Anionic detergent  
• pH 5.0 to 9.0 (1% aqueous 
solution) 
• CMC: 2-6 mM (0.083 to 
0.249%, w/v). Micelle 
Molecular Weight: 2000 g 
(average), at concentrations 
above 2 mM  
• Soluble at 20°C; Soluble in 
water in less than 5% solution 
• Common 
component of 
RIPA lysis buffer. 
• Suitable for 
isolating 
membrane 
associated 
proteins, and 
liposome 
preparation. 
Disrupts protein-
lipid interactions.  
Digitonin • Nonionic detergent 
• pH: data not available 
• CMC: <0.5 mM, at 20-25°C. 
Micelle Molecular Weight: 
70,000 g (average)  
• Soluble in water at ~5% (w/v); 
Must be heated to 95-98°C 
first, then cooled to room 
temperature. Soluble in 
• Suitable for 
analyzing 
membrane-bound 
proteins and 
solubilizing lipids. 
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ethanol at 10 mg/mL 
Octyl-beta-
glucoside 
• Nonionic detergent 
• pH: data not available 
• CMC: 23-25  mM (0.6716 to 
0.7300%, w/v); Micelle 
Molecular Weight: 8000 g 
• Soluble in water 
• Suitable for 
studying 
membrane-
associated 
proteins 
• Readily integrated 
with mass 
spectrometry 
studies (i.e.., does 
not interfere as 
much as other 
detergents with 
ionization in 
MALDI MS 
experiments) 
Nonidet P-40 • Nonionic detergent 
• pH 5.0 to 8.0 (5% aqueous 
solution)  
• CMC: 0.059 mM (20-25C)  
• Soluble in water 
• Milder alternative 
to Triton X-100; 
depending on the 
concentration it 
may not penetrate 
nuclear 
membranes. 
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Table A2.2. Examples of lysis buffers used for immunoaffinity purification of 
protein complexes. 
Bait 
(GFP-
tagged) 
Description 
& 
Localization 
Species & 
Sample 
type 
Optimized Lysis Buffer   Ref. 
Apl1  beta-adaptin 
of  AP-2 
complex; 
cellular 
membrane   
 
 
S. 
cerevisiae 
cells 
20 mM K-HEPES, pH 7.4, 
110 mM KOAc, 2 mM MgCl2 
, 0.1% Tween, 0.4% Triton, 
200 mM NaCl, 1/100 (v/v) 
protease inhibitor mixture 
(20 mg/mL PMSF + 0.4 
mg/mL pepstatin A), and 
1/200 (v/v) protease 
inhibitor cocktail) 
(Criste
a et 
al., 
2005) 
Nup37  Member of 
nuclear pore 
complex; 
subunit of 
Nup107-160 
subcomplex 
Homo 
sapiens 
cells 
20 mM K-HEPES, pH 7.4, 
110 mM KOAc, 2 mM 
MgCl2, 0.1% Tween, 0.5% 
Triton, 200 mM NaCl, 1/100 
(v/v) protease inhibitor 
mixture (20 mg/mL PMSF + 
0.4 mg/mL pepstatin A), and 
1/200 (v/v) protease 
inhibitor cocktail) 
(Criste
a et 
al., 
2005) 
HDAC5 Histone 
deacetylase 
5; Nucleus 
and 
Cytoplasm 
 
Homo 
sapiens 
cells 
20 mM HEPES-KOH, pH 
7.4, 0.1 M potassium 
acetate, 2 mM  MgCl2, 0.1% 
Tween-20, 1 µM  ZnCl2, 1 
µM  CaCl2, 0.5% Triton X-
100, 250 mM NaCl, 4 µg/mL 
DNase, 1/100 (v/v) protease 
and phosphatase  inhibitor 
cocktails 
(Greco 
et al., 
2011) 
PAP I poly(A) 
polymerase 
I; Cytoplasm 
and inner 
membrane 
Escherichi
a coli 
cells 
20 mM HEPES, pH 7.4, 
0.11 M KOAc, 2 mM MgCl2, 
0.1% Tween-20 (v/v), 1 µM 
ZnCl2, 1 µM CaCl2, 1% 
Triton X-100, 0.5% 
Deoxycholate, 150 mM 
NaCl, 1:100 protease 
inhibitor cocktail, 1:200 
phenylmethylsulphonyl 
fluoride 
(Carab
etta et 
al., 
2010) 
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H3 Histone 3 
isoforms; 
Nucleus 
Mus 
musculus 
ES cells 
20 mM K-HEPES, pH 7.4, 
110 mM K-acetate, 0.1% 
Tween 20, 0.5% Triton, 300 
mM NaCl, and 1/100 (v/v) 
protease inhibitor cocktail 
(Goldb
erg et 
al., 
2010) 
nsP3 Sindbis 
nonstructural 
protein 3; 
Cytoplasm 
Sindbis-
infected 
Rattus 
Norvegicus 
cells  
20 mM K-HEPES, pH 7.4, 
110 mM KOAc, 2 mm 
MgCl2, 0.1% Tween 20, 1% 
Triton, 0.5% deoxycholate, 
500 mM NaCl, 25 units/mL 
DNase, 1/100 (v/v) protease 
inhibitor mixture  
(Criste
a et 
al., 
2006) 
PSD (via 
VGluRδ
2) 
postsynaptic  
densities; 
cerebellar 
excitatory 
synapses 
Mus 
musculus 
tissue 
10 mM HEPES, pH  7.4, 2 
mM CaCl2 , 132 mM NaCl, 
3 mM KCl, 2 mM MgSO4, 
1.2 mM NaH2PO4, 0.5%  
Triton  X-100, 1/100 (v/v/) 
protease inhibitor cocktail 
(Selimi 
et al., 
2009) 
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